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Abstract 
Most bacteria can exist in two fundamentally different life styles, as motile 
single cells and as sessile, surface-grown communities called biofilms. A key 
factor triggering the formation and maintenance of biofilms in a multitude 
of bacterial species is the second messenger bis-(3’-5’)cyclic dimeric 
guanosine (c-di-GMP). While low intracellular levels of c-di-GMP promote 
planktonic behavior, where cells are generally motile and express virulence 
factors, increasing concentrations of c-di-GMP promote the expression of 
adhesive matrix components and result in multicellular behavior, biofilm 
formation and persistence. 
The opportunistic pathogen Pseudomonas aeruginosa is responsible for 
chronic infections in the lungs of cystic fibrosis patients, a process that is 
eventually accompanied by the formation of small-colony variants (SCVs). 
The appearance of SCVs is caused by elevated levels of c-di-GMP and 
correlates with increased persistence of infection and antibiotic resistance. 
The YfiBNR-system has been previously identified as a key regulator of the 
SCV phenotype. While the mechanistic principles of interaction between the 
three proteins have been established by extensive in vivo studies, no 
structural information was available for any of the three proteins so far. 
Moreover, in vitro investigations of the effector of the system YfiN and its 
repressor YfiR were still missing. 
In this thesis, the structure of YfiR was solved by X-ray crystallography, 
which revealed a dimeric assembly of the protein. Moreover, YfiR was 
shown to adopt a novel fold. The core of the protein is made up by a seven-
stranded mixed β-sheet, flanked on the convexed side by three helices, and 
embracing a long N-terminal α-helix with its concave side. The β-sheet 
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topology is 2-3-1-4-5-6-7, where strand 2 and 7 are aligned in an antiparallel 
fashion in regards to the rest of the sheet. The protein is stabilized by two 
intramolecular disulfide bonds, mediated by Cys71-110 as well as Cys145-
Cys152.  SEC-MALLS analysis of wildtype YfiR and a dimeric-interface 
mutant demonstrated that the protein is dimerizing with a high affinity in 
solution, via the same interface observed in the crystal structure. In a next 
step, a functional assay was established using membrane-bound YfiN, which 
allowed the investigation of YfiN activity and regulation in vitro. 
Production of c-di-GMP was observed in a time-dependent fashion, 
indicating that YfiN showed diguanylate cyclase (DGC) activity. Further 
evidence was provided that YfiN activity is negatively regulated by YfiR 
and c-di-GMP, which implied that YfiN is undergoing allosteric feedback 
inhibition. Based on these results, a homology model of the inactive state of 
YfiN was generated, which gave insight into the presumable mode of 
feedback inhibition, involving c-di-GMP mediated cross-linking of the 
GGDEF and HAMP domains. It is therefore proposed that YfiN activity is 
regulated either by repression upon binding of dimeric YfiR or by non-
competitive product inhibition to avoid excessive substrate consumption.
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1 Introduction 
1.1 The bacterial second messenger c-di-GMP 
Most bacteria can exist in two fundamentally different life styles, either as 
free-swimming single cells or as sessile, multicellular communities forming 
biofilms. C-di-GMP has emerged as a regulatory mastermind to orchestrate 
the switch between the two states by influencing a multitude of downstream 
effector systems [1]. Whereas low levels of c-di-GMP promote a planktonic, 
motile lifestyle, increasing levels of c-di-GMP enhance the expression and 
production of adhesins [2],[3] exopolysaccharides [4]–[6] and attachment 
factors [7]  and in addition curb various forms of motility, thereby leading to 
biofilm formation [4], [8], [9]. Moreover, c-di-GMP signaling also plays a role 
in bacterial virulence [10], [11] and persistence [12]–[14]. It has been shown 
that cells growing in biofilms are protected from phagocytosis [12], [15] and 
show enhanced resistance against antibiotics due to slow growth or 
increased persister cell populations [13], [16] compared to their free-living 
counterparts. Because of this tolerance against antibiotics and the host 
immune system, biofilm associated infections, such as chronic infections in 
the airways of cystic fibrosis patients caused by Pseudomonas aeruginosa, or 
fatal systemic infections after lung transplantations by Burkholderia species 
[17], are notoriously difficult to treat and thus represent a major health 
problem. As conventional antimicrobials cannot efficiently disperse biofilms, 
there is an urgent need to develop alternative measures in order to combat 
infections associated with biofilms. C-di-GMP mediated signaling could 
therefore pose a viable target for the control of biofilm formation. 
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1.2 The structure of c-di-GMP 
C-di-GMP is a two-fold symmetrical molecule that consists of two GMP 
moieties forming a characteristic 12-member ribose-phosphate-ring in the 
center of the molecule (Figure 1-1). The first structure of an isolated cyclic 
dinucleotide was the one of c-di-dAMP determined by nuclear magnetic 
resonance (NMR) [18] and X-ray crystallography [19]. These c-di-dAMP 
structures were followed by crystal structure analyses of c-di-GMP [20]–[22]. 
They all show similar conformations for the ribosyl and phosphate moieties, 
suggesting a rather rigid backbone, with only the torsion angle around the 
glycosidic bond, and thus the position of the guanlyl base, showing 
conformational freedom.  
C-di-GMP was shown to form a homodimer with intercalated bases and two 
isologous intermolecular base-phosphate hydrogen bonds (Figure 1-1 (B)). In 
some structures, Mg2+ or Co2+ ions are coordinated by the N-7 atoms of the 
two central bases, however they do not alter the structure significantly. 
Binding of dimeric c-di-GMP has been observed at the inhibition site of 
diguanylate cyclases [23]–[26], PilZ receptors [27]–[30] a response regulator 
[31], a riboswitch [32] as well as the active site of a diguanylate cyclase [33]. 
Monomeric c-di-GMP was observed in the active sites of phosphodiesterases 
[34]–[36], a PilZ receptor [37] in the active site of a diguanylate cyclase [23] 
and in the eukaryotic innate immune sensor STING [38]. In a recent study, 
binding of a c-di-GMP tetramer was observed to be triggering effective 
dimerization of the transcriptional factor BldD [39]. It is therefore not 
surprising that c-di-GMP has been reported to display a rich polymorphism 
of various oligomeric forms at concentrations higher than 1 mM [40], [41].   
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Figure 1-1: Three-dimensional structures of cyclic-di-GMP. Carbon atoms are shown in white, 
nitrogen in blue, oxygen in red amd phosphorus in orange. (A) The monomeric form of c-di-GMP 
(from Protein Data Bank (PDB) entry 4LJ3). This state is usually binding to the active site of EAL 
domains. (B) c-di-GMP forming an intercalated dimer (from PDB entry 1w25). This form is usually 
seen bound to the allosteric I-site of diguanylate cyclases and PilZ domains. 
 
In a recent NMR study, it was found that the association of the monomer to 
the dimeric form is in fast exchange (<milliseconds) with an equilibrium 
constant of about 1 mM [42]. Higher oligomers were found in the presence of 
cations such as K+ at concentrations above 100 µM. Thus, at the low 
micromolar concentrations of c-di-GMP present in the cell and in the 
(A) 
(B) 
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absence of additional compounds that stabilize oligomers, c-di-GMP should 
be predominantly monomeric. 
 
1.3 Biosynthesis and degradation of c-di-GMP 
c-di-GMP is produced from two GTP molecules by diguanylate cyclases 
(DGC) and degraded to 5'-phosphoguanylyl-(3'-5')-guanosine (pGpG) by 
phosphodiesterases (PDE) (Figure 1-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2: C-di-GMP signaling pathways. In the cell, c-di-GMP is generated by diguanylate cyclases 
(red) that carry a catalytic GGDEF domain, and is degraded by phosphodiesterases (blue) that carry 
either a catalytic EAL or HD-GYP domain respectively. These enzymes are regulated by internal or 
external input signals that are sensed by their N-terminal accessory domains. Diguanylate cyclases are 
subjected to non-competitive product inhibition via c-di-GMP. The interaction of c-di-GMP with 
downstream receptors produce an output in a range of cellular processes and functions, such as 
downregulation of cell motility and acute virulence on one hand and on the other stimulation of 
diverse biofilm-associated functions. 
 
The catalytically active part of the DGC is the GGDEF domain that is 
named after the amino acid sequence motif, which constitutes an essential 
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part of the active site of the enzyme [43], [44] . The GGDEF domain 
consists of a five-stranded central β-sheet surrounded by five helices [23]. 
The displayed fold is similar to that of class III nucleotide cyclases and type 
I DNA polymerases, which implies a similar catalytic mechanism using 
magnesium as metal ions [43], [45], [46]. 
The GGDEF-sequence motif is forming a β-hairpin, where the first two 
residues (Gly) were shown to be important for GTP binding, while the 
fourth residue (Glu) is involved in metal ion coordination. The third amino 
acid (Asp/Glu) is crucial for catalysis and additionally plays a role in metal 
coordination [23], [24].  Any point mutation in this motif (except for a D to 
E mutation) abolishes enzymatic activity [44]. 
The active DGC is a dimer of two GGDEF domains, where both active sites 
are located at the dimer interface [23], [24]. This allows an antiparallel 
alignment of two GTP molecules and the formation of two intermolecular 
phosphodiester bonds, resulting in the production of c-di-GMP.  
In order to prevent excessive substrate consumption and set an upper limit 
for product accumulation at the same time, most DGCs are subjected to 
allosteric product inhibition with an inhibition constant in the range of 
cellular c-di-GMP concentrations [23], [47]. This involves binding of a base-
intercalated dimer of c-di-GMP molecules to a primary inhibition site (Ip) 
with an RxxD sequence motif (in which x denotes any amino acid) and 
binding to a secondary inhibition site (Is), which can come either from a 
regulatory domain or from the GGDEF domain of another protein monomer 
[23]–[25]. This allows the intercalated c-di-GMP dimer to block the 
movement of the GGDEF domain, which is required for formation of the 
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catalytically active homodimer. Despite primary sequence proximity 
between the A and I sites, they are located antipodal to each other, 
separated by a linker composed of five amino acids.  
C-di-GMP is degraded to the linear dinucleotide 5’-phosphoguanylyl-(3’-5’)- 
guanosine (pGpG) by either EAL or HD-GYP domains, named after their 
conserved active site residues [48], [49]. EAL-containing PDEs show high 
substrate specificity with a low sub-micromolar Km [48], [50], [51] which is 
consistent with the low cellular concentration of c-di-GMP.  These proteins 
require the presence of either Mg2+ or Mn2+ to function but are strongly 
inhibited by Ca2+ and Zn2+ [48], [49]. EAL domains exhibit a typical TIM-
barrel fold, where the active site is located at the C-terminal part of the 
barrel. The glutamate of the EAL-sequence motif is involved in cation 
coordination [35]. 
The second class of c-di-GMP-specific PDE is made up by HD-GYP-domain 
proteins, which form a subfamily of the metal-dependent phosphohydrolases 
and are unrelated to EAL proteins [52]. In contrast to EAL proteins, these 
proteins break the phosphodiester bond in c-di-GMP to produce 5’-pGpG 
and can then further degrade it to GMP.   
One interesting class of the c-di-GMP processing proteins is the so-called 
“composite proteins” composed of GGDEF and either one of the PDE 
domains, EAL or HD-GYP. The sheer number of proteins containing 
GGDEF-EAL tandems is large, as many as ~1/3 of all GGDEF domains 
and as many as ~2/3 of all EAL domains are present on the same 
polypeptide chain [53]. Only a few of them show bifunctionality, with both 
domains being active [54], [55]. One of them is the protein called ScrC, 
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which is responsible for the switch between the motile swarmer state and 
biofilm formation in Vibrio parahaemolyticus [56]. ScrC is composed of an 
N-terminal periplasmic sensor domain, followed by a GGDEF-EAL module. 
When expressed alone, ScrC is acting as a DGC leading to elevated 
intracellular c-di-GMP concentrations. In presence of its interaction partners 
ScrA and ScrB however, the protein is displaying PDE activity [56].  
By far more common is the class of composite proteins, where one of the 
two domains is enzymatically inactive or catalytically incompetent [48], [50], 
[57], [58]. These inactive domains have evolved to carry out new functions 
such as binding but not processing of a substrate molecule as it was 
observed for an inactive GGDEF domain [48] or inactive EAL domains [59]–
[61]. In the case of PdeA from Caulobacter crescentus, the degenerate 
GEDEF domain no longer shows catalytic activity but it is still able to bind 
GTP with a high affinity (Kd= 4 µM). This in turns stimulates the PDE 
activity by bringing the Km for c-di-GMP from the physiologically irrelevant 
level of ~100 µM to the physiologically relevant level of 0.42 µM [48]. This 
provides thus an example of a c-di-GMP signaling domain that has evolved 
beyond its role as an enzyme. 
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1.4 Regulation of the enzymatic activity by signal 
input domains 
A vast majority of proteins that either generate or degrade c-di-GMP 
harbor N-terminal accessory domains, which are regulating the enzymatic 
activity of the GGDEF, EAL or HD-GYP output domains in response to 
various stimuli. This suggests that several environmental and cellular signals 
are part of the c-di-GMP signaling network [62], [63]. Typical examples of 
sensory domains are small molecule- and protein binding PAS and GAF 
domains, light sensing BLUF domains, HAMP domains, phosphoryl group 
accepting receiver domains (REC) and many others [53]. A majority of 
those domains, e.g. PAS, HAMP and REC domains, can be found in other 
types of sensory and signaling proteins such as the two-component histidine 
kinases (HK) or the methyl-accepting chemotaxis proteins (MCP).  
PAS (Per-Arnt-Sim) domains are usually about 100 amino in length and are 
found connected to a wide range of enzymatic or nonenzymatic effector 
domains, such as HK, GGDEF and MCP. As these effectors are involved in 
diverse cellular pathways, PAS domains perform a variety of functions, such 
as promotion of protein-protein interactions [64], [65], signal-transfer [66] as 
well as sensing perceived stimuli in a direct way [67]. PAS domains have 
developed a remarkable plasticity in binding different ligands and cofactors 
over the course of evolution. The binding of small ligands to the PAS 
domain can either serve as a direct signal [68], or act as cofactors that are 
capable of sensing redox potential [69], [70] light [71], [72] or dissolved gases 
[73].   
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On the structural level PAS domains share a common three-dimensional fold 
[74], although they show little primary sequence identity. Two structural 
clades can be defined, depending on the cellular localization of the PAS 
domains, either in the cytoplasm or outside of the cell in the periplasm. 
Slight differences have been observed between the structures of cytoplasmic 
and periplasmic PAS domains: even though both types are characterized by 
a conserved β-sheet core, extracellular PAS domains are often anchored to 
the membrane by a long N-terminal α-helix, and most of them show a 
reduced set of helices between the second and the third β-strand (Figure 
1-3) [74]–[76]. The term PDC (for Pho/DcuS/DctB/CitA) domain was 
therefore introduced by [77] for this type of PAS domain topology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3: α-helical and β-sheet structures of periplasmic PASp or PDC domains in comparison to 
cytoplasmic PASc domains. The PDC is characterized by an „αααββα(α)βββα“ arrangement of 
secondary structure elements, whereas the PAS fold shows an „αββααααβββ“ arrangement. PASp 
and PASc stand for periplasmic and cytoplasmic PAS domains, respectively. PASpD and PASpP for 
distal and peripheral PAS domains. Topological arrangements refer to structures of DcuS (Escherichia 
coli), CitA (Klebsiella pneumoniae), PhoQ (Salmonella typhimurium), DctB (Sinorhidobium meliloti), 
PhoR (Bacillus subtilis) and FixL (Sinorhidobium meliloti). The figure was produced using TopDraw 
[159]. 
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HAMP domains, named after their occurrence in histidine kinases, adenylyl 
cyclases, methyl-accepting chemotaxis proteins and some phosphatases [78], 
form a second type of sensory input domains. They are also found coupled 
to other effector domains such as GGDEF [12], [14] and GGDEF-EAL [79]. 
In membrane-associated signaling proteins, HAMP domains play a key 
mechanistic role in transmembrane signaling. They usually lie near the 
cytoplasmic side of the membrane, between the periplasmic sensing and 
cytoplasmic signaling domains of the protein, where they promote 
conversion of signal-induced conformational changes into behavior-
controlling output signals [78], [80].  
The first HAMP structure was solved by NMR, occurring in the putative 
protein Af1503 from Archaeglobus fulgidus [81]. The structure revealed that 
the HAMP domain is organized as a symmetric, homodimeric parallel coiled 
coil. Each monomer is composed of two α-helices, AS1 and AS2, connected 
by a flexible linker segment of 14-15 residues in length. The same topology 
has been seen in many HAMP crystal structures that followed thereafter 
[82] [83] [84]. Coiled coils are bundles of helices that are building up a 
superhelix. Supercoiling results from the characteristic packing of side chains 
at the interface of the helices, called knobs-into-holes packing [85]. This 
packing mode is characterized by seven-residue sequence repeats, whose 
positions are labeled a–g, where residues a and d point towards the core of 
the bundle. The experimentally-determined Af1503 HAMP structure 
exhibits a “complementary x-da” packing arrangement of the helices in the 
bundle [81]. The two bundle structures are related by a coordinated 26° 
counter-rotation of each of the four helices, analogous to meshed gears in a 
transmission (therefore termed the “gearbox-model”). In the same study it 
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was suggested that the more conventional “a-d” packing arrangement might 
represent an alternative HAMP signaling conformation. Indeed, structures of 
Af1503 HAMP domain-dimerization/histidine phosphorylation (DHp) 
domain fusions show that the rotation of the HAMP helices results in 
rotation of adjacent helices of DHp [86] [87] and that this mechanism might 
explain the signal transduction mediated by HAMP domains in receptor 
histidine kinases. 
  
 
 
 
 
 
 
 
 
 
(A) 
d    g a   d      a    d   a   d    g a   d      a  
Figure 1-4: HAMP sequence features and bundle-packing arrangement. (A) Multiple sequence 
alignment of well characterized HAMP domains. Af1503 is from Archaeoglobus fulgidus; Tsr, Tar, 
Aer, EnvZ, and NarX are from Escherichia coli; Tar_st is the Tar protein of Salmonella 
typhimurium; HtrII-1 and HtrII-2 are two HAMP domains in HtrII from Natronomonas pharaonis. 
Secondary structure elements are annoted above the alignment. Residues shaded in red and grey are 
important for helical packing, residues shaded in green are noncritical for packing. Residues colored in 
yellow are highly conserved HAMP residues, whereas residues shaded in salmon are important for 
bundle stability. The nonspecific part of the linker region was colored in grey. (B) Schematic view of 
the gearbox model. Transformation from complementary x-da packing to knobs-into-holes packing is 
achieved by a coordinated axial rotation of all four helices by ∼ 26°. 
(B) 
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For c-di-GMP signaling proteins, only a handful have been characterized in 
terms of ligand specificity and how the sensory domain conveys the 
conformational change triggered by the binding event to the downstream 
effector domain. The DGC DocC and the PDE DoSP from E. coli as well as 
the PDE AxPDE1 from Acetobacter xylinum have been shown to sense 
oxgen [73], [88]. The tandem GGDEF-EAL protein AxDGC2 also from A. 
xylinum, containing a catalytically active GGDEF domain, is responding to 
altered redox conditions via a non-covalently bound FAD cofactor [69].  
Two phosphodiesterases, BlrP1 from K. pneumoniae and SL2 from 
Synechococcus elongatus, have been shown to react to light via their 
associated BLUF or LOV domains [35], [89]. Based on the crystal structures 
of BlrP1, the activation mechanism was proposed, where light absorption by 
the flavin molecule causes conformational changes in the BLUF domain, 
which are in turn propagated to the EAL active site. 
Amongst the most well characterized proteins are the DGCs PleD from C. 
crescentus and WspR from P. aeruginosa, which both carry a N-terminal 
REC domain and become activated upon phosphorylation [90], [44]. 
Phosphorylation of the aspartate localized on the REC1 domain of PleD 
induces structural rearrangement in the REC1-REC2 interfaces, which in 
turn, allows the tight dimerization of PleD, a prerequisite for c-di-GMP 
production. For PleD as well as WspR, the input signals for their cognate 
histidine kinases remain yet to be identified. 
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1.5 C-di-GMP receptors 
To exert its function, c-di-GMP has to bind to a downstream receptor and 
trigger structural or functional changes. C-di-GMP specific effectors are 
highly diverse, accounting for the broad range of cellular functions and 
processes that are controlled by c-di-GMP.  
The best-studied class is the PilZ family of proteins. The name originated 
from the P. aeruginosa PilZ (PA2960) protein, which consists of the c-di-
GMP binding domain only.  Structural studies revealed the presence of two 
short stretches with a RxxxRx20-30(D/N)x(S/A)xxG sequence motif, which 
are involved in c-di-GMP binding [28]–[30], [37], [91]. This event then 
triggers dramatic structural changes, where the primary binding loop wraps 
around the c-di-GMP molecule, bringing the second stretch into closer 
proximity. High c-di-GMP affinity has been observed for PilZ domain 
proteins, with dissociation constants being in the sub-micromolar range [5], 
[27], [92], [93] consistent with the cellular concentration of c-di-GMP. 
Interestingly, c-di-GMP can bind to the domain either as an intercalated 
dimer [27], [28], [30], or as a monomer [37]. It has been established that PilZ 
domains can occur as a standalone module or come as an attachment to 
other domains that generate a molecular output such as the production of 
cellulose [94] or alginate [5], changes in motility levels [93], [92], [95] and 
virulence of pathogens  [92], [95].  
Another class of c-di-GMP receptors is the degenerate GGDEF or EAL 
proteins, which lost their catalytic activity but retained the ability of c-di-
GMP binding, either to the inhibiting I-site or to the degenerate EAL motif. 
One of these catalytically inactive GGDEF proteins that functions as a c-di-
GMP receptor is the response regulator PopA from Caulobacter crescentus, 
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which recruits the cell cycle regulator CtrA to the cell pole after c-di-GMP 
binding to the I-site, thereby targeting CtrA for degradation [96]. Another 
protein called LapD is a GGDEF-EAL c-di-GMP receptor from 
Pseudomonas fluorescens, where both catalytic domains lost their activity 
but c-di-GMP is binding to its degenerate EAL domain with high affinity 
[3], [97], [98]. This binding event triggers a conformational change in LapD, 
leading to the recruitment of the periplasmic protease LapG, preventing it 
from cleaving a cell surface-bound adhesion and thereby promoting cell 
adhesion.  
A third type of a c-di-GMP binding domain termed “GIL” has only very 
recently been discovered [99]. It shows an “RxGD” binding motif, which is 
comparable to the RxxD motif involved in c-di-GMP binding in the I-sites 
of the GGDEF domains. Furthermore, the region in the vicinity of the 
apparent c-di-GMP-binding site on the GIL domain has the same predicted 
secondary structure as the corresponding part of the GGDEF domains [99]. 
Yet another type of c-di-GMP binders comprises proteins that can not be 
classified or predicted as receptors for c-di-GMP as they do not not have 
amino acid motifs that resemble previously defined c-di-GMP binding 
domains. FleQ is a transcription factor in Pseudomonas aeruginosa, 
involved in flagellar gene expression and exopolysachharide synthesis [100]. 
FleQ has been shown to bind to pel promoter DNA, leading to repression of 
pel transcription and that this repression is relieved by binding of c-di-GMP 
to FleQ.  
Ultimately, riboswitches have been shown to bind to c-di-GMP via a 
conserved GEMM domain and serve a direct role in gene expression [101]. 
They generally exhibit a very high affinity for c-di-GMP with a Kd around 
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1 nM, which is comparable to the highest RNA:small molecule interaction 
known [102]. 
1.6 The YfiBNR-system from Pseudomonas 
aeruginosa 
The opportunistic pathogen Pseudomonas aeruginosa is responsible for 
chronic infections in the lungs of patients suffering from cystic fibrosis (CF) 
or patients with compromised host defense mechanisms [103]. Eventually, 
respiratory failure caused by the infection is often the ultimate cause of 
death. During long-term lung colonization, P. aeruginosa undergoes genetic 
and phenotypic adaptation [104], [105], resulting in reduced virulence [106] 
as well as increased persistence [107]. Phenotypic adaptations lead to the 
appearance of small colony variants (SCV) in the sputum of CF patients, 
which are characterized by high auto-aggregation, attachment to surfaces, 
slow growth and enhanced exopolysaccharide production [108]. These 
persistent variants of P. aeruginosa constitute adaptions to the host 
environment and correlate with antibiotic resistance [13], [16], resistance 
against phagocytosis [12] and increased persister cell populations [16]. These 
findings suggest that the SCV phenotype may provide fitness advantages 
during the process of chronic lung infections and therefore plays an 
important role in the pathogenesis of P. aeruginosa. 
It has been shown that the appearance of the SCV phenotype is strongly 
linked to elevated levels of c-di-GMP [12], [109], [110]. A genetic screen in 
the PA01 strain for SCV-related loci, identified the YfiBNR operon, coding 
for the three proteins YfiB, YfiR and YfiN, which are responsible for 
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regulating c-di-GMP levels in P. aeruginosa in response to a still unknown 
environmental signal [12] [14].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YfiN thereby constitutes the effector of the system functioning as a DGC, 
which is located in the inner-membrane with its N- and C-termini facing the 
cytosol. It is composed of three domains: a periplasmic PAS (or PDC) 
domain, two transmembrane helices and the cytosolic part of the protein, 
which encompasses a HAMP domain followed by the catalytic GGDEF 
domain. In order to produce c-di-GMP, YfiN has to dimerize and adopt a 
catalytically competent arrangement of the GGDEF domains. YfiR is the 
Figure 1-5: Schematic representation of the YfiBNR system from P. aeruginosa. OM stands for “outer 
membrane”, PG for peptidoglycan and IM for “inner membrane”. YfiN is an inner-membrane protein, 
which is functioning as a DGC. It is repressed by interacting with YfiR, most presumably with its 
periplasmic PAS domain. YfiB, the outer-membrane bound OmpA/Pal-like protein activates YfiN by 
sequestering YfiR to the outer-membrane upon a still uncharacterized signal. YfiB also possesses a 
peptidoglycan-binding site, which has been shown to be crucial for YfiB function [14].  
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second member of the system and has been shown to reside exclusively in 
the periplasm [12]. By analyzing the phenotypes of a series of mutations in 
vivo, YfiR was found to be repressing YfiN function allosterically by directly 
binding to the protein. In addition, YfiR was suggested to sense the redox 
status of the periplasm via its two highly conserved disulfide bonds, 
providing one way of controlling the activity of YfiR [14].  Another control 
mechanism involves the third component of the system YfiB, an 
OmpA/Pal-like outer-membrane lipoprotein with a peptidoglycan-binding 
site. YfiB has been shown to sequester YfiR to the outer-membrane, thereby 
relieving YfiN repression, thus leading to c-di-GMP synthesis. This in turn 
will lead to increased production of Pel and Psl exopolysachharides, which 
are characteristic traits of the SCV phenotype [12]. Taken all these findings 
into account, this establishes the YfiBNR-system as a key regulator of 
biofilm formation in P. aeruginosa and thereby the persistence of chronic 
infections.  
1.7 Aim of the thesis 
The opportunistic pathogen Pseudomonas aeruginosa is responsible for 
chronic infections in the lungs of cystic fibrosis patients. The long-term 
survival strategy of P. aeruginosa in the host environment is based on 
phenotypic and genetic adaptations, resulting in the progressive loss of 
virulence and leading to increased persistence. This process is accompanied 
by adaptations of colony morphology, leading to the appearance of small-
colony variants (SCVs), which are characterized by auto-aggregation and 
enhanced exopolysaccharide production.  
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The YfiBNR system has been previously identified to be a key regulator of 
the formation of small-colony variant (SCVs) in Pseudomonas aeruginosa.  
Major work has been done on establishing an interaction model between the 
three members of the system by a combination of genetic and biochemical 
analysis. The YfiBNR system has been shown to function via tightly 
controlled competition between allosteric binding sites, which are highly 
conserved and hydrophobic and found on all three Yfi proteins. YfiN 
activity was shown to be suppressed in vivo by interacting with the 
periplasmic protein YfiR. Release of repression is mediated by the outer-
membrane (OM) lipoprotein YfiB, which upon undergoing a conformational 
change is sequestering YfiR to the OM. Despite the fact that the epistasis 
and the mechanistic principles of interaction have been determined, no 
structural information was available on any of the three Yfi proteins.  
 The aim of this thesis is therefore to investigate the interaction between the 
effector of the system, YfiN, and its repressor, YfiR, in more detail on a 
structural and functional level. Structures of the individual proteins, and 
potentially of the complex, would give detailed information about the 
residues, which are relevant for binding and allow further investigation of 
the allosteric binding sites. As YfiN has to dimerize in order to be active but 
no data is available on the oligomeric state of YfiR, in vitro characterization 
has to be performed in order to get information about the stoichiometry of 
the YfiR-YfiN complex.  
On the functional side, the establishment of an assay would allow the 
quantification of YfiN activity in vitro. The same assay could then be used 
in a second step to check if YfiR-mediated repression of YfiN activity is also 
observed in vitro and if YfiN is undergoing non-competitive product 
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inhibition as it was observed for other DGCs. Taken all these investigations 
together, this should help to provide missing information and thereby 
contribute to a more complete understanding of the YfiBNR system. 
 
2 Material and Methods 
2.1 Cloning of constructs 
2.1.1 Cloning of YfiN 
 
A synthetic DNA fragment coding for YfiN from Pseudomonas aeruginosa 
was ordered from MrGene (Life Technologies) and optimized in regard to 
codon-usage and GC-content. This fragment was then cloned into the 
expression plasmid pET28a (Novagen) using restriction sites NcoI/XhoI, 
yielding a C-terminally hexahistine-tagged protein. In order to obtain a N-
terminally his-tagged protein, the his-tag was introduced to the protein 
sequence in a first step by a set of primers. In a second step, the construct 
was then cloned into pET28a using the NcoI/XhoI restriction sites but with 
a primer bearing a stop-codon after the XhoI sequence.  
2.1.2 Cloning of the periplasmic YfiN constructs 
 
Three YfiNPAS constructs of different lengths have been generated by 
standard polymerase chain reaction using the pET28a/YfiN vector as a 
template. YfiNPAS38-159 and YfiNPAS44-149 were cloned into pET28a (Novagen), 
resulting in a C-terminally his-tagged protein, in pET28a-SUMO (modified 
pET28a-vector) generating an N-terminally SUMO-tagged protein, into 
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pMal-c2X (NEB) yielding an N-terminally MBP-tagged protein for 
expression in the cytoplasm, into pMal-p5x (NEB) yielding an N-terminally 
MBP-tagged protein for expression in the periplasm, and into pET-GSTx 
(pET21a, modified with the GST-coding region of pGEX-KT) generating N-
terminally GST-tagged protein. All fusion-constructs were either untagged 
at the C-terminus or carried a his-tag. The N-terminal fusion tags SUMO, 
MBP and GST were cleavable by the SUMO-protease and Factor Xa 
respectively. 
The third construct YfiNPAS44-154 was cloned into pET28a, generating a C-
terminally his-tagged protein. 
 
2.1.3 Cloning of the cytoplasmic constructs from different YfiN 
homologs 
 
The coding region corresponding to YfiNHAMP-GGDEF (residues 178-435) from 
Pseudomonas aeruginosa, was amplified by standard polymerase chain 
reaction using the pET28a/YfiN vector as a template, leading to a C-
terminally his-tagged protein.  Synthetic DNA fragments coding for 
YfiNHAMP-GGDEF from Pseudomonas fluorescens (residues 174-420), Yersinia 
enterocoliticae (residues 188-448) and Sphingopyxis alaskensis (residues 179-
408) were ordered from MrGene (Life Technologies) and optimized in regard 
to codon-usage and GC-content. The YfiN homologs were then cloned in the 
expression plasmid pET28a (Novagen) using restriction sites NcoI/XhoI, 
yielding C-terminally hexahistine-tagged proteins. 
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2.2 Protein production 
2.2.1 Protein expression 
 Expression tests of YfiN 2.2.1.1
 
The pET28a/YfiN plasmid was transformed into the E. coli strain 
BL21(DE3) (Novagen). 50 mL LB-medium supplemented with antibiotics 
was inoculated with overnight culture to a starting OD600 of 0.1. The cells 
were grown at 37 to an OD600 of 0.6, at which the protein expression was 
induced with 200 µM IPTG (isopropyl-—-D-1- thiogalactopyranoside). The 
temperature was then lowered to either 30 °C or 20 °C. For expression in 
TB-medium, a LB-starter culture was grown overnight, supplemented with 
antibiotics and 1% glucose to prevent leaky expression. The next day, cells 
were harvested by centrifugation at 5000 g and 4 °C for 15 minutes and the 
cell pellet was resuspended in the equivalent amount of TB-medium as the 
volume of the initial starter culture, supplemented with antibiotics. After a 
1h incubation at 37 °C, protein expression was induced by the addition of 
50 µM IPTG and the temperature was dropped to either 30 °C or 20 °C. 
Before and at several time points after induction samples were taken, which 
were centrifuged (10000g, 10min, room temperature) and the cell pellet was 
resuspended in lysis buffer (50 mM Tris-HCl, pH 8, 200 mM NaCl,) where 
the volume of buffer used corresponded to the cell density of the sample. 
The cells were lysed according to the BugBuster procedure (Novagen) and 
centrifuged (16’000g, 20 min, 4 °C) to yield a fraction containing insoluble 
proteins and cell debris. The supernatant containing the soluble protein 
fraction was loaded on an SDS-PAGE to follow YfiN expression.  
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 Expression of YfiN 2.2.1.2
 
YfiN was produced using the E. coli BL21(DE3) strain transformed with the 
pET28a/YfiN plasmid. Cells were grown at 37 °C overnight in LB-medium 
supplemented with kanamycin (50 µg/mL) and 1% glucose to prevent 
protein expression. The next day, cells were harvested by centrifugation at 
5000 g and 4 °C for 15 minutes and the cell pellet was resuspended in the 
equivalent amount of TB-medium as the volume of the initial starter 
culture, supplemented with kanamycin (50 µl/mL). After growing the 
shaking cultures at 37 °C for 1 hour, 50 µM IPTG was used to induce 
protein expression. The temperature was decreased to 30 °C and after 4 h of 
incubation, the cells were harvested by centrifugation (5000 g, 10 min, 4 °C) 
and the pellets were frozen at -20 °C. 
 
 Expression tests of YfiNPAS 2.2.1.3
 
The different YfiNPAS constructs were transformed into the E. coli strains 
BL21(DE3) (Novagen), BL21 Star™ (DE3) (Life Technologies), BL21-AI™ 
(Life Technologies) and ArcticExpress™ (DE3)RIL (Agilent Technologies). 
For the BL21(DE3) and BL21 Star™ (DE3) strains,  50 mL LB-medium 
supplemented with antibiotics was inoculated with overnight culture to a 
starting OD600 of 0.1. The cells were grown at 37 °C to an OD600 of 0.6, at 
which the protein expression was induced with 100 µM, 250 µM or 500 µM 
IPTG respectively. For the expression test at lower temperatures, cells were 
grown at 37°C until an OD600 of 0.5 was reached before temperature was 
reduced to 30 °C or 20 °C.  
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For the expression tests using the ArcticExpress E. coli strain, cells were 
cultivated at 37 °C to an OD600= 0.8 and protein induction was initiated 
by the addition of 250 µM IPTG.  
For the expression tests using the BL21-AI™ strain, the cells were treated 
as described for BL21(DE3) and BL21 Star™ (DE3), except that the 
protein induction was induced by the addition of either 0.2 % or 1 % 
arabinose and 500 µM IPTG.  
For the expression tests using TB-medium, the same protocol was applied as 
described in 2.2.1.1 for YfiN.  
In all cases, samples were taken right before and at several time points after 
induction and treated as described in 2.2.1.1 to monitor protein expression 
levels. 
 
 Expression of MBP-tagged YfiNPAS38-159 and MBP-tagged YfiNPAS44-149  2.2.1.4
 
Both constructs were produced using the E. coli BL21(DE3) strain 
transformed with the pMal-c2X/YfiNPAS44-149  or the pMal-c2X/YfiNPAS38-159  
plasmids respectively. Cells were grown at 37 °C overnight in 1 L LB-
medium supplemented with kanamycin (50 µg/mL) and 1% glucose to 
prevent protein expression. The next day, cells were harvested by 
centrifugation at 5000 g and 4 °C for 15 minutes and the cell pellet was 
resuspended in 1 L of TB-medium, supplemented with kanamycin (50 
µl/mL). After growing the shaking cultures at 37 °C for 30 min, 50 µM 
IPTG was used to induce protein expression. For YfiNPAS38-159, the 
temperature was decreased to 30 °C and protein expression was allowed to 
take place for 4 hous. For YfiNPAS44-149, the temperature was decreased to 
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20°C and protein expression was taking place overnight. Ultimately, the 
cells were harvested by centrifugation (5000 g, 10 min, 4°C) and stored at -
20 °C for further use. 
 
 Expression tests of YfiNHAMP-GGDEF from P. aeruginosa, P. 2.2.1.5
fluorescens, Y. enterocoliticae and S. alaskensis 
 
The different YfiNHAMP-GGDEF constructs were transformed into the E. coli 
strains BL21(DE3) (Novagen), BL21 Star™ (DE3) (Life Technologies). 50 
mL LB-medium supplemented with antibiotics was inoculated with 
overnight culture to a starting OD600 of 0.1. The cells were grown at 37 °C 
to an OD600 of 0.7, at which the protein expression was induced with 250 
µM IPTG. The temperature was then either kept at 37 °C or lowered to 30 
°C and 20 °C. In all cases, samples were taken right before and at several 
time points after induction and treated as described in 2.2.1.1 to monitor 
protein expression levels 
 
 Expression of YfiNHAMP-GGDEF from P. aeruginosa, P. fluorescens, Y. 2.2.1.6
enterocoliticae and S. alaskensis 
 
The different YfiNHAMP-GGDEF constructs were produced using the E. coli 
BL21(DE3) strain transformed with the pET28a/YfiNHAMP-GGDEF plasmids. 1 
L LB-medium supplemented with antibiotics was inoculated with 1 % v/v 
overnight culture. The cells were grown at 37 °C to an OD600 of 0.6, at 
which the protein expression was induced with 250 µM IPTG. The 
temperature was decreased to 30 °C and after 5 h of incubation, the cells 
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were harvested by centrifugation (5000 g, 10 min, 4 °C) and the pellets were 
frozen at -20 °C.  
 
2.2.2 Protein purification 
 Purification of YfiN 2.2.2.1
 
Cells were resuspended in 25 mL lysis buffer (50 mM Tris-HCl, pH 8, 200 
mM NaCl), lysed with a French press at 15 000 psi and centrifuged (10’000 
g, 15 min, 4 °C) to remove unbroken cells and inclusion bodies. The 
supernatant was ultracentrifuged (100’000 g, 30 min, 4 °C) for collection of 
the total membrane fraction, which was resuspended in 15 mL lysis buffer, 
supplemented with 21 mM DM. The solubilization process was allowed to 
take place for one hour with steady stirring applied. After another 
centrifugation step (100’000 g, 15 min, 4 °C), the supernatant was then 
loaded onto a 5 mL HisTrap column (GE Healthcare). After washing the 
column with YfiN-Ni-A buffer (50mM Tris-HCl, pH 8, 200 mM NaCl, 5 mM 
imidazole, 3.1 mM DM) for a length of 10 column volumes (CV), the 
protein was eluted with a linear gradient of imidazole from 5 to 500 mM in 
10 CV. YfiN containing fractions were pooled and concentrated to 4 mL. As 
an increased 260/280 ratio was observed after IMAC, indicating the 
presence of co-eluting nucleotides, YfiN was further purified by running a 
size-exclusion chromatography overnight at 0.2 mL/min flowspeed using a 
HiLoad-26/60-Superdex-200 prep grade column (GE Healthcare) and YfiN-
GF buffer (50 mM Tris-HCl, pH 8, 200 mM NaCl, 3.1 mM DM). The 
purification process was monitored by SDS-PAGE. Protein concentration 
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was determined by measuring the absorbance at 280 nm (ε280= 28420 M-
1cm-1).  
 
 Purification of YfiNPAS constructs 2.2.2.2
 
For the purification of YfiNPAS44-149, cells were resuspended in 25 mL lysis 
buffer (50 mM Tris-HCl, pH 8, 200 mM NaCl), lysed with a French press at 
15 000 psi and ultracentrifuged (100’000 g, 35 min, 4 °C) to remove cellular 
debris and insoluble material. The supernatant was then loaded onto a 5 mL 
HisTrap column (GE Healthcare). After washing the column with Ni-A 
buffer (50mM Tris-HCl, pH 8, 200 mM NaCl, 5 mM imidazole) for a length 
of 10 CV, the protein was eluted with a linear gradient of imidazole from 5 
to 500 mM in 10 CV. YfiNPAS4-149 containing fractions were pooled and 
concentrated to 3 mL and further purified by size-exclusion chromatography 
using a HiLoad-16/60-Superdex-75 prep grade column (GE Healthcare) and 
GF buffer (50 mM Tris-HCl, pH 8, 200 mM NaCl). The purification process 
was monitored by SDS-PAGE. Protein concentration was determined by 
measuring the absorbance at 280 nm (ε280= 15470 M-1cm-1). 
For MBP-tagged YfiNPAS38-159 and YfiNPAS44-149, the cells were lysed in the 
same way as described above but in a lysis buffer with a different 
composition (50 mM Tris-HCl, pH 7.4, 200 mM NaCl, 1 mM EDTA). The 
supernatant was then loaded onto a 5 mL MBPTrap column (GE 
Healthcare). After washing the column with lysis buffer for a length of 10 
column volumes (CV), the protein was eluted with a linear gradient of 
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maltose from 0 to 10 mM in 10 CV. YfiNMBP fusion protein containing fractions 
were pooled and concentrated to 3 mL and further purified by size-exclusion 
chromatography using a HiLoad-16/60-Superdex-75 prep grade column (GE 
Healthcare) and GF buffer (50 mM Tris-HCl, pH 7.4, 200 mM NaCl). The 
purification process was monitored by SDS-PAGE. Protein concentration 
was determined by measuring the absorbance at 280 nm (ε280= 81820 M-
1cm-1).   
 
 Refolding of the YfiNPAS44-149 construct 2.2.2.3
 
For the refolding of YfiNPAS4-149 expressed in inclusion bodies, cells were 
resuspended in 25 mL lysis buffer (50 mM Tris-HCl, pH 8, 200 mM NaCl), 
lysed with a French press at 15 000 psi and ultracentrifuged (100’000 g, 35 
min, 4 °C) to separate the soluble fraction from the insoluble material. The 
pellets were resuspended in lysis buffer containing 2 % Triton X-100, to 
solubilize the membranes, followed by a ultracentrifugation step (100’000g, 
10 min, 4 °C). This procedure was repeated three times to get rid of all 
membranes. The purified inclusion bodies were then resuspended overnight 
in lysis buffer containing 8 M urea. The next day, a final ultracentrifugation 
step was applied and the supernatant was loaded onto a 5 mL HisTrap 
column for on-column refolding. 
 
Material and Methods 
 
   28 
 Purification of YfiNHAMP-GGDEF from P. aeruginosa, P. fluorescens, Y. 2.2.2.4
enterocoliticae and S. alaskensis 
 
The purification was performed as described in 2.2.2.2 for YfiNPAS4-149, except 
that all buffers were supplemented with 5 % glycerol and contained protease 
inhibitor (Roche). Protein concentration was determined by measuring the 
absorbance at 280 nm (P.aer. ε280= 8480 M-1cm-1 ; P.fluor. ε280= 9970 M-
1cm-1 ; Y.ent. ε280= 19035 M-1cm-1; S.alas. ε280= 10095 M-1cm-1). 
 
2.3 Crystallization of YfiNHAMP-GGDEF from P. 
aeruginosa and Y. enterocoliticae 
For protein crystallization, the vapor diffusion method was used. Initial 
screening was performed with commercial screens in 96-well plates using the 
sitting drop method. For each drop, 0.2 µL protein solution was mixed with 
an equal amount of reservoir buffer. The reservoir volume was 75 µL. 
Afterwards the trays were sealed and stored at a constant temperature of 20 
°C.  
 
2.4 Production of membranes expressing YfiN 
The membrane fraction for activity tests was prepared as described in 
2.2.2.1, except that after the second centrifugation step, no extraction was 
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performed. Instead, the membrane pellet was collected, resuspended and 
thoroughly washed in 10 mL lysis buffer (50 mM Tris-HCl, 200 mM NaCl) 
by pipetting up and down, followed by a centrifugation step (10’000 g, 10 
min, 4 °C). This procedure was repeated 4 times. 
 
2.5 Activity measurements 
2.5.1 FPLC-based nucleotide quantification 
 
To test for diguanylate activity, washed membranes expressing YfiN were 
incubated with 2 mM GTP (Sigma) in 50 mM Tris-HCl, pH 8.0, 200 mM 
NaCl and 5 mM MgCl2. 200 µl of sample were taken at different time points 
and the reaction was stopped by heating the sample to 80 °C for 10 min. 
The reaction mixture was then centrifuged (10’000 g, 2 min, 4 °C) and 
subsequently, 100 µL were diluted in 900 µL 5 mM NH4HCO3, pH 8.0, 
filtered (0.22 µm) and 500 µl were loaded on an ion-exchange column 
(ResourceQ 1 µL, GE Healthcare). The nucleotides were separated with a 
gradient from 0.005 M to 1 M NH4HCO3, pH 8.0, in 14 CV. The elution of 
the reaction was compared to the elution profiles of GTP and c-di-GMP 
(own production). 
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2.5.2 Phosphate sensor assay 
 
In order to establish the phosphate sensor for quantification of DGC activity 
(Figure 3-30), DgcZ was used first as a well-characterized reference protein. 
The experiments were set up as follows: 0.5 µM phosphate sensor (PS), 130 
nM pyrophosphatase (PP), different concentrations of GTP (5 µM, 10 µM, 
20 µM, 50 µM and 100 µM) and 200 µM zinc-free DgcZ [111] were added 
sequentially to 30 µL of a 10 x stock solution of reaction buffer (50 mM Tris 
pH 7.5, 150 mM NaCl, 50 mM Arg/Glu, 5 mM MgCl2) and adjusted with 
H20 to yield a final volume of 300 µL. After addition of every component 
the resulting fluorescence was recorded by a spectrofluometer Jasco (Jasco 
analytical instruments) and the reaction was allowed to take place for 14 
min. After termination of the enzymatic reaction, 100 µM Pi was added to 
the experimental setup to fully saturate the PS.  
For the characterization of the enzymatic activity of YfiNHAMP-GGDEF from P. 
aeruginosa the same protocol was used as described above. 5 µM YfiNHAMP-
GGDEF were incubated with 50 µM GTP in reaction buffer (50 mM Tris-HCl, 
200 mM NaCl, 5 mM MgCl2) and the reaction was monited for 20 min.  
 
2.5.3 Malachite green assay 
 
To measure the enzymatic activity of detergent-solubilized YfiN the Baykov 
assay [112] was used in a 96-well format. The setup was adapted for DGCs 
by replacing the alkaline phosphatase by pyrophosphatase, allowing the 
detection of phosphate as a readout for DGC activity. The well-
characterized DGC DgcZ was again used as a reference protein to optimize 
the assay before using it with YfiN. The reaction mixture contained 200 nM 
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zinc-free DgcZ in 50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 5mM MgCl2, 130 
nM pyrophosphatase from bakers yeast (Sigma) and either 1 µM or 10 µM 
GTP. The volume was adjusted with reaction buffer to 200 µL in each well. 
In order to stop the reaction at different time points, 40 µL of phosphate 
detection solution (0.55 M H2SO4, 0.46 mM malachite green, 2.66 mM 
(NH4)6Mo7O24, 0.04% Tween) was added to each well and the absorption 
was measured at 630 nm 15 min after incubation. The production of 
phosphate was quantified with a phosphate calibration curve.  
For the characterization of the enzymatic activity of YfiN the same protocol 
was used as described above except that the reaction buffer was 
supplemented with 3.1 mM DM. 
 
2.5.4 Theoretical concepts and formulas used for the performed 
activity assays 
 The formula to calculate the concentration of a protein complex 2.5.4.1
depending on the total protein and ligand concentrations and the 
Kd 
 
The formation of a protein complex (AB) by protein (A) and protein (B) 
can be described as follows: 
 
      A+ B   ⇋ AB 
 
where A and B are the concentrations of the free proteins and AB describes 
the concentration of the protein complex.  
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The corresponding dissociation constant is defined as: 
 𝐾𝑑 =    ! × !!"      (1) 
 
 
The total amount of A and B are each made up by two fractions, free 
protein and complexed protein: 
 𝐴𝑡𝑜𝑡𝑎𝑙 = 𝐴! = 𝐴!"## +    𝐴𝐵 ,𝑤ℎ𝑖𝑐ℎ  𝑐𝑎𝑛  𝑏𝑒  𝑟𝑒𝑤𝑟𝑖𝑡𝑡𝑒𝑛  𝑎𝑠: 
 𝐴!"## = 𝐴! −    𝐴𝐵     (2) 
    𝐵𝑡𝑜𝑡𝑎𝑙 = 𝐵! = 𝐵!"## +    𝐴𝐵 ,𝑤ℎ𝑖𝑐ℎ  𝑐𝑎𝑛  𝑏𝑒  𝑟𝑒𝑤𝑟𝑖𝑡𝑡𝑒𝑛  𝑎𝑠 ∶ 
 𝐵!"## = 𝐵! −    𝐴𝐵     (3) 
 
 
Substituting (2) and (3) in (1): 
 𝐾𝑑 =    𝐴! − 𝐴𝐵 × 𝐵! − 𝐴𝐵𝐴𝐵  
 
This equation can be solved for x using WolframAlpha [113]. 
 
 
𝐴𝐵 = 0.5×    𝐴! + 𝐵! + 𝐾𝑑 ±𝐴! ! − 2 𝐴! × 𝐵! + 2 𝐴! ×𝐾𝑑+ 𝐵! × 𝐴! + 𝐵! ! + 2 𝐵! ×𝐾𝑑 + 𝐾𝑑!  
Equation 1: Equation used to calculate the concentration of a protein complex depending on the 
concentrations of the total concentrations of the components and the Kd. 
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 General enzyme kinetics and derivation of the Michaelis-Menten 2.5.4.2
Equation 
 
Enzymes are biological catalysts that accelerate or catalyze chemical 
reactions. The molecules at the beginning of the process upon which 
enzymes may act are called substrates and the enzyme converts these into 
molecules called products. 
The substrate S binds reversibly to an enzyme E to form an enzyme-
substrate complex ES. ES then in turn reacts irreversibly to generate a 
product P and to regenerate the free enzyme E. This system can be 
represented schematically as follows:  
 
 𝐸 + 𝑆   ⇌   𝐸𝑆  ⟶ 𝐸 + 𝑃 
Equation 2 
         
In the above scheme there are two different reactions. The first reaction 
depicted with the double arrow is a reversible reaction describing the 
reversible binding and dissociation of the enzyme and the substrate with the 
rates k1 and k-1 respectively. The second reaction is an irreversible chemical 
reaction where the enzyme-substrate complex is converted into product and 
free enzyme symbolized by the single arrow. The rate of this reaction (v) is 
proportional to the concentration of the enzyme substrate complex [ES] and 
the catalytic rate kcat, which is a measure for how many substrate 
molecules are turned over per enzyme molecule per second (s-1).  
 
 
k1  
k-­‐1  
kcat  
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𝑣 = 𝑑 𝑃𝑑𝑡 = −𝑑𝑆𝑑𝑡 = 𝑘𝑐𝑎𝑡× 𝐸𝑆  
Equation 3 
 
ES is an intermediate state and its concentration is therefore unknown but 
it can be expressed employing known values if the following assumptions are 
fulfilled: 
• As long as initial velocity v0 is considered, the concentration of 
product can be neglected (compared to that of the substrate, thus [P] 
<< [S]), and the concentration of substrate is in large excess over 
that of the enzyme ([E] << [S]). 
 
• Mass conservation equations for the reactants state that: 
𝑆!"!#$ = 𝑆! = 𝑆!"## + 𝐸𝑆 + 𝑃 ,  which now approximates to 𝑆! = [𝑆] 
and 
𝐸!"!#$ = 𝐸! = 𝐸!"## + 𝐸𝑆  
During the initial phase of the reaction, as long as the reaction velocity 
remains constant, the reaction is in a steady state, resulting in ES being 
formed and consumed at the same rate. During this phase, the rate of 
association of ES equals its rate of dissociation. According to Equation 2: 
  
Formation of the complex: ! !"!" = 𝑘!  ×   𝐸 ×  [𝑆] 
Dissociation of the complex: ! !"!" = 𝑘!! + 𝑘𝑐𝑎𝑡 ×[𝐸𝑆] 
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So in the steady state,         
𝑘!! + 𝑘𝑐𝑎𝑡 ×[𝐸𝑆] = 𝑘!  ×   𝐸 ×  [𝑆] 
Rearranging 
𝑘!! + 𝑘𝑐𝑎𝑡𝑘! = 𝐸 𝑥 𝑆𝐸𝑆  
 
Express [E] in terms of [ES] and 𝐸!  to limit the number of unknowns: 
𝐸 = 𝐸! − 𝐸𝑆   
Defining Km, the Michaelis-Menten constant, as 
𝐾𝑚 = 𝑘!! + 𝑘𝑐𝑎𝑡𝑘!  
Leading to 
𝐾𝑚 = 𝐸! − 𝐸𝑆 𝑥 𝑆𝐸𝑆   
The term [ES] can then be defined as: 
 𝐸𝑆 = 𝐸! × 𝑆𝐾𝑚 + 𝑆  
Equation 4 
 
Substituting Eq. 4 in Eq. 3 
 𝑣0 = 𝑘𝑐𝑎𝑡× 𝐸𝑆 = 𝑘𝑐𝑎𝑡× 𝐸! × 𝑆𝐾𝑚 + 𝑆  
Equation 5 
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The maximum reaction velocity, Vmax, is reached when all enzyme sites are 
saturated with substrate. This is true for the condition when [S] >> Km, 
leading to [S]/(Km+[S]) approaching 1. In this case, Vmax can be expressed 
as: 𝑉𝑚𝑎𝑥 = 𝑘𝑐𝑎𝑡× 𝐸!  
 
Substituted in Eq. 5  𝑣0 = 𝑉𝑚𝑎𝑥 𝑆𝐾𝑚 + 𝑆  
 
Equation 6: This equation, also termed Michaelis-Menten equation, expresses the initial rate of 
reaction in terms of a measurable quantity, the initial substrate concentration. The two kinetic 
parameters, Vmax and Km , will be different for every enzyme-substrate pair. 
 
 
2.6 Bioinformatical analysis 
2.6.1 Identification of YfiN homologs predicted to crystallize 
more readily 
 
Identification of YfiN homologs was performed by performing an NCBI-
BLAST against the sequence of the full-length protein, with a filter of 40 % 
- 70 % sequence identity applied. Potential candidates had to have the same 
domain architecture as YfiN, namely a PAS, HAMP and an intact GGDEF 
domain plus I-site. In addition, the organism had to have a complete 
YfiBNR operon [14] as it is the case in P. aeruginosa. Xtalpred analysis 
[114] was then performed with the most promising candidates, and three 
homologs were finally selected that fulfilled all the previously stated criteria 
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and were predicted to crystallize more readily than YfiN from P. 
aeruginosa.  
2.6.2 Identification and localization of the potential secondary I-
site in the HAMP domain of YfiN 
 
The YfiN protein sequence from P. aeruginosa was retrieved from the 
Uniprot database [115], corresponding to accession number Q9I4L5. In order 
to generate a multiple sequence alignment (MSA) for HAMP domains 
occurring exclusively in YfiN homologs, the sequence of YfiN was blasted 
against the nr70 database. Hits that did not cover at least 75 % of the 
sequence or did not represent DGC entries were omitted.  Finally, 95 
sequences were retrieved and aligned to the sequence of YfiN.  
For the second alignment, Tar, a methyl accepting chemotaxis protein 
containing a HAMP domain, was blasted against the nr70 database. The 
resulting 100 target sequences were then aligned against YfiN, yielding a 
second MSA with a presumably different consensus sequence for the HAMP 
domains as the first one. A sequence logo was then generated using 
Geneious for both MSA using the sequence of YfiN as a reference. 
 
2.6.3 Non-competitive product inhibition model of YfiNHAMP-
GGDEF 
The structure of YfiNGGDEF (pdb accession code 4iob) was superposed onto 
the GGDEF domain of feedback-inhibited PleD (pdb accession code 1w25). 
A homology model was then generated of YfiNHAMP using HHpred [116] 
based on the HAMP domain of the osmolarity sensor protein EnvZ (E-value 
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6 x 10-12). The second helix of the HAMP-model was then aligned to the last 
helix (α5) of PleD. The structural coordinates for the intercalated c-di-GMP 
dimer were taken from PleD and added to the theoretical model of the 
product-inhibited state of YfiNHAMP-GGDEF. As the YfiNHAMP and YfiNGGDEF 
domains are connected by a linker, which is not seen in the structure, 
allowing rotational and translational freedom between the two domains, the 
position of the GGDEF domain was slightly adjusted in order to 
accommodate Arg208 from the HAMP domain as a third c-di-GMP 
coordinating residue.  
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3 Results  
3.1 Research article I (Kauer et al., in 
preparation) 
 
 
The crystal structure of YfiR is providing new 
insights into YfiR-mediated repression of YfiN, a 
key regulator of biofilm formation in Pseudomonas 
aeruginosa 
 
Stefanie Kauera, Pablo Manfredib, Jacob G. Maloneb, Tina Jaegerb, 
Timothy Sharpec, Urs Jenalb* and Tilman Schirmera* 
a Focal Area Structural Biology and Biophysics, Biozentrum, University of Basel, 
Klingelbergstrasse 50/70 CH - 4056 Basel, Switzerland.  
b Focal Area Infection Biology, Biozentrum, University of Basel, Klingelbergstrasse 
50/70 CH - 4056 Basel, Switzerland.  
c Biophysics Facility, Biozentrum, University of Basel, Klingelbergstrasse 50/70 CH 
- 4056 Basel, Switzerland.  
 
 
*Corresponding authors. 
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Manuscript in preparation 
 
Statement of my own contributions 
I designed and performed all the experimental parts presented in the 
research article I. I cloned, expressed, purified and crystallized YfiR. 
Furthermore, I have solved the crystal structure. Ultimately, I analyzed the 
oligomeric state of YfiR and the mutant in solution by size-exclusion 
chromatography coupled to multi angle laser light scattering (SEC-MALLS).  
The YfiBNR system was originally investigated and characterized by Jacob 
Malone and Tina Jaeger, including the discovery of the activating YfiR and 
YfiN mutations. Pablo Manfredi performed the bioinformatical analysis and 
provided me with the multiple-sequence alignments used in this study. I 
wrote the manuscript except for the section “Bioinformatical analysis of 
DUF5145 proteins” (Material and Methods), which was written by Pablo 
Manfredi. Furthermore, I prepared and assembled all the figures and tables 
presented in the manuscript, except for the two figures in the supplementary 
data, which were produced by Pablo Manfredi. 
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Abstract 
The opportunistic pathogen Pseudomonas aeruginosa is responsible for 
chronic infections in the lungs of cystic fibrosis patients, a process that is 
eventually accompanied by the formation of small-colony variants (SCVs). 
The appearance of SCVs in the sputum of patients is caused by elevated 
levels of c-di-GMP and correlates with increased persistence of infection and 
antibiotic resistance. The YfiBNR-system has been previously identified as a 
key regulator of the SCV phenotype. The effector of this tripartite system is 
the inner-membrane bound diguanylate cyclase (DGC) YfiN. While the 
mechanistic principles of interaction between the three proteins have been 
established by extensive in vivo studies, no structural information has been 
available for any of the three proteins so far.  
We have solved the crystal structure of YfiR from P. aeruginosa, which 
revealed that it forms a dimer and adopts a novel protein fold. By SEC-
MALLS analysis, we provide evidence that YfiR is dimerizing in solution as 
well, via the same interface observed in the crystal structure. The data 
yielded a physiologically relevant dissociation constant (Kd) in the nM 
range. The crystal structure allowed the investigation of the proposed YfiN 
binding site, which revealed a highly conserved hydrophobic groove at the 
C-terminal end of the protein. Furthermore, as YfiR belongs to the domain 
of unknown function (DUF)4154 family, we investigated this class by 
bioinformatical means, which assigned them  a regulatory role for c-di-GMP 
related proteins and histidine kinases.  
It is therefore proposed that YfiR is regulating YfiN activity as a dimer via 
a conserved and hydrophobic site located at the very C-terminal end of the 
protein.  
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Introduction 
Bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP) is an 
ubiquitous second messenger that regulates the switch between the motile 
planktonic and sedentary biofilm-associated lifestyles of bacteria [117]–[119]. 
c-di-GMP is produced from two GTP molecules by diguanylate cyclases 
(DGC) and degraded to 5'-phosphoguanylyl-(3'-5')-guanosine (pGpG) by 
phosphodiesterases (PDE). The catalytically active part of the DGC is the 
GGDEF domain that is named after the amino acid sequence motif, which 
constitutes an essential part of the active site of the enzyme [23], [43], [120].  
Phosphodiesterase activity is generally associated with the presence of EAL 
[8], [48], [50], [121]  or HD-GYP domains [52]. 
While low intracellular levels of c-di-GMP promote planktonic behavior, 
where cells are generally motile and express virulence factors, increasing 
concentrations of c-di-GMP promote the expression of adhesive matrix [2], 
[5]–[7] components and result in multicellular behavior, biofilm formation 
and persistence [107]. 
The opportunistic pathogen Pseudomonas aeruginosa is responsible for 
chronic infections in the lungs of patients suffering from cystic fibrosis [103] 
or patients  with compromised host defense mechanisms. With progressive 
lung colonization, P. aeruginosa undergoes genetic and phenotypic 
adaptations to the host environment, resulting in reduced virulence [106] 
and increased persistence [104], [105]. Phenotypic adaptations lead to the 
formation of small colony variants (SCV), which are characterized by high 
auto-aggregation, attachment to surfaces [108], slow growth and enhanced 
exopolysaccharide production [108], [122]. These variants appear in sputum 
samples of CF patients and correlate with antibiotic resistance due to slow 
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growth or increased persister cell population [13], [16], resistance to 
phagocytosis [12] and prolonged persistence of infections. These findings 
suggest that the SCV phenotype may provide fitness advantages during the 
process of chronic lung infections and therefore plays an important role in 
the pathogenesis of P. aeruginosa. 
It has been proposed that the appearance of the SCV phenotype is strongly 
linked to enhanced levels of c-di-GMP [12], [45], [109], [110]. The YfiBNR-
system has been previously identified as a tripartite signaling system, which 
is regulating c-di-GMP levels in P. aeruginosa in response to a still 
uncharacterized environmental input signal [12], [14]. YfiN thereby 
constitutes the effector of the system as an inner-membrane bound DGC, 
which consists of a periplasmic PAS domain and cytoplasmic HAMP and 
GGDEF domains. The YfiBNR system has been shown to function via 
tightly controlled competition between allosteric binding sites, which are 
highly conserved and hydrophobic and which are found on all three Yfi 
proteins [14]. YfiN activity was shown to be suppressed in vivo by 
interacting with the periplasmic protein YfiR [12]. Release of repression is 
mediated by the outer-membrane lipoprotein YfiB, which is undergoing a 
conformational change in response to an unidentified signal and thereby 
sequesters YfiR to the outer membrane. SCV formation is then caused by 
enhanced c-di-GMP production by YfiN, which in turn leads to elevated 
transcription of the pel and psl operons [12].  
A key role in the regulation of biofilm formation is therefore attributed to 
the periplasmic protein YfiR as it shuttles between the presumable sensor 
YfiB in the outer membrane and the inner-membrane DGC YfiN. However, 
no structural or mechanical information is available on any members of the 
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YfiR family. According to pfam analysis, it is annotated as a member of the 
domain of unknown function (DUF) 4154 family [123].  
In this study, we have solved the crystal structure of YfiR from P. 
aeruginosa, which revealed that YfiR is exhibiting a novel protein fold. By a 
combination of X-ray crystallography and SEC-MALLS analysis, we provide 
evidence that YfiR is dimerizing in solution using the same interface 
observed in the crystal structure. The Kd of dimerization was determined to 
be in the nM range. Furthermore, we sought to investigate the DUF5145 
family bioinformatically to shed some light on their possible function in 
nature.  
 
Material and Methods 
Cloning, Expression and Purification 
A synthetic DNA fragment coding for YfiR comprising residues 36-190, 
which lacks the original N-terminal signal peptide from Pseudomonas 
aeruginosa, was ordered from MrGene (Regensburg, Germany) and 
optimized in regard to codon-usage and GC-content. The construct was 
subcloned into a pET-22b (+) vector (Novagen), which provides an N-
terminal pelB leader sequence resulting in export of the target protein to the 
periplasm, and addition of a C-terminal His6-tag to the polypeptide chain. 
Overexpression was performed in the E. coli strain BL21 StarTM (DE3). 
Cells were grown at 37 °C to an OD600 of 0.6. After induction with 0.5 mM 
IPTG, the protein was expressed over night at 20 °C. Cells were disrupted 
by French Press and sonication in lysis buffer (20 mM Tris-HCl pH 8.0, 100 
mM NaCl, 25 mM imidazole). After centrifugation at 100’000 g, the protein 
was purified by Ni- NTA affinity column (Ni-Sepharose, GE Healthcare, 
Results 
 
   46 
Germany), eluting at approximately 370 mM imidazole. The pooled protein 
fractions were concentrated and further purified by size-exclusion (SEC) 
chromatography using a Superdex 75 16/60 column (GE Healthcare) and 20 
mM Tris-HCl pH 8.0, 100 mM NaCl as running buffer. 
 
Crystallization and Data Collection 
Crystallization of YfiR was performed at room temperature by the sitting-
drop vapor-diffusion technique. A 0.2 µl + 0.2 µl mixture of protein (10 
mg/ml) and well solution (0.8 M Potassium sodium tartrate tetrahydrate, 
0.1 M Tris-HCl pH 8.0, 0.5 % Polyethylene glycol monoethyl ether 5000) 
gave rise to small crystals of needle shape belonging to the space group P21. 
These crystals were used as source of microcrystals for streak-seeding, 
leading to the formation of larger rod-like crystals. Crystals were 
cryoprotected by stepwise increasing the glycerol concentration to 30 % and 
flash cooled in liquid nitrogen. The same protocol was applied for 
selenomethionine-labelled YfiR. 
 
Crystal Structure Determination and Refinement 
A SAD dataset at the selenium K-edge was collected at beamline X06DA , 
Swiss Light Source, Paul-Scherrer-Institute, Villigen and data processing 
was performed with MOSFLM/SCALA [124] [125]. At this step, a set of 5 % 
reflections (Rfree set) was taken out for cross validation. Selenium positions 
were found with SHELXD [126], and the initial model was built by 
ARP/wARP [127]. Structure refinement and model building was performed 
using iterative cycles of phenix.refine [128] and COOT [129]. Ligand 
molecules were modeled in the Fo – Fc difference electron density map. 
Results 
 
  47 
Finally, water molecules were placed where the Fo – Fc map exceeded 3σ 
and potential hydrogen bonds could be formed. Model validation was carried 
out with MolProbity [130].  All structure figures were produced by using 
DINO [131].  
 
SEC Exclusion Chromatography (SEC) Coupled with Multiangle 
Light Scattering (MALS)  
A Wyatt silica SEC column (4.6 × 300 mm, 5 µm bead, 300 Å pore) on an 
Agilent 1100 series HPLC was employed for the determination of the 
oligomeric state of YfiR and YfiRD80R at different loading concentrations. 
The instrument was coupled to a Wyatt miniDawn TriStar multiangle light 
scattering detector and a Wyatt Optilab rRex refractive index detector. The 
column was equilibrated for 3 h to obtain stable baseline signals from the 
detectors before data collection. The inter-detector delay volumes and band 
broadening, the light-scattering detector normalization, and the 
instrumental calibration coefficient were calibrated using a standard 2 
mg/ml of BSA solution (Thermo Pierce) run in the same buffer, on the 
same day, according to standard Wyatt protocols. The absolute refractive 
index of the buffer was measured using the refractive index detector. 
The protein sample (20 µl) was loaded on the column. All experiments were 
performed at 6 °C at a flow rate of 0.5 ml/min in SEC buffer (see the 
purification section).  
The molecular weight and mass distribution of the samples were then 
determined using the ASTRA 5 software (Wyatt Technology).  
SEC-MALS derived apparent mass values were used to derive the 
dimerization affinity of YfiR, assuming a fast monomer-dimer equilibrium. 
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According to the mass action law, the monomeric molar fraction, xm = 
[M]/[M0], is given, by, 
 𝑥! =    8×   𝑀0 ×𝐾𝑑 + 𝐾𝑑! !/! − 𝐾𝑑 / 4× 𝑀0  
 
with [M0] = [M] + 2 x [MM], total protein concentration at elution; [M], 
monomer concentration; [MM], dimer concentration. 
This yields for the weight-averaged apparent mass (see also [132]) 𝑚!""!#$%& = 𝑥!×  𝑚!"#" + 1− 𝑥! 𝑚!"#$% = (2− 𝑥!)×𝑚!"#"         (Eq.1) 
 
The experimental data (Figure 3) were fitted (program ProFit) to Equation 
1 with a fixed mmono of 18 kDa to yield the dimerization Kd. 
 
Bioinformatical analysis of DUF5145 proteins 
All sequences of single DUF4154 domain proteins (1721 protein sequences) 
were extracted from NCBI via the architecture service [133]. Only protein 
sequences that were related to genomic background information were 
considered. All protein sequences encoded by genes located up to two genes 
downstream or upstream the DUF4154 domain protein were submitted to 
PFAM annotation (2996 sequences) [123]. Single DUF4154 domain proteins 
where then categorized according to the functional annotation found in their 
respective neighboring genes. Prior processing by WebLogos using 
GENEIOUS [134], the datasets were subjected to blasclust (-L75 -b70) in 
order to reduce bias from overrepresented sequence sources. 
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Results 
Structure Determination 
The crystal structure of recombinant processed YfiR from P. aeruginosa 
(residues 1-150, corresponding to 36-190 of the mature protein) was solved 
to a resolution of 1.8 Å in space-group P21 with 4 monomers per asymmetric 
unit. Crystallographic data are given in table 1. Initial phases were obtained 
by single-wavelength anomalous dispersion phasing of SeMet-derivatized 
crystals and the resulting experimental electron density map allowed 
placement of the full structure using ARP/wARP.  
The four subunits with similar structures (RMSD of 0.2-0.5 for all Cα 
positions) are arranged in two identical dimers: A-B and C-D. Refinement 
with non crystallographic symmetry restraints yielded a final model with an 
R/Rfree of 17.3/21.3. The final electron density is of high quality and the 
entire main-chains of the 4 subunits are well defined except for the N-
terminal region from residues 35-39 in A, and 35-37 in B and D and 35-38 in 
C; the C-terminal region from residues 182-190 in A, 186-190 in B and 185-
190 in C and D, and the purification tag in subunits B and D. These 
residues were therefore not included in the final model. Additionally, weak 
electron density was observed for several side-chains in two loop regions of 
the protein (142-144; 156-159). The following discussion is restricted to the 
A–B dimer. 
 
Crystal Packing 
The monomers within the dimer are held together by a set of 3 hydrogen 
bonds, 4 salt bridges (as suggested by the PISA-server [135]), as well as two 
van der Waals interactions, resulting in an approximate dimeric interface 
Results 
 
   50 
area of 675 Å2 (table 2). Residues belonging to the N-terminus, the loop 
between beta strand 1 and helix α2 (dimerization loop) and the loop 
between beta strand 3 and helix α3 account for most of the intermonomeric 
contacts within the dimers (Figure 2).  
 
The overall structure of YfiR reveals a new fold 
The entire polypeptide chain folds into a single globular domain of 
approximate dimensions 26 Å × 37 Å × 26 Å (Figure 1). The core of the 
protein is made up by a seven-stranded mixed β-sheet, flanked on the 
convexed side by three helices, and embracing a long N-terminal α-helix 
with its concave side. Additionally, there is a second small α-helix present 
on the concave side that is mediating a crossover between β1 and the β2-β3 
hairpin loop. The β-sheet topology is 2-3-1-4-5-6-7, where strand 2 and 7 are 
aligned in an antiparallel fashion in regards to the rest of the sheet. There is 
an additional small β-sheet present, formed by β0 and β8, located at either 
end of the protein. The protein is stabilized by two intramolecular disulfide 
bonds, mediated by Cys71-110 as well as Cys145-Cys152. The latter seems 
to be important to keep the loop-region between β5 and β6 in place. 
At the very C-terminus of molecules B, C and D, the formation of an 
additional α-helix is observed (residues 178-185) but not in A, as the 
electron density of this subunit was overall of a lesser quality and therefore 
it was built only up to residue 181. For all four subunits, no electron density 
was observed for residues 186-190 but in subunits A and C placement of the 
following C-terminal his-tag was at least partially possible. 
A search with FATCAT [136] identified that the highest structural 
similarity is with a 5-formyltetrahydrofolate cycloligase-related protein 
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(PDB entry: 1wkc, NagB/RpiA/CoA transferase-like fold) and 
hypoxanthine phosphoribosyltransferase (PDB entry: t1tc, PRTase-like 
fold). DALI [137] showed significant hits for several ABC domain or ATP 
binding proteins (PDB entries: 3lft, 3lkv, 3lft, rossman fold). All three folds 
fall into the class of α/β proteins and assume a 3-layered α/β/α sandwich 
like YfiR. However, superposition of YfiR onto all five identified hits with 
an r.m.s.d of 3.1 Å, revealed that even though there are structural 
similarities, the resulting topology diagrams look completely different. YfiR 
is thus adopting a novel fold, characterized by a α/β/α sandwich, displaying 
a strand order of 2-3-1-4-5-6-7 (Fig. 1 B). 
 
Fast concentration-dependent YfiR monomer-dimer equilibrium 
The oligomeric state of YfiR in-vitro was analyzed using SEC coupled with 
MALS. The data showed that the retention time and apparent mass values 
are dependent on the YfiR concentration (Figure 3), which is indicative of a 
self-association equilibrium that is fast on the time-scale of the experiment. 
The weight-averaged mass values were fitted to the indicated monomer-
dimer equilibrium model (see “Material and Methods”). The protein is 
largely dimeric even at the lowest eluting concentration of 1 µM, and nearly 
all proteins are forming dimers at an eluting concentration of 9 µM. The 
corresponding Kd of dimerization was determined to be 139 nM.  
For further functional studies, a mutant was generated with the aim to 
prevent dimer formation. Therefore, the salt-bridge, formed by Asp80 and 
Arg98, was specifically disrupted by mutating residue Asp80 to an Arginine. 
As indicated by the SEC-MALS chromatogram, the D80R mutant is still 
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forming a fast monomer-dimer equilibrium but with a dissociation constant 
Kd of 21 µM that is two orders of magnitude larger than for the wild-type. 
 
Conservation Score Analysis 
Conservation score analysis revealed that there are multiple conserved 
patches in the protein (Figure 4, A, B, C). The central beta-strands situated 
in the hydrophobic core of the protein are overall well conserved, as are 
residues involved in positioning of the disulfide-bonds and the cysteines 
themselves. Another well-conserved patch of the protein is clustering around 
the second part of the long N-terminal helix as well as β0 and the following 
loop region until Pro62 (Figure 4, B, D). By far the largest conserved area is 
situated at the far C-terminal end of the protein, involving β7, α5, β8, α6 as 
well as all interconnecting loop regions. Interestingly, the conserved patch 
around β0 could be seen as an extension of this hyperconserved C-terminal 
region, forming together a large conserved patch at the opposite end of the 
dimeric interface. If this patch is portrayed as a surface representation it 
becomes evident that this is the only conserved part, that is solvent-
accessible, and that the rest of the protein is rather variable in terms of 
amino-acid composition (Figure 4C). Zooming into this conserved region of 
the protein, reveals a hydrophobic platform, formed by residues Ile169, 
Ala170, Val176 and L181 framed by a highly conserved rim, consisting of 
residues R60, L166, D167, R171, G173, R175 and Pro178 (Figure 4, D, E). 
Overall, the rim is contributing to the hydrophobic nature of the platform, 
except for the few charged residues R60, D167, R171 and R175 (Figure 4 F).  
Interestingly, the dimeric interface is only moderately conserved. However, 
this can explained by the observed types of interactions between the 
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monomers, which are not requiring high specificity in terms of residues that 
are present, such as van der Waals interactions or hydrogen bonds between 
main chain atoms (table 2). Furthermore, Glu140 was found to be engaging 
in hydrogen-bond formation with the backbone nitrogens of residues Glu77 
and Tyr78, thereby forcing the dimerization loop to adopt its proper 
conformation (Figure 2). Interestingly, Glu140 is fully conserved and 
completely buried (2 % exposed) which is rather uncommon for such a 
highly charged amino acid. 
 
Activating YfiR-mutations 
Constitutively active YfiN variants that show reduced binding or fail to 
bind to YfiR altogether have been previously identified [14] (Figure 6 F). In 
the same study, complementary mutations in YfiR have been identified that 
restored wild-type colony morphology in the presence of some of the 
activated YfiN variants. Most of these mutations clustered either in the 
signal sequence region or at the C-terminal end of the protein. It was shown 
that signal sequence mutants led to increased expression of the protein, 
pointing towards a mere quantitative effect, which restored YfiR binding 
[14]. These mutations were therefore not further analyzed in the present 
study. The position of the residual mutations might help to shed some light 
on potentially interesting regions of the protein and therefore they were 
classified according to their conservation score and located in the structure 
(Table 3, Figure 5). Mutated residues, ranked in a moderately conserved 
class, were found either at the surface of the protein (K63E, Q125L and 
E163G) or completely buried in the core of the protein (V112A). All highly 
conserved residues (R60H, F151L and I169V) that showed a gain-of-function 
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effect are located at the C-terminal end of the protein in the highly 
conserved patch.  
 
YfiNPAS homology model 
No structural information is available for the periplasmic domain of YfiN. 
Therefore, a homology model was generated using HHPred based on the 
template CitA, which showed a E-value of 5.7e-7 [116]. According to the 
model, YfiN is adopting a classical periplasmic PAS fold (Figure 6B). 
Mapping the conservation score of each residue onto the structure revealed 
that all completely conserved residues are situated in the first three helices 
of the protein (Figure 6A, 6C). As it was already proposed before, the 
putative YfiR binding site, characterized by the hydrophobic amino acid 
motif A-A-V-V-F, is nearly completely conserved and faces towards the 
aqueous environment (Figure 6D, 6E) [14]. Localization of the previously 
identified mutations, which lead to a constitutively active YfiN revealed 
four residues situated in the first helix, four in the hydrophobic stretch and 
one residue at the end of helix 3 (Figure 6F) [14]. Interestingly, four out of 
five possible positions in the potential YfiR binding site have been identified 
as activating YfiN mutations.  
 
Discussion 
In this study, we have successfully solved the structure of YfiR by X-ray 
crystallography, which revealed that YfiR is adopting a new fold as neither 
FATCAT nor DALI found any identical folding patterns. It is made up by a 
α/β/α sandwich, displaying a strand order of 2-3-1-4-5-6-7 that has not been 
observed yet in the structural classification of proteins database (SCOP) 
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[138] (Figure 1). Moreover, the fact that a dimeric YfiR was found in the 
crystal structure, raised questions about the physiological relevance of this 
dimer. (Figure 2). SEC-MALLS analysis of wildtype YfiR and a dimer-
interface mutant demonstrated that YfiR is also dimerizing in solution with 
a Kd of 139 nM, via the same interface observed in the crystal structure 
(Figure 3). Intracellular concentrations of YfiR have not yet been quantified 
to our knowledge; however considering that it is binding to a dimeric YfiN, 
which leads to an increase in local YfiR concentrations, the Kd is certainly 
in a physiologically relevant range. 
Interestingly, despite the high affinity for dimerization, conservation score 
analysis revealed that the dimeric interface is only moderately conserved 
(Figure 4B). However, as the observed types of interactions between the 
monomers consist predominantly of mainchain-mainchain and van der 
Waals interactions, there is not much selective pressure on the preservations 
and conservation of a certain kind of side-chains (Table 2). Moreover, a 
highly conserved Glu (E140) was found completely buried in the protein 
(0.02% surface accessibility), which appeared to be positioning and 
stabilizing the dimerization loop by coordinating the backbone nitrogens of 
residues Glu77 and Tyr78. The same feature of loop stabilization by a so 
called “anchoring glutamate” is widespread among phosphodiesterases, 
where a Glu residue, e.g. E235 in YahA [36] or E268 in RocR [139], is 
involved in coordination of the dimerization loop β5-α5 (loop 6) . Proper 
positioning of loop6 is crucial for catalytic activity and a E268A mutation in 
RocR rendered the protein inactive accordingly [139]. A similar importance 
for dimerization might be attributed to Glu140 in this study.  
Besides the dimeric interface, conservation score analysis revealed an overall 
rather moderately conserved protein, except for one hyperconserved patch at 
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the C-terminal end of the protein. It has been proposed before by a 
combination of mutagenesis and analysis of sequence conservation that YfiR 
may bind to YfiN via a hydrophobic binding site located at the C-terminus 
[14]. We hereby provide the crystal structure to investigate the potential 
binding site in closer details. The well-conserved C-terminal part of YfiR, 
made up by the helices 5 and 6 and beta-strand 8, appears to form a sort of 
hydrophobic groove, which could easily accommodate another hydrophobic 
binding site (Figure 4D). In agreement with this hypothesis, highly 
conserved compensatory mutations in YfiR that are able to suppress 
activated YfiN are clustering in immediate proximity of this groove (Figure 
5) [14]. The presumable YfiR binding site on YfiN is made up by a 
hydrophobic stretch of five highly conserved residues (A-A-V-V-F) localized 
on the surface of the periplasmic PAS domain. Even conservative mutations 
in this stretch abolished YfiR binding and thereby led to YfiN activation 
(Figure 6F) [14]. Considering the hydrophobic groove of YfiR acting as a 
potential binding site, it seems very appealing that YfiN is exhibiting such a 
highly conserved and hydrophobic stretch on the surface. It could therefore 
be speculated that the Ala and Val residues might be involved in the correct 
positioning of Phe70, which could then in turn be recognized by the 
hydrophobic groove of YfiR.  
On the other side of the periplasmic space, YfiR is interacting with YfiB, 
which is an OmpA/Pal-like lipoprotein that is anchored to the outer 
membrane. Mutational studies on YfiB revealed a hydrophobic patch 
located immediately proximal to the insertion site of the protein to the 
membranes, which is proposed to serve as the potential YfiR binding site 
[14]. However, as complex structures of YfiR together with either of its 
interaction partners YfiB and YfiN are still missing, it remained to be 
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investigated, which YfiR residues are crucial for binding of YfiN or YfiB 
respectively. 
We therefore sought to further investigate the DUF4154 family of proteins 
by bioinformatical analysis. All sequences of single DUF4154 domain 
proteins (1721 protein sequences) were extracted from NCBI via the 
architecture service. The protein sequences encoded by genes located up to 
two genes downstream or upstream the DUF4154 domain proteins were then 
submitted to PFAM annotation (2996 sequences). This revealed that the 
family is found most often together with c-di-GMP related proteins, 
followed by Plug, HAMP, histidine kinases and OmpA-like proteins (Table 
S1). We then categorized the DUF4154 domains in respect to their 
neighboring genes and generated sequence logos for each of them in order to 
get information about which residues might be involved in interactions with 
the aforementioned proteins (Figure 7).  As YfiR is interacting with YfiN 
and YfiB, comparison of the DUF4154 + cdG and DUF4154 + OmpA 
sequence logos were of primary interest to this study (Figure 7A, 7B). 
Overall, the sequence conservation appears rather similar between the two 
groups, however the strength of global conservation seems to be more 
pronounced for DUF4154 proteins interacting with OmpA than with c-di-
GMP related proteins. Significant differences can be found in the 
conservation of the second disulfide bond of YfiR, consisting of C145 and 
C152 and R60, which all appear completely conserved in DUF4154 proteins 
interacting with OmpA-like proteins in contrast to the c-di-GMP group 
(Figure 7A, 7B). From YfiR knockout studies we know, however, that the 
second disulfide bond is of lesser importance for protein stability, as a 
corresponding mutant was still able to complement a ΔYfiR-strain 
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(unpublished results, Jenal et al.).  In contrast, the first disulfide bond, 
consisting of Cys71 and Cys110, is absolutely crucial for correct functioning 
of YfiR, as a corresponding mutant failed to complement a ΔYfiR-strain 
due to protein misfolding (unpublished results, Jenal et al.).  
Of even bigger interest may be the strong conservation of residue Arg60 in 
OmpA-like proteins in comparison to the c-di-GMP group, which might 
constitute a YfiB specific interaction site. Moreover, the same residue has 
been identified before as a compensatory mutation in YfiR (R60H), which 
was able to suppress an activated YfiN (Table 3, Figure 4D) [14]. Initially, 
it was proposed that the R60H mutation was a gain-of-function mutation of 
YfiR in terms of YfiN binding, however it seems that, in fact, it was a loss-
of-function mutation in terms of binding to YfiB. This finding seems 
reasonable as loss-of-function mutations are usually occurring at a higher 
frequency than their gain-of-function counterparts. In conclusion it is 
proposed that the YfiN-YfiR interaction, which is exhibiting a 2:2 complex, 
is in a dynamic equilibrium, with fractions of bound and unbound YfiN and 
YfiR in the periplasm. Rather than directly competing with the YfiN-YfiR 
interaction, activated YfiB would deplete the periplasm from unbound YfiR, 
thereby shifting the equilibrium to unbound and therefore active YfiN 
(Figure 8). The stoichiometry of the YfiB-YfiR complex, however, still 
remains to be investigated. 
In addition to regulating the activity of c-di-GMP related proteins, the 
DUF4154 family was also found in the vicinity of genes coding for histidine 
kinases. Interestingly, several fusion events have been reported, where the 
DUF4154 domain is located at the N-terminal part of the polypeptide chain 
of histidine kinases, presumably regulating enzymatic affinity 
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intramolecularly [123]. The sequence logo of this class looks rather different 
than for c-di-GMP proteins, likely implying another mode of binding and 
regulation (Figure 7A, 7C). Ultimately, DUF4154 proteins are often 
occurring in the proximity of genes coding for plug domains, which are 
associated with outer membrane transporters. The sequence logo of this 
class also proposes a mechanism of interaction, which is substantially 
different from the one observed for c-di-GMP related proteins  (Figure 7D). 
This led us to propose that the DUF4154 family is presumably involved in 
the regulation of either histidine kinases or c-di-GMP related proteins but 
most likely via different modes of interaction, which remain to be 
elucidated. 
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Figure 1:  
 
Overall structure of P.aeruginosa YfiR36-190. 
(A) Cartoon representation with secondary structure elements, disulfide bonds and 
chain termini labeled. The numbers noted at the N- and C-terminal end designate 
the terminal amino acid residues of the molecule observed in the crystal. The 
protein was colored according to a red to yellow gradient.  
(B) A topology diagram of the secondary structure of YfiR. The beta-sheet strands 
are shown in red, a-helices in yellow, disulfide bonds in green and connecting loops 
in black. Alpha helices lying on the concave side of the sheet are marked in bold, 
whereas the ones lying on the convexed side are labeled in grey. The start of alpha 
helix 6 is observed in subunits B, C and D but not in A as residues 182-185 could 
not be modeled in that chain. 
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Figure 2:  
 
Dimeric assembly of YfiR molecules in the crystal.  
(A) The four YfiR molecules observed in the asymmetric unit associate to form two 
dimers, each of which is related by a noncrystallographic two-fold (shown in 
magenta). The subunits are distinguished by color.  
(B) View along the local two-fold onto the dimeric interface. The same color code 
was used as in (A).  Side-chains of residues engaging in molecular interactions are 
shown in sticks and were labeled for one monomer only, except for residues 38 and 
39 that were labeled in the symmetry-related molecule (marked by a ‘) as no 
density was observed in the other chain. 
 For residue T76 the backbone atoms are shown in sticks as well as they are 
engaging in mainchain-mainchain interactions. All hydrogen bonds are colored in 
grey, while van der Waals interactions are colored in magenta.  
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Figure 3: 
 
A set of MALS data (weight-average molecule mass) acquired at various loading 
concentrations for wild-type YfiR (blue) and YfiRD80R (red). The data were fitted 
with a dynamic monomer-dimer model in fast exchange, with the values of the pure 
species set to their nominal values (horizontal lines).  
A SEC-chromatogram of  YfiRD80R  at different loading concentrations (green, blue, 
red)  is shown as inset. Continuous lines represent the dRI singal (left axis), broken 
lines the MALS derived apparent mass values (right axis).  
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Figure 4: 
 
(A) Sequence of YfiR from P. aeruginosa (UNIPROT accession name Q9I4L4) with 
HMM logo based on a non-redundant set of 59 homologous DUF4154 protein 
sequences. Only DUF4154 proteins were chosen that occur together with YfiN and 
YfiB as neighboring genes in a radius of +/- 2 positions. Every tenth residue is 
labeled with its number. Residues that are highly conserved (class 8 and 9 
according to ConSurf) and exposed (= / > than 40 % surface accessibility) were 
labeled according to their properties: charged amino acid (•), hydrophobic nature 
(#), polar (u) and structural importance (+). E140, which stabilizes the 
dimerization loop was labeled with a (★). Residues E140, I169 and V176 had a 
surface accessibility that was lower than 40%, however they were still shown for 
completeness reasons.  The secondary structure elements observed in the structure 
are shown schematically. 
(B) The YfiR dimer was colored according to the conservation score of each 
residue, using the same scala and coloring scheme as ConSurf. The residues labeled 
in (A) are shown as sticks. 
(C) Surface representation of (A), where the surface was colored as well according 
to the conservation of each residue. 
(D) Same view as in (B) but rotated by 90 degrees around the local two-fold. Only 
monomer B is shown. All residues that are labeled in (A) are shown as sticks. 
(E) Same view as in (C) but rotated by 100 degrees around the local two-fold. 
(F) Same view as (E) but showing the hydrophobicity mapped onto the surface. 
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Figure 5: 
 
The positions of previously identified activating YfiR mutations are shown within 
the structure [14]. The mutated residues are shown in sticks. The YfiN gain-of-
function backgrounds in which the complementary YfiR mutations have been 
identified are noted in subscript (Table 3).  
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Figure 6: 	  
(A) Sequence of YfiNPAS from P. aeruginosa (UNIPROT accession name Q9I4L5) 
with HMM logo based on a non-redundant set of 38 homologous YfiN sequences. 
Only YfiN proteins were chosen that occur together with DUF4154 proteins and 
YfiB as neighboring genes in a radius of +/- 2 positions. Every tenth residue is 
labeled with its number. Residues that are completely conserved (class 9 according 
to ConSurf) and exposed (= / > than 40 % surface accessibility) were labeled 
according to their properties: charged amino acid (•), hydrophobic nature (#), 
polar (u) and structural importance (+). The secondary structure elements were 
predicted by Jpred and are shown schematically [140]. 
(B) A homology model of the YfiNPAS dimer was generated based on the template 
CitA (PDB entry 1p0z). The two subunits are distinguished by color. The numbers 
noted at the N- and C-terminal end designate the terminal amino acid residues of 
the homology model. 
(C) The YfiNPAS dimer was colored according to the conservation score of each 
residue, using the same scala and coloring scheme as ConSurf. The residues labeled 
in (A) are shown as sticks. 
(D) Same view as in (C) but rotated by 90 degrees around the local two-fold. Only 
monomer A is shown. All residues that are labeled in (A) are shown as sticks. 
(E) Surface representation of (D), where the surface was colored according to the 
conservation of each residue. 
(F) Same view as in (D) but rotated by 20 degrees around x. The positions of the 
previously identified activating YfiN mutations are shown within the structure [14]. 
The mutated residues are shown in sticks. 
(G) Surface representation of (F) where the surface was colored according to the 
conservation of each residue. 
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Figure 7 
Multiple sequence alignment of DUF4154 proteins that occur with genes coding for 
either c-di-GMP related proteins (A), OmpA-like proteins (B), histidine kinases 
(C) or PLUG (D) that are localized up to two positions upstream or downstream 
of the DUF4154 proteins. Prior generation of the WebeLogos by Geneious [134], 
the datasets were subjected to blastclust (-L75 -b70) in order to reduce bias from 
overrepresented sequence sources. Every tenth residue is labeled with its number. 
The secondary structure elements observed in the structure are shown 
schematically.  
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Figure 8: 
 
The YfiBNR system from P.aeruginosa. The three proteins, the individual domains 
and the nucleotides are shown schematically. OM stands for “outer membrane”, 
PG for “peptidoglycan layer” and IM for “inner membrane”. YfiN constitutes the 
effector of the system as a diguanylate cyclase that is integral to the inner 
membrane. In the on state, the OmpA/Pal-like lipoprotein YfiB is binding to the 
periplasmic repressor protein YfiR, thereby sequestering it to the outer membrane 
and activating YfiN. YfiB also has a peptidoglycan-binding site, which was shown 
to be necessary for its function. In the off state, YfiB is undergoing a 
conformational change, thereby hiding its YfiR binding site, which results in the 
release of YfiR to the periplasm and YfiN inactivation.   
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Table 1: 
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Table 2 
 
A list of all interactions found in the dimeric interface of YfiR. The distances as 
well as the type of interactions are indicated. mc stands for main chain, whereas sc  
denotes side chain. 
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Table 3 
 
A list of all the compensatory mutations in YfiR with their corresponding 
conservation score and the fraction of solvent-accessible area noted. The preceding 
activating mutations in YfiN are marked in the second column. 
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Supplementary tables 
 
Table S1 
 
A table illustrating all the proteins, which are found 2 positions upstream or 
downstream of the 1721 DUF4154 members. Domains and proteins occurring 8 
times or more are indicated in (A), whereas in (B) only hits that are occurring 45 
times or more are shown.  
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3.2 In vitro characterization of YfiN, a key 
regulator of biofilm formation in 
Pseudomonas aeruginosa 
 
3.2.1 Functional characterization of membrane-bound and 
detergent-extracted YfiN 
 
 Design and cloning of the YfiN constructs 3.2.1.1
 
In the beginning of project, the sequence of YfiNGGDEF was aligned to the two 
GGDEF domains of the diguanylate cyclases PleD and DgcZ (Figure 3-1) 
[23], [111]. GGDEF domain boundaries of YfiN were determined by Pfam 
[141] and predicted to range from residues 249 – 407. The sequences of the 
GGDEF domains of PleD and DgcZ were aligned starting from α0 to the C-
terminal ends of the proteins, omitting the region forming the β0-β0’-
hairpin, which is often seen in DGC structures upstream of α0. 
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Figure 3-1: Multiple sequence alignment of YfiNGGDEF, DgcZGGDEF and PleDGGDEF with secondary 
structural elements indicated. Strictly conserved residues are boxed in white on a red background, 
and highly conserved residues are boxed in red on a white background. Every 10th residue is indicated 
with a dot. The α-helices are depicted by a coil, whereas β-strands are shown by an arrow. The 
secondary structure of PleD and DgcZ are according to [23] and [111], respectively. The alignment 
was performed using CLUSTAL OMEGA [142] [143]. The figure was generated using ESPript [144]. 
 
At the C-terminus, YfiNGGDEF is about 14 - or 22 residues longer than DgcZ 
or PleD, respectively. However, according to secondary structure prediction 
[145], the C-terminus is not flexible but predicted with the highest 
confidence score to be involved in helix formation. Therefore, it was 
included in the YfiN construct (Figure 3-2).  
 
 
 
 
 
Figure 3-2: Secondary structure prediction for YfiN by psipred analysis [145]. α-helices are colored in 
blue, whereas β-strands are colored in purple. The figure was generated using Geneious [134].  
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All YfiN constructs investigated within the framework of this thesis are 
listed in table Table 3-1. 
 
Name Feature N-terminal tag C-terminal tag 
pET28a/YfiN full-length (1-435) 
his6 - 
- his6 
pET28a/YfiNPAS38-159 periplasmic domain   his6 
pET28a-SUMO/YfiNPAS38-159 
periplasmic 
domain, fusion 
SUMO his6 
SUMO - 
pMal-c2X/YfiNPAS38-159 
periplasmic 
domain, fusion 
MBP his6 
MBP - 
pMal-p5X/YfiNPAS38-159 
periplasmic 
domain, fusion 
MBP his6 
MBP - 
pET-GSTx/ YfiNPAS38-159 
periplasmic 
domain, fusion 
GST his6 
GST - 
pET28a/YfiNPAS44-149 periplasmic domain   his6 
pET28a-SUMO/ YfiNPAS44-149 
periplasmic 
domain, fusion 
SUMO his6 
SUMO - 
pMal-c2X/YfiNPAS44-149 
periplasmic 
domain, fusion 
MBP his6 
MBP - 
pMal-p5X/YfiNPAS44-149 
periplasmic 
domain, fusion 
MBP his6 
MBP - 
pET28a/YfiNPAS44-154 periplasmic domain   his6 
pET28a/YfiNHAMP-GGDEF178-435 cytoplasmic domain   his6 
pET28a/ P. fluorescence 
YfiNHAMP-GGDEF174-420 
cytoplasmic 
domain, homolog   his6 
pET28a/ Y. enterocoliticae 
YfiNHAMP-GGDEF188-448 
cytoplasmic 
domain, homolog   his6 
pET28a/ S. alaskensis 
YfiNHAMP-GGDEF179-408 
cytoplasmic 
domain, homolog   his6 
 
Table 3-1: YfiN constructs used in the frame of this thesis. The color code is reflecting the different 
groups of constructs: full-length (yellow), YfiNHAMP-GGDEF constructs from different species (purple) and 
three YfiNPAS constructs of different length (38-159: orange, 44-149: green and 44-154: blue). 
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 Expression of the YfiN constructs 3.2.1.2
 
Expression tests of YfiN were performed in either LB - or TB-medium using 
BL21(DE3) at either 20 °C or 30 °C respectively. Protein expression was 
induced by addition of 250 µM IPTG in the case of LB-medium and 50 µM 
IPTG in the case of TB-medium. The highest expression levels in 
membranes were achieved using TB-medium and an expression duration of 
5 hours at 30 °C. Placement of the his-tag appeared to be crucial for protein 
stability, as proteolysis was occurring for the C-terminally his-tagged 
protein. Two expression gels and their corresponding western blots are 
shown in Figure 3-3. For protein production, bacteria were cultivated for 5 
hours at 30 °C in 2 L Erlenmeyer flasks using TB-medium. 
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 Optimization of the preparation protocol of membranes used for a 3.2.1.3
YfiN activity assay  
 
Before proceeding to activity assays using solubilized protein, an assay was 
established that allowed characterization of enzymatic activity of YfiN in its 
native membrane environment. Initially, membranes were collected as 
described in 2.2.2.1 and rinsed only once with reaction buffer (50 mM Tris-
HCl, pH 8.0, 200 mM NaCl, 5 mM MgCl2) prior to the activity assays. They 
were then incubated with 100 µM GTP and the reaction was allowed to 
Figure 3-3: SDS-PAGE and western blots for expression tests of either N- or C-terminally his-tagged 
YfiN. Same amount of cells were loaded in each lane. (A) N-terminal his-tag: 1: marker, 2: before 
induction, 3: cell debris (3h of expression at 30°C), 4: membranes (3h of expression at 30°C), 5: 
soluble fraction (3h of expression at 30°C), 6: cell debris (5h of expression at 30°C), 7: membranes (5h 
of expression at 30°C), 8: soluble fraction (5h of expression at 30°C), 9: cell debris (5h of expression at 
20°C), 10: membranes (5h of expression at 20°C), 11: soluble fraction (5h of expression at 20°C), 12: 
cell debris (overnight (o/n) expression at 20°C), 13: membranes (o/n expression at 20°C), 14: soluble 
fraction (o/n expression at 20°C). (B) C-terminal his-tag: the sample order is the same as in (A), 
except for 1: before induction, 2: marker. 
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take place for 30 - and 60 min respectively, where a sample was then taken 
and analyzed as described in 2.5.1. The resulting chromatograms appeared 
completely overcrowded with loads of unidentified peaks, making it 
impossible to draw a conclusion if any GTP consumption or c-di-GMP 
production was taking place (Figure 3-4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therefore, the preparation of the membranes has to be optimized. Instead of 
rinsing them only once with reaction buffer in the beginning, they were 
washed up to four times by completely resuspending the pellet in 4 mL of 
fresh buffer each time, followed by a centrifugation step to collect the 
membranes again. This procedure was repeated while the resulting 
supernatant was analyzed by FPLC. For the activity assay, only membranes 
Figure 3-4: Chromatograms of the individual washing steps. The absorption 
observed at 280 nM is depicted in red, whereas the absorption at 253 nM is 
colored in green. 
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were used that showed no longer any background contamination, suggesting 
that they were now free from any nucleotides, which were originally present 
in the cell. 
Additionally, reference spectra were generated by running GMP, GDP, GTP 
and c-di-GMP in different combinations on the ResQ column to establish at 
which retention volume each nucleotide is eluting and to ensure that all 
compounds can be separated at sufficient resolution (Figure 3-5). All 
nucleotides were present at a final concentration of 200 µM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5: Reference spectra of the nucleotides GMP, GDP, GTP and c-di-
GMP. The absorption at 253 nm is colored in green, whereas the absorption at 
280 nm is depicted in red. The color code for the superposition is as follows: 
green: sample 1, grey: sample 2, pink: sample 3, blue: sample 4, orange: sample 5. 
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Table 3-2: A list of the analyzed nucleotides with the experimentally determined retention volumes 
and the corresponding conductivity.  
 
 Quantification of DGC activity using membrane-bound YfiN  3.2.1.4
 
3.2.1.4.1   Non-competitive inhibition  
 
Non-competitive inhibition characterizes a system where the inhibitor and 
the substrate may be bound to the enzyme at any given time. When both 
the substrate and the inhibitor are bound, the enzyme-substrate-inhibitor 
complex cannot form product and can only be converted back to the 
enzyme-substrate complex or the enzyme-inhibitor complex.  
A noncompetitive inhibitor binds to a different (allosteric) site that is not 
the active site and thereby induces changes in the structure of the enzyme. 
The enzyme is thereby prevented from forming product, leading to a 
decrease in the rate of the chemical reaction of enzyme and substrate, which 
cannot be changed by increasing concentration of substrate. The binding of 
an uncompetitive inhibitor thus decreases Vmax by a factor α but has no 
change on the Km of the chemical reaction. 
 𝛼 = 1+    [!]!!          and    𝛼! = 1+    !!!!  
Equation 7:  𝐾!    is the dissociation constant for binding of the inhibitor to the enzyme whereas K’I 
describes binding of the inhibitor to the enzyme-substrate complex. 
 
 
nucleotide retention volume [mL] conductivity [mS/cm] 
GMP 11.0 19.6 
GDP 12.8 26.5 
GTP 14.0 31.0 
c-di-GMP 15.8 37.2 
Results 
 
   100 
  
Type of 
inhibition 
Km 
apparent 
Vmax apparent 
Ki = Ki’ α= α’ non-competitive Km Vmax/ α 
 
Table 3-3 
 
3.2.1.4.2 The function used to quantify DGC activity using membrane-
bound YfiN 
 
In the system present there are 2 enzymatic reactions that are taking place 
simultaneously involving the same substrate (GTP) but not the same 
enzymes (DGC and GTPase).  
 
Reaction 1: DGC + GTP à c-di-GMP + PP 
Reaction 2: GTPase + GTP à GDP + P 
 
In the case of DGCs (enzyme 1) non-competitive inhibition by the product 
c-di-GMP and - if added to the experiments – the repressor YfiR was 
observed (Figure 3-6, Figure 3-7). According to Table 3-3 illustrating the 
effects of non-competitive inhibition on Km and Vmax, the apparent kcat 
(kcat1’) can be expressed as a function of the effective kcat (kcat1), the 
product c-di-GMP concentration (P10) and the dissociation constants of the 
inhibitors c-di-GMP (Ki) and YfiR (Kr): 
 𝑘𝑐𝑎𝑡1′ =    𝑘𝑐𝑎𝑡11+ 𝑃10𝐾𝑖 ×    1+ 𝑅𝐾𝑟  
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Based on Equation 5 (2.5.4.2), the reaction rate of c-di-GMP production can 
be expressed as follows: 
 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛  1 =    𝐸1 ×   𝑆1 ×  𝑘𝑐𝑎𝑡1′(𝐾𝑚1+ 𝑆1 )  
 
For the GTPases (enzyme 2) a time-dependent inactivation was observed 
that was accounted for by the introduction of an additional parameter “t1/2” 
to the formula.  
 𝑘𝑐𝑎𝑡2! =   𝑘𝑐𝑎𝑡2×  (𝑒 !!!!/!) 
 
Analogous to reaction 1, reaction 2 can therefore be expressed as follows: 
 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛  2 =    𝐸2 ×   𝑆1 ×  𝑘𝑐𝑎𝑡2(𝐾𝑚2+ 𝑆1 )   ×  𝑒 !!!_!!"# 
 
The total reaction rate !"!"  is therefore a sum of both reactions that are 
taking place in the system simultaneously and can be expressed as follows: 
 𝑑𝑃𝑑𝑡 = 𝑘𝑐𝑎𝑡1!  𝑥   𝐸1 𝑥   𝑆1𝐾𝑚1+ 𝑆1 + 𝑘𝑐𝑎𝑡2!  𝑥   𝐸2 𝑥   𝑆1𝐾𝑚2+ 𝑆1  
 
Equation 8 
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3.2.1.4.3 Experimental setup used to quantify DGC activity 
 
Membranes containing YfiN were prepared as described in section 2.4 and 
used for a series of experiments using different conditions. In a first 
experiment (I), the membranes were incubated with reaction buffer (50 mM 
Tris-HCl, pH 8.0, 200 mM NaCl, 5 mM MgCl2) containing 2 mM GTP to 
screen for DCG activity. In a second experiment (II), the reaction buffer 
was supplemented with 155 µM c-di-GMP in addition to 2 mM GTP to 
verify if potential DGC activity could be abolished by non-competitive 
product inhibition. In a third experiment (III), 148 µM purified YfiR was 
added to the membranes in buffer containing 2.2 mM GTP to test if YfiR is 
inhibiting YfiN also in vitro. Two negative controls were included as well, 
incubating either GTP or c-di-GMP in the reaction buffer over the same 
amount of time as the experiments. Samples were then taken and analyzed 
at the start and at the end of the experiment, which revealed complete 
stability of the nucleotides over the time-course investigated  (data not 
shown).When incubated with membranes, there is a clear indication that 
GTP got turned over to either GDP or c-di-GMP and indirectly to GMP 
over time (Figure 3-6 (A), (C), (E)). The appearance of GDP as a side-
product indicates that other enzymes, notably GTPases, are present in the 
membranes and show catalytic activity. However, this activity is clearly 
slowing down within the first 30 min of the experiments, most probably due 
to inactivation of the proteins in question. This observation was accounted 
for by introducing an additional parameter, “t1/2”, to the formula used to fit 
the data (3.2.1.4.2, Equation 8), which described the half-life of the 
GTPases. 
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I 
II 
III 
Figure 3-6: Activity test using membranes containing YfiN + 2 mM GTP (first row, experiment I), 2 
mM GTP + 155 µM c-di-GMP (second row, experiment II) and 2.2 mM GTP + 148 µM YfiR (third 
row, experiment III). (A)(C)(E) The obtained chromatograms showing nucleotide turnover after 
different time points: green (20 sec), orange (30 min), black (120 min), blue (240 min) and purple 
(360 min). The different species are labeled accordingly. (B)(D)(F) The peak areas of the data 
points were plotted against the time and fitted to a Michaelis-Menten model (Equation 5).  GMP 
production was not included in the model as only minor amounts were generated and the reaction is 
not interferring with the GTPase and diguanylate cyclase activity. Data points are colored in black 
(GMP), pink (GDP), green (GTP) and blue (c-di-GMP). The experimentally obtained peak areas of 
GMP, GDP, GTP and c-di-GMP were summed up (grey diamonds) and the theoretical sum of the 
nucleotides is marked with a grey bar. 
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All three data sets were evaluated in the following way. First, the kinetic 
constant, kcat2, which stands for the turnover rate of the GTPases, was 
fitted for each experiment individually (Figure 3-6, (B), (D), (F), pink line). 
For experiment I, only the first three data points were used for the fitting as 
a decrease of absorption was observed, which cannot be explained by the 
applied model. For the same reason the last data point was omitted for 
fitting in experiment II.  
In a second step, the kcat1, which describes the turnover rate of the 
DGC(s), was fitted for each experiment individually and the resulting curve 
was plotted in blue (Figure 3-6, (B), (D), (F), blue line). As it was observed 
before for the kcat2 value, the last two data points of experiments I and II 
were decreasing and hence they were omitted for the fitting.  
As the decrease in GTP concentration can be exclusively attributed to the 
synergistic activities of DGCs and GTPases, the previously individually 
fitted kcat values (kcat1, kcat2) were then used as input values for each 
experiment and the decrease in substrate concentration was chosen as an 
output. This yielded a progression curve that was reflecting the decrease in 
substrate concentration as a function of the two kcat values (Figure 3-6, 
(B), (D), (F), green line).   
In addition to GDP, GMP was observed as a side-product, however, only 
very small amounts were detected. The GMP-producing activity was found 
to be interfering with neither DGCs nor GTPases, as both enzymes were 
still in full substrate saturation, and therefore the activity was neglected for 
the fitting procedure.  
It was observed that a small amount of nucleotides was lost during the 
course of all three experiments, often starting around prolonged incubation 
times (Figure 3-6, (B), (D), (F), grey data points). For experiments I and II, 
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the sum of all nucleotides at the end of the experiment was still comparable 
to the amount present in the beginning of the experiment.  Nucleotide loss 
was especially pronounced in experiment III, possibly explaining the rather 
large discrepancy between the theoretical GTP progression curve and the 
actual amount of GTP present in the sample (Figure 3-6, green data points 
and green line). The experiments should be repeated in order to establish if 
this observations  
In a final step, global fitting of the kcat1 and the Kr, which is the 
dissociation constant of the YfiR-YfiN binding, was performed based on 
DGC activity data from all three experiments and the resulting curves were 
plotted in Figure 3-7. An overview of all input and output parameters used 
for the fitting is presented in Table 3-4.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7: DGC activity, which was observed in the presence of GTP 
only (experiments I, green data points), GTP and c-di-GMP (experiment 
II, blue data points) as well as GTP and YfiR (experiment III, red data 
points).  
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Table 3-4: Summary of all input and output parameters described in the Michaelis-Menten model 
that was used for fitting of the data. Columns 2-4 report values that were obtained by individual 
fitting of the data, whereas in column 5 globally fitted values are stated. Numbers 1 and 2 in 
conjunction with a term indicate that the value is either associated with the DGC activity (1) or the 
GTPase activity (2). The symbol “=” indicates that the number marked in one of the columns was 
the same for all three experiments. [E1] and [E2] represent the unknown concentrations of the DGC 
and GTPases, which were fixed at 1 nM each. The substrate concentration is in-fact made up of two 
contributions, as even a freshly prepared GTP [S] stock shows a GDP contamination [P20], which 
amounts to roughly 5 % of the total concentration ([S]+[P20]). [P10] and [R] refer to the 
concentrations at which c-di-GMP and YfiR were added to the experimental set-up.  Km1 and Ki1 
are associated with the diguanylate cyclase(s), whereas Km2 refers to the GTPases. As the GTPase 
activity decreased steadily over time, most probably caused by inactivation of the proteins, the 
parameter “t1/2” was introduced to account for this observation. “t_start” is referring to the time 
delay between setting up the experiment and the heat inactivation of the protein for the first time 
point sample. The three scaling factors are relating the determined peak area to the corresponding 
concentrations of each nucleotide. The kcat1 and kcat2 values referring to the turnover rate (relative 
units) of either DGC or GTPase, were refined locally for each dataset and the resulting ratio is 
indicated in the last row. In addition, kcat1 and Kr were fitted globally using the DGC activity data 
from all three experiments. The scaling factors (sc0,sc1,sc2) are required to convert the obtained 
peak areas into concentrations of the nucleotides. 
 
GTP GTP + c-di-GMP 
GTP + 
YfiR 
Global fit of 
data 
Unrefined 
parameters    
 [E1] [M] (DGC) 1.00E-09 = = 
 [E2] [M] (GTPase) 1.00E-09 = = 
 [S] [M] 1.90E-03 = 2.09E-03 
 [P10] [M] (c-di-
GMP) - 1.55E-04 - 
 [P20] [M] (GDP) 1.00E-04 = 1.10E-04 
 [R] [M] (YfiR) - - 1.48E-04 
 Km1 [M] 4.00E-05 = = 
 Km2 [M] 4.00E-05 = = 
 Ki1 [M] 1.00E-06 = = 
 t1/2 [s] 2000 = = 
 t_start [s] -800 = = 
 sc0 (GTP) 4.20E+05 = = 
 sc1 (c-di-GMP) 8.40E+05 = = 
 sc2 (GDP) 4.20E+05 = = 
 Refined 
parameters 
    kcat1 [rel. units] 
(DGC) 5676.5 4205.9 4533.7 5095.8 
kcat2 [rel. units] 
(GTPase) 394.4 427.4 363.9 
 Kr [M] - - 2.83E-05 2.53E-05 
Ratio 
kcat1/kcat2 14.4 9.8 12.5  
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 Solubilization and purification of YfiN  3.2.1.5
 
The first step of the purification of YfiN was its extraction from the inner 
membrane. Therefore, the total membrane fraction was collected and 
incubated in three different experiments with the same buffer supplemented 
with various detergent concentration for solubilization/purification: 21 
mM/3 mM DM, 20 mM DDM/0.3 mM DDM and 51 mM/35 mM β-OG. 
The solubilization process was allowed to take place for one hour with 
steady stirring applied. After a centrifugation step to separate the 
solubilized fraction from the residual insoluble material, the supernatant was 
then loaded onto a 5 mL HisTrap column for a subsequent Ni-affinity 
chromatography. Already at this stage it became evident that barely no 
protein (48.8 kD) was extracted when β-OG was used as detergent (Figure 
3-8) and therefore, no further SEC was pursued and the experiment was 
terminated.  
 
 
 
 
 
 
Figure 3-8: IMAC purification step of YfiN solubilized by β-OG. (A) Chromatogram of YfiN 
purification by IMAC using a 5 mL HisTrap column. (B) SDS-PAGE illustrating each step of YfiN 
purification: 1: marker, 2: whole cell, 3: non-solubilized membrane fraction, 4: load IMAC, 5: flow-
through IMAC, 6: IMAC 45 mL-50 mL, 7: IMAC 50 mL-55 mL, 8: IMAC 55 mL-60 mL, 9: IMAC 60 
mL-65 mL, 10: IMAC 65 mL-70 mL, 11: IMAC 70 mL-75 mL, 12: IMAC 75 mL-80 mL, 13: IMAC 80 
mL-85 mL, 14: IMAC 85 mL-90 mL. 
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Figure 3-9: IMAC purification step of YfiN solubilized by DM. (A) Chromatogram of YfiN 
purification by IMAC using  5 mL HisTrap column. The major part of YfiN starts eluting at an 
imidazole concentration of 300 mM. Fractions pooled and used for subsequent purification are marked 
by a line. (B) SDS-PAGE illustrating each step of YfiN purification: 1: marker, 2: whole cell, 3: non-
solubilized membrane fraction, 4: load IMAC, 5: flow-through IMAC, 6: IMAC 45 mL-50 mL, 7: 
IMAC 50 mL-55 mL, 8: IMAC 55 mL-60 mL, 9: IMAC 60 mL-65 mL, 10: IMAC 65 mL-70 mL, 11: 
IMAC 70 mL-75 mL, 12: IMAC 75 mL-80 mL, 13: IMAC 80 mL-85 mL, 14: IMAC 85 mL-90 mL, 15: 
85 mL-90 mL. 
The solubilization capacity of DM (Figure 3-9) was found to be superior to 
the one from DDM (Figure 3-11) but nonetheless a size-exclusion 
chromatography was performed for both of them to screen for the quality of 
the protein. A huge aggregation peak was observed for both detergents after 
SEC, with only very little protein not eluting in the void volume in the case 
of DM (Figure 3-10). Due to time limitations, it was decided to proceed 
with DM as detergent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-10: SEC purification step of YfiN solubilized by DM. (A) Chromatogram of YfiN 
purification by gel filtration chromatography using a HiLoad- 26/60-Superdex-200 prep grade column. 
(B) SDS-PAGE illustrating each step of YfiN purification: 1: marker, 2: SEC 110 mL-114 mL, 3: SEC 
114 mL-118 mL, 4: SEC 118 mL-122 mL, 5: SEC 122 mL-126 mL, 6: SEC 126 mL-130 mL, 7: SEC 
162 mL-166 mL, 8: SEC 166 mL-170 mL, 9: marker, 10: SEC 162 mL-166 mL, 11: 166 mL-170 mL, 
12: SEC 170 mL-174 mL, 13: SEC 186 mL-190 mL, 14: SEC 190 mL-194 mL, 15: SEC 194 mL-198 
mL. Fractions pooled and used for subsequent activity assays are marked by a line. 
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The SEC for DM-solubilized YfiN was run at the very low flowspeed of 0.2 
mL/min to separate the protein from a nucleotide that has been found 
bound (Figure 3-12).  
 
 
 
 
 
 
Figure 3-12: The obtained absorption spectra of YfiN before (A) and after (B) SEC illustrating 
nucleotide binding.  
Figure 3-11: IMAC and SEC purification steps of YfiN solubilized by DDM. (A) Chromatogram of 
YfiN purification by IMAC using  5 mL HisTrap column. The major part of YfiN starts eluting at an 
imidazole concentration of 300 mM. Fractions pooled and used for subsequent purification are marked 
by a line. (B) SDS-PAGE illustrating each step of YfiN purification: 1: marker, 2: whole cell, 3: non-
solubilized membrane fraction, 4: load IMAC, 5: flow-through IMAC, 6: IMAC 45 mL-50 mL, 7: 
IMAC 50 mL-55 mL, 8: IMAC 55 mL-60 mL, 9: IMAC 60 mL-65 mL, 10: IMAC 65 mL-70 mL, 11: 
IMAC 70 mL-75 mL, 12: IMAC 75 mL-80 mL, 13: IMAC 80 mL-85 mL, 14: IMAC 85 mL-90 mL. (C) 
Chromatogram of YfiN purification by gel filtration chromatography using a HiLoad- 26/60-Superdex-
200 prep grade column revealing only aggregated protein.   
Results 
 
   110 
YfiN has been shown to co-elute with c-di-GMP before by Malone et al. 
[12]. 500 µl of the aggregation peak (Figure 3-10(A)) were removed, cooked 
at 75 °C for 10 min and the precipitate was collected by centrifugation. The 
resulting supernatant was diluted 1:10 with running buffer (5 mM 
NH4HCO3, pH 8.0), loaded onto a 5 mL ResQ column and analyzed by 
FPLC. C-di-GMP was included as a reference (Figure 3-13). 
 
 
 
 
 
 
 
 
 
 
 
 
The bound nucleotide was identified as c-di-GMP as it eluted at the same 
position as the c-di-GMP reference (Figure 3-13). The observed 260/280 
ratio before SEC amounted to 1.15 (Figure 3-12, (A)), corresponding to a 
YfiN:c-di-GMP ratio of 1:1.5. After SEC a molar ratio of 1:0.3 was obtained, 
corresponding to almost nucleotide-free protein.  
SEC fractions, which contained YfiN eluting from 162 mL-174 mL and 186 
mL-198 mL (Figure 3-10), corresponding to the small peaks 2 and 3, were 
Figure 3-13: Superposition of the absorption spectras of c-
di-GMP (green) and the supernatant of YfiN (blue), 
recorded at 253 nM. Both nucleotides were loaded onto a 5 
mL ResQ column and eluted by a gradient of 0.005 M to 1 
M NH4HCO3. 
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concentrated to 1 mg/mL each and analyzed by dynamic light scattering 
(DLS).  
 
 
Hydrodynamic 
radius ± SD [nm] 
Estimated MW ± SD 
[kD] 
% 
Polydispersity 
Peak 2 4.36 ± 1.92 105.6 ± 51.5 50.4 
Peak 3 3.77 ± 1.38 74.9 ± 29.9 42.6 
Table 3-5: The hydrodynamic radius as well as the corresponding molecular weight of YfiN eluting in 
peak 2 and 3 was determined by DLS. 
 
The size of of a YfiN monomer amounts to 48.8 kD, whereas a DM micelle 
has the size of a globular protein of roughly 60-70 kD [146]. As the observed 
standard deviations are quite high, it is difficult to get a reliable estimation 
of the oligomeric state of YfiN in solution (Table 3-5). Peak 3 could 
correspond to a monomer, whereas peak 2 most probably corresponds to a 
slightly different, e.g. more elongated monomeric state. The data is 
discussed in more detail in 3.5.2. Unfortunately, an attempt to get more 
reliable information about the oligomeric state of YfiN by multiple-angle 
laser light-scattering (MALLS) failed due to the necessary strong 
concentration of the protein, resulting in too high detergent concentrations 
present in the sample (data not shown). It was decided to go ahead with the 
protein from the two peaks, as even when the oligomeric state was not 
resolved, the protein clearly was not aggregated and therefore presumably 
suited for an activity assay. 
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 Enzymatic characterization of detergent-solubilized YfiN using the 3.2.1.6
malachite-green assay  
 
 Establishing the assay in a 96-well plate format using the well 3.2.1.7
characterized DGC DgcZ 
 
Before carrying out the assay with YfiN, DgcZ was used as a reference 
protein to verify if the previously obtained kcat values could be reproduced 
if the assay was performed in a 96-well format [111], [147] . Therefore, 200 
nM zinc-free DgcZ was incubated with either 1 µM or 10 µM GTP and 
samples were analyzed after 0 min, 5 min, 10 min, 20 min and 30 min as 
described in section 2.5.3. A negative control was included in both 
experiments, where GTP was incubated with the reaction buffer over the 
time span of the experiment without the addition of protein (Figure 3-14).  
 
 
 
 
 
 
 
The obtained increase in absorption values could be directly linked to the 
amount of generated inorganic phosphate using a scaling factor 
Figure 3-14: Characterizing the activity of DgcZ using the malachite-green assay in a 96-well plate 
format. (A) The obtained absorption values were plotted against the time and fitted to yield the kcat 
value. of 0.19 s-1. (B) The formation of the [malachite green-Pi] complex is leading to the 
characteristic color change from yellow to green, therefore being a direct measure for the amount of Pi 
in the reaction mixture.  
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(5.3299E+04) previously determined by a calibration curve with a 
correlation coefficient of 99.88 %. The linear range of the assay was 
determined to lie between 0 µM and 21 µM Pi, corresponding to an 
absorption limit of ~ 0-1.5 [AU]. The resulting kcat was determined to be 
0.19 s-1, which is in agreement with the previously determined kcat of 0.6 s-1 
[111]. The malachite green assay has therefore been successfully established 
in the 96-well plate format for the characterization of DGC activity.  
 
 Using the established protocol to characterize the activity of 3.2.1.8
detergent-solubilized YfiN 
 
Before presenting the performed experiments, it has to be mentioned that 
the presumable DGC activity observed in one of the following experiments 
was actually due to a GTPase contamination in the YfiN sample. The 
nature of the assay does not allow discrimination between GTPase activity 
and DGC activity if pyrophosphatase (PPase) is present in the sample, as 
both lead to the production of inorganic phosphate, which is the readout of 
the assay. As the assay has been used before by others to characterize DGC 
(+PPase) as well as PDE (+alkaline phosphatase, AP) activity and none 
actually routinely included a negative control omitting the PPase/AP, it 
was not evident in the beginning to perform said negative control. However, 
after having observed that a YfiR sample incubated with GTP showed very 
low enzymatic activity (Figure 3-18), most likely due to a GTPase 
contamination, an experiment was conducted, where YfiN was incubated 
with GTP in presence and absence of PPase (Figure 3-15, Table 3-6). 
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The experiment showed that in presence and absence of PPase, the same 
initial slope was obtained, confirming that the observed activity is not 
caused by a DGC but by a GTP-hydrolyzing enzyme. Incubation of YfiN 
and GTP without PPase should not lead to any change in signal as it 
exclusively produces pyrophosphate, which is not detected by the assay.  
Table 3-6: Summary of the data fitted by linear regression to obtain the initial velocity v of the 
protein. vcorr stands for the corrected intial velocity where the value of the negative control was 
substracted to take potential GTP hydrolysis as well as other effects into account. 
 100 µM GTP v [µM/s] vcorr [µM/s] 
2.3 µM YfiN + 
PPase 
- 3.8E-5  
+ 3.6E-4 4.5E-4 
2.3 µM YfiN - PPase + 3.1E-4 4.0E-4 
no protein 
- 0.0  
+ 4.7E-5  
Figure 3-15: Activity assay in presence and absence of PPase. (A) The measured absorption values 
were plotted against the time and linear fit of the data was performed. For both experiments (YfiN + 
GTP + PPase) and (YfiN + GTP – PPase), only the first three data points were used for the fitting, 
in order to compare only the initial slopes of the curves and to exclude data that might not be lying 
in the linear range of the assay anymore. The resulting fits are indicated by solid lines and are colored 
according to the experiment: YfiN + GTP + PPase (red), YfiN + GTP - PPase (blue), YfiN + buffer 
(green), GTP + buffer (brown) and buffer alone (pink). (B) Time-course of the activity showing the 
formation of the molybdophosphoric acid complex, which is directly related to the free inorganic 
phosphate concentration.  Lanes 1-5 correspond to the following time-points: 24 hours, 20 hours, 6 
hours, 4 hours and 0 hours. Row A shows the buffer only control, row B the YfiN + buffer control, 
row C the GTP + buffer control, row D the YfiN + GTP + PPase time-course and row E the YfiN + 
GTP time-course. 
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In the following, the performed experiments are nonetheless described to 
demonstrate how characterization of the presumable YfiN activity was 
tackled. 
For the first activity test, YfiN was used directly after eluting from SEC 
without further concentrating the protein. The overall concentration was 
thus very low, amounting to less than 100 nM protein. The three different 
SEC peak fractions containing YfiN were kept separate and each of them 
was screened for potential activity. GTP was present at a concentration of 
20 µM for all experiments and a negative control, containing only GTP and 
buffer was included as well.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3-16: Malachite green assay using unconcentrated YfiN 
directly eluted from SEC. The measured absorption values were 
plotted against the time and linear fit of the data was 
performed.  
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The starting point of the negative control was clearly an outlier, most 
probably due to a pipetting error, as the value was even higher than in the 
experiments containing GTP and protein (Figure 3-16). Overall, no clear 
trend could be detected for any of the peaks. Instead, the data seemed to 
rather fluctuate randomly, most probably due to the very low protein 
concentration, leading to little or no change in signal (Table 3-7).  For the 
next experiments it was thus decided to concentrate the protein after SEC. 
In the next experiment, YfiN was present at a final concentration of 2.5 µM 
and thus had to be strongly concentrated due to repeatedly low protein 
yields, leading to a simultaneous increase of DM present in the sample. In a 
second experimental set-up, YfiR was added to YfiN in a final concentration 
of 7.5 µM, to check if inhibition of the potential DGC activity is taking 
place.  Based on these concentrations, a simulation was made assuming 
different Kd-values for the YfiR([A0])-YfiN(B0]) interaction, what 
concentration of the complex [AB] is obtained using the equation derived in 
2.5.4.1. A complex concentration of 2.5E-06 M therefore corresponds to the 
 20 µM GTP v [µM/s] vcorr (µM/s) 
SEC peak 1 + -9.5E-06 1.0E-04 
SEC peak 2 + -1.8E-05 9.2E-05 
SEC peak 3 + 4.7E-06 1.15E-04 
no protein + -1.1E-04 - 
Table 3-7: Summary of the data fitted by linear regression to obtain the initial velocity v of the 
protein.   vcorr stands for the corrected initial velocity where the value of the negative control was 
subtracted to take potential GTP hydrolysis into account. 
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maximum, as it is limited by the lowest concentration of the individual 
components forming the complex, which was in this case YfiN. 
 
 
 
 
 
 
 
 
 
 
 
 
[A0] [M] [B0] [M] Kd [M] [AB] [M] 
7.5E-6 2.5E-6 1.0E-6 2.1E-6 
7.5E-6 2.5E-6 1.0E-5 9.9E-7 
7.5E-6 2.5E-6 5.0E-5 3.1E-7 
7.5E-6 2.5E-6 1.0E-4 1.7E-7 
Table 3-8: Complex concentrations [AB] that are expected assuming different Kd values for the YfiR-
YfiN interaction and [A0] = 7.5E-6 M and [B0] = 2.5E-6 M.  
 
According to the simulation, only a Kd of 1.0E-06 M would lead to an 
almost fully complexed YfiN at the concentrations used in the experiment, 
whereas for the other Kds, the amount of the expected complex is 
significantly reduced (Table 3-8).  
In addition to the two experiments containing either YfiN alone or YfiN in 
presence of YfiR, a third experiment was set up, where 25 µM c-di-GMP 
Figure 3-17: Theoretical concentrations of the complex [AB] in 
relation to varying concentrations of [A0], assuming different Kd-
values values for the YfiR-YfiN interaction. [B0] amounted to 2.5E-06 
M, thereby posing the upper limit for the expected amount of 
complex.  
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was added to the protein to check if non-competitive product inhibition is 
taking place. In all three experiments, GTP was present at a concentration 
of 20 µM. Negative controls included incubation of either the protein alone 
or GTP alone in buffer and incubation of YfiR in presence of GTP and 
buffer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-18: The measured absorption values were plotted against the 
time and linear fit of the data was performed. For all three 
experiments (YfiN + GTP, YfiN + GTP +YfiR as well as YfiN + 
GTP + c-di-GMP), only the first four data points were used for the 
fitting, in order to compare only the initial slopes of the curves and to 
exclude data that might not be lying in the linear range of the assay. 
The resulting fits are indicated by solid lines and are colored 
according to the experiment: YfiN + GTP (red), YfiN + GTP + 
YfiR (blue), YfiN + GTP + c-di-GMP (purple), YfiR + GTP (blue-
green), YfiN + buffer (green) and GTP + buffer (brown). 
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Table 3-9: Summary of the data fitted by linear regression to obtain the initial velocity v of the 
protein in absence of any inhibiting agent or in presence of either YfiR or c-di-GMP.   vcorr stands for 
the corrected initial velocity where the value of the corresponding negative control(s) was/were 
subtracted to take into account potential GTP hydrolysis or other effects. The cells containing the 
final initial velocities exhibited by YfiN in all conditions investigated are colored according to the 
same color scheme as in Figure 3-18 to facilitate comparison. Accordingly, the catalytic activity 
observed in the YfiR sample was colored in green.  
 
As indicated by the data (Table 3-9), there was no significant difference in 
initial slopes detectable. This can be explained by the fact that the observed 
signal change was not due to the activity of YfiN but the GTPase 
contamination present in the sample, which is neither regulated by YfiR nor 
product-inhibited by c-di-GMP. YfiR most likely was contaminated with a 
GTPase as well as it showed low enzymatic activity, which was in the same 
range as the YfiN sample. Both activities appear very low, however 
considering the fact that YfiN as well as YfiR are 99 % pure according to an 
SDS-PAGE (Figure 3-19) and thus only very minor amounts of GTPases 
are present, their kcat-values are actually considerably high.  
 
 
 
 
 20 µM GTP 7.5 µM YfiR v [µM/s] vcorr [µM/s]  
2.5 µM YfiN 
- - 4.3E-07 - 
+ - 3.7E-04 3.8e-04 
+ + 4.2E-04 4.3e-04 
2.5 µM YfiN 
+ 25 µM cdG + - 4.4E-04 4.5e-04 
no protein 
+ - -1.2E-05 - 
+ + 1.4E-04 1.5e-04 
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3.3 Individual domains of YfiN 
3.3.1 The periplasmic PAS domain 
 Design and cloning of the YfiNPAS constructs 3.3.1.1
 
In the beginning of this project, the YfiN sequence was subjected to 
transmembrane-prediction analysis using TMHMM to determine the 
boundaries of the periplasmic PAS domain [148]. The first transmembrane-
helix was predicted to range from residues 21-43 and the second one from 
residues 155-177. The sequence corresponding to the PAS domain was then 
subjected to HHPred analysis, to screen for already existing structures of 
structurally closely related proteins. This search resulted in four templates 
with an E-score higher than 10-7 (Table 3-10, E-value 2011), with the 
highest score being 10-9.  
Figure 3-19: An SDS-PAGE illustrating the puritiy of the YfiN and YfiR 
stock solution as well as the complex mixture. 1) marker, 2) YfiN stock 
solution (4.5 µM), 3) YfiR stock solution (15 µM), 4) YfiN-YfiR complex 
sample. 
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PDB identifier template protein 
Sequence 
identity [%] E-value, 2011 E-value, 2014 
1p0z CitA 21 1.7E-09 2.8E-05 
3b42 GSU0935 MCP 17 2.9E-07 9.1E-07 
3by8 DcuS 13 1.0E-08 2.1E-03 
3b47 GSU0582 MCP 14 4.4E-07 3.2E-06 
3pjv LapD 15 1.6E-04 6.4E-07 
Table 3-10: A list of the four proteins identified by HHPred in 2011 that showed an E-value which 
was larger than 10-4. The corresponding PDB identifiers and the sequence identities between YfiN and 
the template proteins are indicated. In 2014, the same procedure was repeated, yielding different E-
values and an additional template. 
 
In 2014, the same procedure was repeated, thereby revealing that the E-
values drastically changed for most proteins. As the PAS domain of LapD 
ranked now amongst the best, it was included as well for the design of an 
additional construct. The HHPred alignment of YfiN against the five 
template proteins revealed that all except LapD proposed the same starting 
residue at the N-terminal end, which was T44 (data not shown). In the case 
of LapD, the alignment suggested a slightly longer construct, starting at 
residue T38. For the design of the C-terminal end, again slightly different 
construct lengths were obtained. In CitA and DcuS, the structures revealed 
a well-ordered C-terminal end, which was found to be forming α6 of the 
classical periplasmic PAS fold (Figure 1-3). Based on these two structures, a 
construct was designed, which was encompassing the whole predicted PAS 
domain of YfiN, ranging from residues 44-154 (Table 3-11). 
The structures of 3b42 and 3b47 revealed a C-terminal end, which was 
involved in β–strand formation, followed by an unstructured linker of 
roughly 10 residues. The end of the structured region of the proteins aligned 
to residue G149 in YfiN and therefore a second, slightly shorter construct 
was generated accordingly, encompassing residues 44-149 (Table 3-11).  
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 In agreement with CitA and DcuS, the C-terminal end of LapD was found 
to be well-structured and engaged in helix formation. However, the last 
ordered residue of the construct was matched to residue G159 in YfiN in the 
HHPred alignment, thus suggesting a slightly longer construct than CitA 
and DcuS, encompassing residues 38-159 (Table 3-11).  
 
 
 
 
 
 
 
 
 Expression of the YfiNPAS constructs 3.3.1.2
 
All three C-terminally his-tagged YfiNPAS constructs (38-159, 44-149, 44-154) 
exclusively got expressed in inclusion bodies, with only very little soluble 
expression for YfiNPAS44-149 (data not shown). Neither expression of the 
constructs at 10 °C overnight in ArcticExpress™ nor the usage of the BL21-
AI™ strain to control potential leaky expression resulted in increased yields 
of soluble protein. Therefore, it was decided to fuse YfiNPAS38-159 and 
YfiNPAS44-149 to either a SUMO-(12 kD), GST- (26 kD) or MBP-tag (42 kD). 
Expression tests of the N-terminally fusion-tagged YfiNPAS constructs were 
performed in either LB–or TB-medium using the BL21(DE3) strain at either 
YfiNPAS 
construct length 
Template 
proteins 
PDB 
identifier 
38-159 LapD 3pjv 
44-149 
GSU0935 3b42 
GSU0582 3b47 
44-154 
CitA 1p0z 
DcuS 3by8 
 Table 3-11: Overview of the YfiNPAS constructs investigated within 
the framework of this thesis and the underlying template proteins 
used for their design. 
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20 °C or 30 °C . Protein expression was induced by the addition of 250 µM 
or 50 µM IPTG in the case of LB-medium or TB-medium, respectively. 
Overall, expression levels did not change in relation to the presence or 
absence of a C-terminal his-tag, therefore only the his-tagged constructs will 
be considered in the following.  
MBP-tagged YfiNPAS38-159 -and YfiNPAS44-149, led to the highest expression 
levels using TB-medium and an expression duration of 4 hours at 30 °C for 
YfiNPAS38-159 and 20 °C overnight for YfiNPAS44-149. Exemplarily, two expression 
gels are shown in Figure 3-20. For protein production, bacteria were 
cultivated in a 2 L scale with the conditions established in the expression 
tests. 
 
 
 
 
 
 
 
 
Figure 3-20: SDS-PAGE of the expression tests of YfiNPAS38-159 and YfiNPAS44-149. The condition chosen 
for expression is marked in bold. The same amount of cells was loaded in each lane. (A) YfiNPAS38-159 
: 1: marker, 2: before induction, 3: insoluble fraction (2h of expression at 30 °C), 4: soluble fraction 
(2h of expression at 30 °C), 5: insoluble fraction (4h of expression at 30 °C), 6: soluble fraction (4h 
of expression at 30°C), 7: insoluble fraction (5h of expression at 20 °C), 8: soluble fraction (5h of 
expression at 20 °C), 9: insoluble fraction (overnight expression at 20 °C), 10: soluble fraction 
(overnight expression at 20 °C). (B) YfiNPAS44-149: lanes 3-8 correspond to the GST-tagged construct, 
whereas lanes 9-14 correspond to the MBP-tagged construct. 1: marker, 2: before induction, 3: 
soluble fraction (3h of expression at 30 °C), 4: insoluble fraction (3h of expression at 30 °C) 5: 
soluble fraction (5h of expression at 20 °C), 6: insoluble fraction (5h of expression at 30 °C), 7: 
soluble fraction (overnight expression at 20 °C), 8: insoluble fraction (overnight expression at 20 °C), 
lanes 9-14: same as lanes 3-8 just fort he MBP-tagged construct.  
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 Purification of the YfiNPAS constructs 3.3.1.3
 
C-terminally his-tagged YfiNPAS44-149 was purified as described in 2.2.2.2. The 
SEC revealed one peak eluting at 40 mL, corresponding to aggregated 
protein (data not shown). In addition, SDS-PAGE analysis revealed the 
presence of numerous contaminants, eluting together with in the aggregated 
YfiNPAS44-149 during SEC. As only very minor amounts of the protein of 
interest were obtained throughout the experiment, the focus was shifted 
towards refolding the protein expressed in inclusion bodies.   
Inclusion bodies were prepared and solubilized as described in 2.2.2.3. As 
expected, large amounts of refolded protein were obtained after IMAC, 
however the subsequent SEC revealed the presence of exclusively aggregated 
YfiNPAS44-149 once again (data not shown). As all the C-terminally his-tagged 
PAS constructs were either not expressed in a soluble form or showed minor 
soluble expression but aggregation-prone behavior, the focus was shifted 
towards the fusion-tagged constructs at this stage. 
Both MBP-tagged YfiNPAS38-159 -and YfiNPAS44-149 constructs were purified as 
described in 2.2.2.2. In the following, only results from YfiNPAS38-159 are shown 
as both constructs behaved in the same way. A chromatogram of a typical 
run is shown in Figure 3-21(A) and the corresponding SDS-PAGE is shown 
in Figure 3-21(B).  
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MBP-tagged YfiNPAS38-159 started eluting at a maltose concentration of about 
1.5 mM, which resulted in a high yield of almost pure fusion-protein. The 
SDS-PAGE showed an additional band running slightly below 15 kD, which 
indicated the presence of the C-terminally his-tagged YfiNPAS38-159 lacking the 
MBP-tag. After Ni-chromatography, MBP-tagged YfiNPAS38-159 was subjected 
to gel filtration as a final purification step.  
 
 
 
 
 
Figure 3-21: IMAC purification step of MBP-tagged YfiNPAS38-159. (A) Chromatogram of YfiNPAS38-159 
purification by IMAC using  5 mL MBPTrap column. The maltose gradient is ranging from 0 mM to 
10 mM in 5 CV. Fractions pooled and used for subsequent purification are marked by a line. (B) 
SDS-PAGE illustrating each step of the purification: 1: marker, 2: whole cell, 3: load MBPTrap, 4: 
flow-through MBPTrap, 5: IMAC 0 mL-5 mL, 6: IMAC 5 mL-10 mL, 7: IMAC 10 mL-15 mL, 8: 
IMAC 25 mL-30 mL, 9: IMAC 30 mL-35 mL, 10: IMAC 35 mL-40 mL. 
Figure 3-22: SEC purification step of MBP-tagged YfiNPAS38-159 using a S75 16/60 column. (A) 
Chromatogram of MBP-tagged YfiNPAS38-159 purification by gel filtration chromatography using a 
HiLoad- 16/60-Superdex-75 prep grade column. (B) SDS-PAGE illustrating each step of the 
purification: 1:marker, 2: SEC 35 mL-40 mL, 3: SEC 40 mL-45 mL, 4: SEC 45 mL-50 mL, 5: SEC 50 
mL-55 mL, 6: SEC 55 mL-60 mL, 7: SEC 60 mL-65 mL, 8: SEC 65 mL-70 mL, 9: SEC 70 mL-75 mL, 
10: SEC 75 mL-80 mL. 
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Most of the MBP-tagged YfiNPAS38-159 was eluting in the form of aggregates 
at 40 mL, resulting in a severely trailing peak (Figure 3-22). A second peak 
at 70 mL was observed containing the free MBP-tag, most probably 
stemming from sample degradation. In an attempt to stabilize the fusion-
protein, two additional purifications were performed with buffers that were 
either supplemented with 0.2 % Tween-20 or 50 mM arginine and glutamate 
(data not shown). However, none of these measures led to an optimization 
of protein behavior and the approach, focusing on the isolated PAS domain 
was thus terminated at this stage. Table 3-12 is giving a short overview of 
all the results obtained for the YfiNPAS constructs investigated within the 
frame of this thesis. 
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YfiNPAS 
construct Tag(s) 
Size of 
fusion-
tag [kDa] 
Status 
38-159 
C-his  0.9 No soluble expression in BL21(DE3) at different expression temperatures. 
SUMO,  
+/-  C-his 12.0 
No soluble expression in LB and TB 
medium at the  temperatures tested (20 
°C, 30 °C) 
GST,  
+/- C-his 26.0 
Little soluble expression in TB medium, 
however the protein did not bind to a 
GST-trap in a first experiment 
MBP,  
cyto. and peri., +/-  
C-his 
42.5 
Abundant soluble expression in 
BL21(DE3) using TB-medium but 
SEC revealed a severely trailing 
aggregation peak (30ml) on a S75 
16/60. 
44-149 
C-his  0.9 
No soluble expression in 
ArcticExpress™ or BL21-AI™. 
Little soluble expression in 
BL21(DE3), but SEC revealed loads of 
impurities and aggregation-prone 
protein. 
 On-column refolding of inclusion 
bodies let to aggregated protein. 
SUMO,  
+/- C-his 12 
No soluble expression in LB and TB 
medium at all temperatures tested (20 
°C, 30 °C and 37 °C) 
GST,  
+/-  C-his 26 
No soluble expression in LB and TB 
medium at the temperatures tested (20 
°C, 30 °C) 
MBP,  
cyto. and peri., +/-  
C-his 
42.5 
Abundant soluble expression in 
BL21(DE3) using TB-medium, 
however severe aggregation revealed by 
SEC. 
 Addition of either detergents (0.2 % 
Tween-20) or 50 mM Arg/Glu to the 
buffers did not improve the quality of 
the protein. 
44-154 C-his  0.9 
No soluble expression in 
ArcticExpress™, BL21-AI™ and 
BL21(DE3)  
Table 3-12: A summary of all the results that were obtained for the YfiNPAS constructs investigated 
within the framework of this thesis. The color code is the same as for Table 3-1. 
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3.3.2 The cytoplasmic HAMP and GGDEF domains 
 Design and cloning of the YfiNHAMP-GGDEF constructs 3.3.2.1
 
In P. aeruginosa, the second transmembrane helix from YfiN is predicted to 
range from 155-177 as determined before in section 3.3.1.1. The cytoplasmic 
part is therefore ranging from residues 178-435. This sequence was then 
analyzed by Pfam, SMART and PROSITE [149] to identify the boundaries 
of the cytoplasmic HAMP domain. Both SMART and PROSITE predicted 
the HAMP domain to range from residues 183-236, whereas Pfam predicted 
164-236, including a part of the transmembrane region. The cytoplasmic 
construct was therefore designed to start at residue 178 to add five 
additional amino acids between the start of the construct and the HAMP 
domain in order to raise the chances for proper folding. 
The C-terminal end was designed in analogy to the full-length protein 
(3.2.1.1), resulting in a P. aeruginosa YfiNHAMP-GGDEF construct that 
encompassed the whole cytoplasmic region from residues 178 to 435. Based 
on this construct, a search was launched as described in 2.6.1 to identify 
YfiN homologs that were predicted to crystallize more readily than the one 
from P. aeruginosa. Several additional criteria had to be met by the 
potential candidates, such as the presence of a PAS, HAMP and a GGDEF 
domain as well as an intact operon coding for all three Yfi proteins. 
Ultimately, three homologs were chosen, meeting all of the above stated 
criteria: YfiN from Pseudomonas fluorescens, sharing 66 % sequence identity 
with YfiN from P. aeruginosa, YfiN from Yersinia enterocoliticae with a 
sequence identity of 58 % and YfiN from Sphingopyxis alaskensis with a 
sequence identity of 48 % (Figure 3-23, Table 3-13).  
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Species 
Length of 
cytoplasmic 
part 
Molecular 
weight [kD] 
Sequence 
identity to 
Ps.aer. YfiN 
[%] 
XtalPred 
crystallization 
class 
P. aeruginosa 178-435 29.7 100 3 
P. fluorescens 174-420 27.8 66 2 
Y. enterocoliticae 188-448 30.4 58 2 
S. alaskensis 179-408 26.2 48 1 
Table 3-13: Table summarizing the properties of all four YfiN homologs. 
 
Figure 3-23: Multiple sequence alignment of the cytoplasmic part of YfiN homologs from four different 
species. Ps.aer. stands for P. aeruginosa, Ps.flu. for P. fluorescens, Ye.ent. for Yersinia enterocoliticae 
and Sp.ala. for Sphingopyxis alaskensis. The numbers of the starting and terminal residues are 
indicated. The HAMP– and GGDEF domain residues are marked with a red box and green box 
respectively as predicted by SMART and PROSITE. Functionally important residues as the I-site 
(blue box) or the A-site (purple box) are indicated separately. The multiple sequence alignment was 
generated by CLUSTAL OMEGA [142] [143].  
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Constructs for the three homologs were designed in the same way as for 
Ps.aer, as all of them were predicted to have a well-structured C-terminal 
end, although of slightly different length (Figure 3-24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
Figure 3-24: Pairwise multiple sequence alignment of YfiNHAMP-GGDEF from Ps.aer. and 
Ye.ent. (A) as well as Ps.flu.  and Sp.ala (B)... Secondary structural elements were 
predicted by Jpred [140] and are either shown on the top or the bottom of the sequences. 
Capital letters refer to the HAMP nomenoclature and Greek letters refer to the GGDEF 
nomenoclature. Strictly conserved residues are boxed in white on a red background, and 
highly conserved residues are boxed in red on a white background. Every tenth residue is 
indicated with a dot (.). The α-helix is depicted by a coil, whereas β-strands are depicted 
as an arrow. The alignment was performed using CLUSTAL OMEGA [142] [143]. The 
figure was generated using ESPript [144]. 
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 Expression of the YfiNHAMP-GGDEF constructs 3.3.2.2
 
Expression tests of the four YfiNHAMP-GGDEF were performed either in 
BL21(DE3) or BL21 Star™ (DE3) at three different temperatures of 20 °C, 
30 °C and 37°C. Protein expression was induced with 250 µM IPTG. In 
most of the tested conditions, the constructs were expressed in abundant 
amounts in the soluble fraction The best expression levels were achieved in 
BL21(DE3) at 30 °C using 5 h of induction. Exemplarily an expression gel 
for each construct is shown in Figure 3-25. For protein production, bacteria 
were cultivated on a 2 L scale with the conditions established in the 
expression tests.  
 
 
 
 
 
Figure 3-25: SDS-PAGE of the expression tests of YfiNHAMP-GGDEF from different species. The condition 
chosen for expression is marked in bold. The same amount of cells was loaded in each lane. (A) 
Ps.aer. YfiNHAMP-GGDEF: 1: marker, 2: before ind., 3: soluble fraction (3h of expression at 30 °C), 4: 
insoluble fraction (3h of expression at 30 °C), 5: soluble fraction (5h of expression at 30 °C), 6: 
insoluble fraction (5h of expression at 30 °C), 7: soluble fraction (7h of expression at 30 °C), 8: 
insoluble fraction (7h of expression at 30 °C) (B) Ps.flu. YfiNHAMP-GGDEF: 1: marker, 2: before 
induction, 3: soluble fraction (3h of expression at 30 °C), 4: insoluble fraction (3h of expression at 30 
°C), 5: soluble fraction (3h of expression at 37 °C), 6: insoluble fraction (3h of expression at 37 °C), 7: 
soluble fraction (5h of expression at 30 °C), 8: insoluble fraction (5h of expression at 30 °C), 9: soluble 
fraction (5h of expression at 37 °C), 10: insoluble fraction (5h of expression at 37 °C), 11: soluble 
fraction (7h of expression at 30 °C), 12: insoluble fraction (7h of expression at 30 °C), 13: soluble 
fraction (7h of expression at 37 °C), 14: insoluble fraction (7h of expression at 37 °C). (C) Ye.ent. 
YfiNHAMP-GGDEF: the sample order is the same as in (B), except for 1: before induction, 2: marker. (D) 
Sp.ala. YfiNHAMP-GGDEF: 1: before induction, 2: marker, 3: soluble fraction (3h of expression at 30 °C), 
4: insoluble fraction (3h of expression at 30 °C), 5: soluble fraction (5h of expression at 30 °C), 6: 
insoluble fraction (5h of expression at 30 °C), 7: soluble fraction (3h of expression at 37 °C), 8: 
insoluble fraction (3h of expression at 37 °C), 9: soluble fraction (5h of expression at 37 °C), 10: 
insoluble fraction (5h of expression at 37 °C). 
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 Purification of the YfiNHAMP-GGDEF constructs 3.3.2.3
 
Ps.aer. YfiNHAMP-GGDEF was purified to homogeneity using a two-step 
purification procedure, consisting of Ni-affinity and size-exclusion 
chromatography. After cell lysis with French press, Ni-affinity 
chromatography using a Histrap column was performed. A chromatogram of 
a typical run is shown in Figure 3-26(A) and the corresponding SDS-PAGE 
is shown in Figure 3-26(B). As imidazole concentrations higher than 270 
mM led to almost exclusively aggregated protein (data not shown) the 
IMAC protocol was modified, applying a less steep gradient, which was 
increasing over 15 CV instead of 10 CV. Furthermore, all buffers were 
supplemented with 5 % glycerol to provide a stabilizing effect. Owing to the 
optimized protocol, Ps.aer. YfiNHAMP-GGDEF was eluting almost completely 
pure from the HisTrap at imidazole concentrations of about 150 mM-230 
mM (Figure 3-26(A)). After Ni-chromatography, the protein was subjected 
to gel filtration as a final purification step. Ps.aer. YfiNHAMP-GGDEF ran as one 
single peak at an elution volume of 70 mL (Figure 3-26(C)). According to a 
calibration curve for the present column, this corresponds to a molecular 
mass of 40 kDa. The mass of one Ps.aer. YfiNHAMP-GGDEF chain is 29.7 kD and 
considering the elongated shape of the protein, this elution volume most 
likely corresponds to a monomer. The final yield was about 2.5 mg/L 
culture. At the end of the SEC run, a second peak was observed with an 
inversed 254/280 nm ratio, clearly indicating the presence of a nucleotide 
that was bound to YfiN. The same has been observed before for the full-
length protein in 3.2.1.5 (Figure 3-13), where the co-eluting nucleotide was 
identified as c-di-GMP.  
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.  
 
 
 
 
 
 
 
 
 
 
Figure 3-26: IMAC and SEC purification steps of Ps.aer. YfiNHAMP-GGDEF. (A) Chromatogram of YfiN 
purification by IMAC using a 5 mL HisTrap column. Fractions pooled and used for subsequent 
purification are marked by a line. (B) SDS-PAGE illustrating each step of YfiN purification: 1: 
marker, 2: whole cell, 3: load IMAC, 4: flow-through IMAC, 5: IMAC 40 mL-45 mL, 6: IMAC 45 mL-
50 mL, 7: IMAC 50 mL-55 mL, 8: IMAC 55 mL-60 mL, 9: IMAC 60 mL-65 mL, 10: IMAC 65 mL-70 
mL. (C) Chromatogram of YfiN purification by gel filtration chromatography using a HiLoad- 16/60-
Superdex-75 prep grade column. Pooled YfiNHAMP-GGDEF fractions are marked by a line. (D) SDS-
PAGE illustrating each step of Ps.aer. YfiNHAMP-GGDEF purification. Relevant lanes are marked in bold. 
1: marker, lane 2 and 3: YfiNHAMP-GGDEF samples from a different preparation, 4: SEC 63 mL-68 mL, 5: 
SEC 68 mL-73 mL. 
 
Surprisingly, all four YfiNHAMP-GGDEF constructs appeared to be prone to 
varying degrees of proteolysis during the process of purification. In some 
cases, the large amounts of protein on the SDS-PAGE impeded proper 
differentiation between one and several bands that were running closely 
together (Figure 3-26(D), lane 4). In the following, examples are shown for 
P.flu. (Figure 3-27) and Y.ent. YfiNHAMP-GGDEF (Figure 3-28), purified in the 
same way as described for Ps.aer, illustrating the appearance of either a 
double band or even a triple band after SEC. Sp.ala. YfiNHAMP-GGDEF was 
subjected to proteolysis as well (data not shown). 
Results 
 
   134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-27: IMAC and SEC purification steps of Ps.flu. YfiNHAMP-GGDEF. (A) Chromatogram of YfiN 
purification by IMAC using a 5 mL HisTrap column. Fractions pooled and used for subsequent 
purification are marked by a line. (B) SDS-PAGE illustrating each step of YfiN purification: 1: 
marker, 2: whole cell, 3: load IMAC, 4: flow-through IMAC, 5: IMAC 30 mL-35 mL, 6: IMAC 35 mL-
40 mL, 7: IMAC 40 mL-45 mL, 8: IMAC 45 mL-50 mL, 9: IMAC 50 mL-55 mL. (C) Chromatogram 
of YfiN purification by gel filtration chromatography using a HiLoad- 16/60-Superdex-75 prep grade 
column. (D) SDS-PAGE illustrating each step of Ps.flu. YfiNHAMP-GGDEF purification: 1: marker, 2: 
SEC 40 mL-45 mL, 3: SEC 45 mL-50 mL, 4: SEC 70 mL-75 mL, 5: SEC 75 mL-80 mL, 6: SEC 80 
mL-85 mL. 
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Figure 3-28: IMAC and SEC purification steps of Ye.ent. YfiNHAMP-GGDEF. (A) Chromatogram of YfiN 
purification by IMAC using a 5 mL HisTrap column. Fractions pooled and used for subsequent 
purification are marked by a line. (B) SDS-PAGE illustrating each step of YfiN purification: 1: 
marker, 2: whole cell, 3: load IMAC, 4: flow-through IMAC, 5: IMAC 30 mL-35 mL, 6: IMAC 35 mL-
40 mL, 7: IMAC 40 mL-45 mL, 8: IMAC 45 mL-50 mL, 9: IMAC 50 mL-55 mL, 10: SEC 55 mL-60 
mL. (C) Chromatogram of YfiN purification by gel filtration chromatography using a HiLoad- 16/60-
Superdex-75 prep grade column. Fractions used for crystallization containing non-aggregated species 
that did not show proteolysis are marked by a line (data not shown). (D) SDS-PAGE illustrating 
each step of Ps.flu. YfiNHAMP-GGDEF purification: 1: marker, 2: SEC 40 mL-45 mL, 3: SEC 45 mL-50 
mL, 4: SEC 70 mL-75 mL, 5: SEC 75 mL-80 mL, 6: SEC 80 mL-85 mL. 
 
In order to identify the degradation products, the three Ye.ent. YfiNHAMP-
GGDEF bands detected on a SDS-PAGE (Figure 3-28) were cut out and sent 
for tryptic digest and mass spectrometry analysis. 
 
 Characterization of the degradation products by tryptic digest/MS 3.3.2.4
 
For all three samples, the generated peptides were found distributed 
throughout the protein sequence, indicating that the whole protein was 
flying in the mass spectrometer (Figure 3-29). However, the frequencies at 
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which some of some of the observed peptides occurred quite drastically 
changed depending on the investigated sample. For simplicity reasons, the 
three samples are referred to as follows: sample 1= upper band of the 
observed double band, sample 2= lower band of the observed double band, 
and sample 3= the lowest band appearing on the SDS-PAGE (Figure 3-28). 
 
 
 
Position Sequence 
observed 
area in 
sample 1 
observed 
area in 
sample 2 
observed 
area in 
sample 3 
Location of 
cleavage site 
14-25 ITEVAHNVSR 9.02e+08 1.38e+09 8.32e+08 
full-length 
cytoplasmic 
construct 
61-72 HLTQENDSLAHR 1.67e+07 4.56e+09 4.62e+08 
within the 
HAMP 
domain 
72-84 AAHDSLTGLANR 5.85e+06 3.73e+07 6.47e+08 
between the 
HAMP and 
GGDEF 
domain 
Table 3-14: Table summarizing the position and sequence of the relevant peptides as well as their 
observed frequencies depending on the sample.  
 
Mass spectrometry analysis revealed that the protein got cleaved at two 
different cleavage sites, one located within the HAMP domain and one 
Figure 3-29: Sequence of the cytoplasmic part of Ye.ent. YfiNHAMP-GGDEF. The parts of the protein that 
were observed in the mass spectrometry analysis are underlied in green. The petides relevant for the 
identification of the degradation products are boxed in blue, red and green. The two HAMP helices, 
the interconnecting linker and the beginning of the GGDEF domain are represented schematically. 
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situated between the HAMP and the GGDEF domain. These findings are 
discussed in more detail in section 3.5.4.2. Nonetheless, the cleaved products 
could usually be separated from the full-length cytoplasmic YfiN constructs 
and crystallization was pursued with Ps.aer. and Ye.ent YfiNHAMP-GGDEF.  
 
 Initial crystallization attempts of Ps.aer. and Ye.ent. YfiNHAMP-GGDEF 3.3.2.5
 
For the crystallization trials of Ps.aer. and Ye.ent. YfiNHAMP-GGDEF, 
commercial crystallization screens were employed at different protein 
concentrations in 96-well sitting drop set-ups. All trials are listed in Table 
3-15. As the first attempts to obtain crystals were not successful, both 
constructs were transferred to SEC-buffer without the addition of glycerol. 
However, no crystals were growing under such conditions either. Instead, 
severe oiling out and precipitation was observed in many of the conditions, 
most probably due to the heterogeneity of the proteins in question. The 
attempt to trap Ps.aer YfiNHAMP-GGDEF in an inhibited state by the addition 
of c-di-GMP in a 1:3 molar ratio resulted in protein precipitation. 
Furthermore, it has never been investigated if the full-length cytoplasmic 
constructs eluted from SEC might still degrade in a time-dependent fashion, 
further impeding crystallization. As initial crystallization attempts failed, it 
was decided to do a functional characterization of the Ps.aer. YfiNHAMP-GGDEF 
construct. 
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Table 3-15: Crystallization trials for Ps.aer. and Ye.ent. YfiNHAMP-GGDEF. 
 
 Functional characterization of Ps.aer. YfiNHAMP-GGDEF by the 3.3.2.6
phosphate sensor assay 
 
3.3.2.6.1 Mechanistic principle of the phosphate sensor assay 
 
 
The phosphate sensor is a simple assay system used to directly measure the 
amount of inorganic phosphate generated in an enzymatic reaction. It is 
based on a phosphate-binding protein from E. coli, chemically modified with 
the MDCC fluorophore [150], which upon binding of inorganic phosphate 
increases its fluorescence between 6-8 times. This simple direct measurement 
of the release of phosphate is not dependent on a specific substrate or 
enzyme, making it suitable for almost any target of interest. In order to 
construct screen protein concentration [mg/mL] 
Ye.ent. YfiNHAMP-GGDEF 
PACT Premier 6.7  
Index 
6.7 
13.1  
PEGRx 6.7  13.1  
PEG-Ion 13.1  
Structure Screen I+II 6.7  
Ps.aer. YfiNHAMP-GGDEF 
PACT premier 
1  
7.6  
15.7  
JCSG 
1  
3.1  
7.6  
PEGRx 7.6  
Index 7.6  
CSS I 7.6  
Structural Screen I + II 7.6  
Results 
 
  139 
study DGC activity, the assay can be coupled with a second enzyme 
pyrophosphatase, which will convert the pyrophosphate, generated during 
the process of c-di-GMP production, to inorganic phosphate (Figure 3-30). 
This slight modification of the assay allows on-line quantification of DGC 
activity, which is less laborious than methods depending on time point 
measurements (2.5.1; 2.5.3). 
 
 
 
 
 
 
 
 
3.3.2.6.2 Establishing the assay for DGCs using the well characterized DGC 
DgcZ as a reference protein 
 
The phosphate sensor has been previously established for the 
characterization of the PDE YahA. In order to establish the assay for the 
characterization of DGC activity, the well-characterized DGC DgcZ was 
used as a reference protein. 200 nM zinc-free DgcZ was incubated with 
either 5 µM, 10 µM, 20 µM, 50 µM or 100 µM GTP and phosphate 
production was monitored in real-time as an indirect output for DGC 
activity. Global fitting of all datasets to a Michaelis-Menten kinetic model 
yielded a kcat-value of 6.2E-02 s-1 (data not shown), which is in perfect 
agreement with the published kcat value of 0.6 s-1 [111].  The assay was 
PS!Pi$
2$GTP$$$$$$$c)di)GMP$+$2$PPi$$$$$$$$4$Pi$
YﬁN$ PPase$
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Figure 3-30: Mechanistic principle of phosphate detection by the phosphate sensor 
assay as a method to quantify DGC activity 
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therefore applied in a next step for the characterization of Ps.aer. YfiNHAMP-
GGDEF.  
 
3.3.2.6.3 Enzymatic characterization of Ps.aer. YfiNHAMP-GGDEF 
 
5 µM Ps.aer. YfiNHAMP-GGDEF was incubated with 50 µM GTP and the 
increase in fluorescence was monitored for 20 min as described in 2.5.2. The 
obtained data points were then fit to the Michaelis-Menten model, described 
in Error! Reference source not found. to obtain a kcat-value of 3.4E-04 
s-1. For a detailed discussion of the results, refer to chapter 3.5.4.2.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-31: The measured increase in fluorescence was plotted against the time and 
the data was fit to a Michaelis-Menten model to yield a kcat of 3.2e-4.  
Results 
 
  141 
3.4  Bioinformatical analysis of YfiN: a model of 
the product-inhibited and the active state of 
YfiN 
As described in 1.3, most DGCs are subjected to non-competitive product 
inhibition, involving c-di-GMP mediated cross-linking between either the 
two DGC domains or the DGC domain and an accessory domain [23] [24]. 
Prerequirement for this binding mode is the presence of an intact primary I-
site (RxxD) on the DGC domain, and a secondary I-site either on the DGC 
or the accessory domain. The crystal structure of the YfiNGGDEF domain, 
which was solved by Giardina et al. [151] revealed a degenerate secondary I-
site, where two of the three arginines required for c-di-GMP binding were 
missing. Therefore, a bioinformatical approach was set-up with the goal of 
identifying highly conserved Arg residues in the HAMP domain of YfiN that 
could potentially serve as a secondary I-site. Consequently, a typical 
sequence logo of HAMP domains found in YfiN orthologs was generated as 
described in 2.6.2 and compared to the sequence logo from HAMP domains 
found in methyl-accepting chemotaxis protein that do not show c-di-GMP 
mediated regulation. For both generated logos, the YfiN sequence was 
portrayed as well to facilitate comparison. 
 
Figure 3-32: Sequence logos of HAMP domains either found in MCPs (A) or in YfiN orthologs (B). 
The secondary structure elements are represented schematically above the logo. The amino acids 
are colored according to polarity. The image was generated using Geneious [134]. 
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Comparison of the sequence logos reveals two highly conserved and one 
completely conserved arginine, which are present in HAMP domains found 
in YfiN orthologs but not in HAMP domains of MCPs (Figure 3-32). One of 
them is located at the end of AS1 of the HAMP domain (R200), whereas 
the following two ones are located in the flexible liner (R203 and R208). As 
a next step, a homology model of the cytoplasmic part of YfiN was 
generated as described in 2.6.3 to verify if a 3D arrangement of the HAMP 
and the GGDEF domain permits these arginines to serve as a potential 
secondary I-site.  
The homology model of YfiNHAMP-GGDEF is showing c-di-GMP mediated cross-
linking of the HAMP and the GGDEF domain (Figure 3-33), resembling the 
product-inhibited state of PleD, where cross-linking is observed between the 
GGDEF and its associated REC domain [23]. A linker of 6 amino acids, 
connecting the HAMP and the GGDEF domain could not be modeled and 
was omitted from the model. Therefore, the effective placement and 
orientation of the GGDEF domain in respect to the HAMP domain might 
be slightly different. C-di-GMP binding is mediated by the primary I-site, 
consisting of the characteristic R(319)xxD(322) motif and the putative 
secondary I-site, consisting of R208 (Figure 3-33(B)). The second Arg 
(R203) located in the linker region seems to be too far away to be actively 
involved in product binding.  
As a feasible model of the inactivated state of YfiN had been proposed, the 
focus was shifted towards generating a model of the active state of YfiN to 
potentially get deeper insights into the domain movements required to link 
the two states. Therefore, a model of the active state of DgcZ (Tilman 
Schirmer, pers. comm.) was used as a template for potentially correct 
orientation and placement of the GGDEF domains. 
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Figure 3-33: The proposed model of the product-inhibited state of YfiN. The homology model of 
the HAMP domain was generated based on EnvZ by HHPred [116]. The structure of the GGDEF 
domain of YfiN (PDB entry 4iob) was superposed onto the GGDEF domain of PleD in the 
product-inhibited state (PDB entry 1w25). Inhibition is mediated by c-di-GMP, which is cross-
linking the GGDEF and the HAMP domain, in analogy to the product-inhibited state of PleD [24]. 
The two subunits are distinguished by colors and chain ends are labeled with their corresponding 
residue numbers.  (A) Two YfiN monomers come together to form a dimeric assembly, where the 
N-termini are facing towards the inner membrane. There is a linker of 6 residues, connecting the 
HAMP to the GGDEF domain, which could not be modeled. (B) Close-up view of the c-di-GMP 
dimer, which is cross-linking the HAMP and the GGDEF domain. The I-site residues of YfiN, R319 
and D322, are shown as sticks and colored in beige. The two-conserved Arg residues, which are 
situated in the linker region are shown as sticks and colored in purple. 
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In a first step, the N-terminal all-helical CZB domain of DgcZ was aligned 
to the HAMP-helices of YfiN and subsequently the structure of the YfiN 
GGDEF domain was superposed onto the two DgcZ GGDEF domains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The model of the active conformation is revealing quite a drastic movement 
of the GGDEF domain in comparison to the inactive state (Figure 3-33, 
Figure 3-34). As a model of both states was available, a morphing was 
performed to illustrate the conformational rearrangements required to 
switch from one state to the other (Figure 3-35). 
 
 
Figure 3-34: The proposed model of hypothetical active state of YfiN. The coloration scheme is the 
same as for Figure 3-33. (A) Overview of the whole protein in the proposed active conformation. (B) 
Zoomed-in view into the active site revealing two GTP molecules, which are aligned in an antiparallel 
fashion for catalysis.  
Results 
 
  145 
 
 
 
 
 
 
 
 
 
3.5 Discussion 
The focus of this thesis was the investigation of the YfiR-YfiN interaction 
and the in vitro characterization of the individual proteins. In order to 
quantify the DGC activity of YfiN, two different approaches were chosen: 
the first one was based on measuring the activity of membrane-bound YfiN 
and the second one involved solubilization and purification of YfiN prior to 
the activity assay. In the following, the results of each subchapter are 
discussed separately. 
3.5.1 Activity assay of membrane-bound YfiN 
 
Measuring the activity of a YfiN sample still embedded in the membranes 
involved extensive washing of the latter in order to get rid of numerous 
nucleotides that had been bound before. In a next step, the purified 
membranes were then incubated either with GTP alone or in combination 
with YfiR or c-di-GMP to check if repression or product inhibition occurred. 
The appearance of GDP as a side-product indicated that GTPases were 
Figure 3-35: Scan the QR code to 
get redirected to the morphing 
video. 
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present in the membranes and showed catalytic activity. This might be a 
proof for the integrity of the membrane fraction, suggesting that the 
washing protocol was not too harsh and retained a quasi-native 
environment. The observed GTPase activity was constant throughout all 
three experiments (Table 3-4) and did not lead to substrate depletion as the 
enzymes got inactivated over time (Figure 3-6). The presence of GTPases 
does therefore not pose a limitation to the activity assay as long as 
substrate concentrations equal or higher than 2 mM are employed. 
The second observation was that the membrane sample clearly showed time-
dependent production of c-di-GMP in all three experiments, however at 
different rates (Figure 3-6, Table 3-4). Comparing the progression curve of a 
sample incubated with GTP to the one from a sample incubated with GTP 
and YfiR, clearly revealed YfiR-mediated repression of the observed DGC 
activity with an affinity constant Kr of 25 µM (Figure 3-7). This result was 
in fact indicative of two findings at the same time: first of all, clear evidence 
was obtained that YfiR-mediated repression is indeed also taking place in 
vitro and second, it proved that the observed DGC activity was to a large 
extend YfiN-specific. In theory, several DGCs are present in E. coli that are 
localized at the inner-membrane including YfiN (E. coli), YcdT [152], YaiC 
[153], YegE [154], YeaI [154] and YedQ [154] for all of which in vivo activity 
have been shown. However, considering the vast excess of overexpressed 
YfiN from P. aeruginosa in the membranes, the potential activity of these 
enzymes can most probably be neglected. Additionally, for YedQ and YegE 
DGCs only basal expression levels have been shown in growing cells, which 
are stimulated by the factor sigma(S) upon the transition from the post 
exponential to the stationary phase [154].  
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However, a control should be included in the next experimental series, 
featuring cells that were transformed with either an empty plasmid or 
ideally a plasmid coding for a catalytically inactive YfiN, having a mutated 
GGDEF motif [44]. This would in turn give indications if a potential 
background c-di-GMP producing activity is observed, catalyzed by other 
membrane-bound DGCs in E. coli.  
The determined YfiR affinity constant Kr of 25 µM is lying in a 
physiological range for protein-protein interactions, especially taking into 
account that YfiR most likely is binding as a dimer to YfiN, which increases 
the local concentration of YfiR molecules. However, the Kr value has been 
determined using only one YfiR concentration so far and the experiment 
should be repeated at additional concentrations especially in the range of 
the Kr to get a more accurate determination of the value.  
The YfiN-YfiR interaction shares some striking similarities with the LapD-
LapG system from Pseudomonas fluorescens and Pseudomonas putida [3], 
[79], [97], [155] . In P. fluorescens, the availability of the essential nutrient 
inorganic phosphate is an environmental signal that controls biofilm 
formation through a c-di-GMP signaling pathway. In presence of low 
amounts of inorganic phosphate, c-di-GMP levels are depleted in the cell 
and these changes are sensed by the transmembrane c-di-GMP receptor 
protein LapD. It shows a similar domain organization as YfiN, containing 
cytoplasmic degenerate GGDEF and EAL domains that lack catalytic 
activity but the phosphodiesterase domain retained the capacity of c-di-
GMP binding. When c-di-GMP levels are low, LapD is kept in an “off” state 
that allows LapG, a periplasmic protease, to interact with LapA and cleave 
the N-terminal domain of this adhesion protein, releasing LapA from the cell 
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surface and thereby leading to biofilm detachment. Under abundant 
phosphate conditions, c-di-GMP is binding to the EAL domain of LapD in 
the cytoplasm, whereupon the signal is then relayed to the periplasmic PAS 
output domain through an inside-out signaling mechanism that utilizes a 
juxtamembrane HAMP domain. This in turn leads to binding and 
sequestering of LapG in the periplasm, promoting cell adhesion via 
maintenance of LapA on the cell surface [97]. 
In analogy to LapD, YfiN also appears to switch between discrete inactive 
and active functional states depending on the presence or absence of the 
inhibitor YfiR. This seems to be a common feature of many well-
characterized transmembrane signaling proteins, such as histidine kinases 
and methyl-accepting chemotaxis proteins, where ligand binding is causing a 
conformational change that is propagated throughout the whole protein 
[156]. However, YfiN activity is controlled by YfiR in an outside-inside 
signaling mechanism in contrast to the inside-outside mechanism observed 
for LapD [14]. Release of repression leads to a conformational shift in YfiN, 
which is relayed through the PAS and transmembrane domains to the 
cytoplasmic HAMP domain, leading to an active conformation. This is then 
in turn transmitted to the effector GGDEF domains, allowing them to form 
a catalytically competent homodimer required for c-di-GMP production. 
In contrast to the proposed 2:2 stoichiometry for the YfiR-YfiN complex, 
the crystal structure of the LapD-LapG complex revealed a 2:1 ratio [98]. 
However, unlike YfiR, LapG has not shown any signs of homodimerization 
in studies so far, which could therefore explain the observed 2:1 ratio [98], 
[157]. The binding mode of LapD-LapG shows distinct similarities to the 
proposed way of interaction between YfiR-YfiN, both involving hydrophobic 
binding sites. This involves a completely conserved tryptophan residue 
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W126 (Legionella pneumophia, corresponding to W125 in P. fluorescens), 
which serves as the major anchor point on LapD as it inserts into a 
hydrophobic pocket at the bottom of LapG (Figure 3-36) [98].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-36: Crystal structure of a P. fluorescens LapG and L. pneumophila LapDPAS complex, based on 
PDB entry 4U65. (A) Side-view of the complex structure. The LapG-LapDPAS complex is shown as a 
ribbon representation, with the two protomer chains of LapDPAS colored in pink and yellow and LapG 
colored in grey. The highly conserved tryptophan residue (W126) is shown as sticks for one of the 
subunits. Two dashed lines indicate the relative position of the inner membrane to the complex. (B) 
The hydrophobic binding pocket for W126 from LapDPAS in LapG is shown as a close-up view. Residues 
forming the pocket are shown as sticks and labeled accordingly. A 90° rotation around x, followed by a 
90° roation around y was applied to LapD from the complex structure to view the interface. (C) Surface 
representation of (B), illustrating the hydrophobic nature of the binding pocket. 
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So far, the activity assay using membrane-bound YfiN has revealed time-
dependent c-di-GMP production, which could be reduced by the addition of 
YfiR to the experimental setup. 
Furthermore, experiment II, where c-di-GMP was added to the membranes 
in addition to GTP revealed that YfiN indeed was subjected to non-
competitive product inhibition (Figure 3-7). This finding is further 
supported by the personal observations made during the purification 
process, where YfiN was co-eluting with c-di-GMP, clearly proving that 
binding is taking place in vivo (Figure 3-12, Figure 3-13). Moreover, this 
result is additionally confirmed by an independent study from the Jenal 
group, where a YfiNHAMP-GGDEF construct was clearly shown to bind to c-di-
GMP [12].  However, this finding stood in clear contrast to another study, 
where the structure of the GGDEF domain of YfiN revealed that the 
presumable secondary I-site present on the GGDEF itself, which is required 
for domain cross-linking, was degenerate (Figure 3-37) [151]. The presence of 
an intact primary and secondary I-site is a prerequisite for the c-di-GMP 
mediated cross-linking of GGDEF domains, which results in the spatial 
separation of the two active sites and thereby inactivation of the protein. 
However, the secondary I-site can also be localized on an accessory domain, 
thereby leading to intramolecular cross-linking of the GGDEF domain to 
the accessory domain upon c-di-GMP binding [23]. 
In the aforementioned study, no binding was observed of YfiNHAMP-GGDEF to c-
di-GMP in an ITC experiment and it was therefore concluded that YfiN is 
not subjected to product inhibition due to lack of a secondary I-site on the 
GGDEF as well as on the HAMP domain. 
Having a closer look at the AUC data, which was performed on the 
YfiNHAMP-GGDEF construct revealed, however, that as it was already observed 
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in the framework of this thesis, the construct used in said study got 
proteolytically cleaved, corresponding to the size of the isolated GGDEF. 
This was also the reason why the HAMP domain was not present in the 
crystal structure. The conclusion drawn in the study was that YfiNHAMP-GGDEF 
was eluting as a monomer from SEC but no references was made to the 
occurring proteolysis. It remains thus unclear, if the authors were aware of 
this issue or not.  
 
 
 
 
 
 
 
 
 
 
 
 
Assuming that the secondary I-site of YfiN is in fact localized on the HAMP 
domain and taking into consideration that the construct got proteolytically 
cleaved, this could thus pose a potential explanation for the fact that no c-
di-GMP binding was observed. This control mechanism is in analogy to 
Figure 3-37: Comparison of the Ip and Is sites of YfiN (PDB entry 4iob) and PleD (PDB entry: 
2v0n). The two subunits of a hypothetical product-inhibited YfiN, which were superposed onto the 
PleD dimer, are shown in magenta and purple, while PleD is shown in green and blue. The 
coordinates for c-di-GMP were taken from PleD and shown in sticks. The residues involved in binding 
are shown in stick as well and are labeled in bold and black for YfiN and in grey for PleD. YfiN lacks 
two of the three arginines required for c-di-GMP binding, which are replaced by D273 and N351. 
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PleD, where besides a c-di-GMP mediated GGDEF-GGDEF domain cross-
link, a second mode of domain immobilization is found, involving c-di-GMP 
mediated cross-linking of the GGDEF domain to the accessory REC domain 
(Figure 3-38) [23] [24].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to identify highly conserved Arg residues in the HAMP domain of 
YfiN, which could potentially serve as a secondary I-site, a sequence logo of 
HAMP domains found in YfiN orthologs was compared to the sequence logo 
from HAMP domains found in methyl-accepting chemotaxis protein that do 
not show c-di-GMP mediated regulation.  
Figure 3-38: The non-competitive product inhibited state of PleD is involving a c-di-GMP mediated 
cross-link between the REC and the GGDEF domains. The c-di-GMP dimer is shown as sticks. The 
residues involved in binding are shown as sticks and labeled in bold and black for the Ip-site and in 
bold and grey for the Is-site.   
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One highly (R203) and one completely conserved Arg (R208) were identified 
in the HAMP domains of YfiN orthologs, which were not present in the 
HAMP domains of MCPs at the equivalent position (Figure 3-32). A 
homology model of the product-inhibited state of YfiN, which was generated 
based on PleD, revealed that R208 is indeed situated close enough to 
coordinate the N7 position and the oxygen of the phosphate group of the c-
di-GMP dimer, comparable to R178 in PleD (Figure 3-33 (B), Figure 3-38). 
There seems to be no direct involvement of Arg203 in c-di-GMP binding but 
it might be conserved for structural reasons such as stabilizing the helix 
bundle. From the model, it is not evident if there are more residues involved 
in the binding and coordination of c-di-GMP besides the primary I-site, 
consisting of the characteristic RxxD motif, and the putative secondary I-
site R208. Taken all these findings together, this concludes that YfiN is 
clearly subjected to non-competitive product inhibition, presumably by c-di-
GMP mediated cross-linking and that product binding is accomplished by 
the primary I-site and a secondary I-site, which is located on the HAMP 
domain. However, the role of Arg208 as the potential secondary I-site 
remains to be verified by mutational studies in vitro or in vivo.  
In summary, the activity assay using membrane-bound YfiN yielded 
astonishingly clean and easy to interpret chromatograms due to the 
improved washing protocol. This might therefore pose a valid approach for 
membrane proteins in general to probe for activity before solubilization and 
investigate the qualitative effect of inhibitors or interaction partners on the 
activity. For quantitative statements, a clear estimation of the protein 
concentration is required, which could be obtained by Western Blot 
analysis.  
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In the future, the protocol should be slightly adapted, using shorter 
experimental durations, as after 2 hours nucleotide loss started occurring. 
This could be caused by nucleotide binding to the membranes, where they 
are withdrawn from the reaction mixture upon heat-deactivation and 
precipitation (Figure 3-6).  
 
3.5.2 Purification of detergent-solubilized YfiN 
 
YfiN was expressed in abundant amounts in the membranes at the 
established condition (Figure 3-3(A), lane 7). Placement of the his-tag at 
the N-terminus turned out to be very important for protein stability, as a 
C-terminally tagged construct appeared completely degraded. In order to 
extract the protein from the membranes and keep it in a solubilized state, 
three different detergents were tested in regards to their extraction 
capacities. DM thereby showed the highest extraction efficiencies in 
comparison to DDM, which still extracted some amounts of protein (Figure 
3-11) and β-OG, which did not lead to any considerable protein extraction 
(Figure 3-8) and was therefore omitted from further tests. SEC revealed 
completely aggregated protein for DDM (Figure 3-11) and a prominent 
aggregation peak for DM (Figure 3-10) but for the latter two peaks were 
obtained corresponding to smaller molecular weights, however the peak 
intensities amounted to only a few mAU units. Due to time limitations, it 
was decided to proceed with DM as detergent, as not so much protein was 
required for the subsequent activity assays. However, what usually should 
be done at this stage is to go for extensive screening of detergents and 
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additives, which stabilize the target protein to maximize the yield of 
working material for downstream applications.  
For all purifications, c-di-GMP binding to YfiN was observed in a 1.5: 1 
molar ratio on average. Therefore, the subsequent SEC was usually run at 
very low flow speeds to get rid of the majority of bound nucleotide (Figure 
3-12). 
In order to get information about the oligomeric state of YfiN in solution, 
DLS analysis was performed for both SEC peaks individually. As the 
observed standard deviations were quite high, it was difficult to get a 
reliable estimation of the oligomeric state of YfiN in solution (Table 3-5). 
Both peaks correspond most probably to a monomeric YfiN but in different 
conformations. It is however not straightforward to deduce the nature of 
these two conformations. Due to the very low absorption values obtained, 
usually lying in the range of 10E-02- 10E-03, both peak fractions had to be 
pooled together and concentrated in order to get reliable measurements. It 
can therefore not be excluded that, for instance, the two peaks show 
different 260/280 ratios. One of the hypotheses could be that as residual c-
di-GMP binding is observed even after SEC at a protein-nucleotide molar 
ratio of 1: 0.3 on average, one of the conformations could correspond to a c-
di-GMP bound and the other one to a c-di-GMP-free form. The product-
inhibited state forms a much more globular shape as the product-free form, 
which is adopting a more elongated shape (Figure 3-33, Figure 3-34). The 
former could therefore correspond to peak 3, whereas the latter is eluting 
earlier from the SEC and therefore would be contained in peak 2. However, 
a protein: nucleotide ratio of 0.3 is equivalent to every 6. protein being fully 
loaded with c-di-GMP and hence  the same difference in peak area should be 
obtained for the two peaks, which is clearly not the case for YfiN (Figure 3-
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10). The identities of the two conformations remain therefore speculative. 
Nonetheless, it is evident that if buffer conditions are identified, which lead 
to higher protein yields, more accurate determination of the molecular 
weight is possible by MALLS, as strong concentration of the protein is no 
longer required.  
 
3.5.3 Activity assay of detergent-solubilized YfiN 
 
A protocol was successfully set-up for the characterization of DGC activity 
in 96-well format using the malachite-green assay. The kcat values obtained 
for the reference protein DgcZ (3.2.1.7), were in perfect agreement with the 
previously published ones [111]. However, when the presumable activity of 
detergent-solubilized YfiN was measured in a next step it turned out to be 
caused by a GTPase contamination present in the YfiN sample (Figure 
3-15). This finding was revealed by a control where YfiN and GTP were 
incubated in presence and absence of PPase. In the absence of PPase, no 
signal should be obtained for a DGC as only inorganic phosphate is detected 
by the assay. However, the experiment revealed no significant differences in 
the initial velocities of YfiN in presence and absence of PPase (Table 3-6), 
conforming that the observed activity was indeed due to a GTPase 
contamination.  
In addition, YfiR also showed activity when incubated with GTP, which 
was in the same range as YfiN (Figure 3-18). This activity is most probably 
caused by a GTPase contamination as well (Figure 3-18) as no 
physiologically relevant GTPase activity is expected of a periplasmic protein 
due to the lack of nucleotides in the periplasm.  
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Taken all these findings together, there was no detectable YfiN activity 
taking place during the experiment. The most likely reason for this is due to 
YfiN inactivation as a result of the necessary strong concentration process, 
which at the same time led to presumably very high DM concentrations of 
30 mM – 60 mM in the sample depending on the experiment. As stated 
before, more time should therefore be invested on the identification of 
buffers, detergents and additives, which increase the amount of extracted 
and well-behaving protein. 
Furthermore, the fact that the malachite-green assay does not provide a 
direct readout for DGC activity but instead needs to be coupled to a second 
enzyme posed a certain limitation in this study. An FPLC-based method 
would have directly visualized that the investigated activity was in fact 
generating GDP instead of c-di-GMP, giving a tighter control on the 
nucleotide turnover, which is taking place during the experiment. However, 
the malachite-green assay constitutes a less laborious and easy-to-use 
alternative if the investigated enzymes show an activity of certain 
significance such as DgcZ, which gave rise to a signal that was at least two 
orders of magnitudes higher than the contamination.  
 
3.5.4 Preliminary results of the individual domains of YfiN 
 The periplasmic PAS domain 3.5.4.1
 
Throughout all experiments, two of the three investigated PAS constructs 
showed no soluble expression at all and only for YfiNPAS44-149 very low 
amounts of soluble protein were obtained. However, the following SEC 
revealed only aggregated protein, which was co-eluting with numerous 
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contamintants. When the same construct was fused to a MBP, GST or 
SUMO-tag, abundant soluble expression was obtained for the MBP-PAS44-149 
fusion, whereas only insoluble expression was observed for the other two 
fusion constructs. However, also the MBP-fusion construct eluted 
exclusively as aggregates from the SEC, again indicating folding problems of 
the PAS domain. One explanation for the observed aggregation-prone and 
unstable behavior of the PAS domain could be that it needs the presence of 
the downstream transmembrane and HAMP domains for dimerization and 
thus stabilization of the protein. The dimerization interface of the YfiNPAS 
domain is overall well conserved, with the potential binding site motif 
AAVVF showing almost complete conservation (3.1), whereas the rest of the 
domain is rather variable. The presence of this hydrophobic patch is distinct 
for YfiN, as none of the other PAS domains investigated so far have been 
shown to operate via a hydrophobic binding site, which is situated on the 
surface of the protein. Even the similarly operating LapD-LapG interaction 
is mediated via a hydrophobic pocket located on LapG, which is shielded 
from the aqueous environment [98]. Taking into account that YfiN 
presumably switches between a discrete inactive and active state, depending 
on the presence or absence of bound YfiR, it is likely that the hydrophobic 
patch is either engaging in YfiR binding or is shielded from the aqueous 
environment by the two PAS domains coming closer together.  
Future experiments should therefore focus on stabilizing either the YfiR-
bound state or generating a leucine-zipper PAS construct, which would lead 
to the stabilization of a PAS dimer. Leucine zippers have been shown to 
form parallel coiled-coils and, hence, serves as a strong dimerization modules 
[158]. A similar approach was used for investigation of the DGC WspR [26].  
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 The cytoplasmic HAMP and GGDEF domains 3.5.4.2
 
The four YfiNHAMP-GGDEF constructs from different species showed overall the 
same kind of behavior. Expression tests revealed that the cytoplasmic 
constructs got expressed in soluble abundant amounts (Figure 3-25). Ps.aer., 
Ps.flu. and Ye.ent. YfiNHAMP-GGDEF were purified to homogeneity by a two-
step purification process including IMAC and SEC. Slight adjustments had 
to be made to the IMAC protocol, applying a less steep imidazole gradient, 
in order to reduce aggregation of the proteins. SDS-PAGE analysis during 
the purification process showed that all constructs were subjected to 
proteolysis (Figure 3-27). Tryptic digest in combination with mass 
spectrometry analysis revealed that Ye.ent. YfiN got cleaved at two 
positions within the protein, once within the HAMP domain and once 
between the HAMP and the GGDEF domain (Figure 3-29, Table 3-14). 
This could indicate that these parts of the sequence are not well structured 
and thus prone for proteolytic degradation. The linker between the two 
HAMP helices could therefore be a likely target for cleavage to occur. 
Nonetheless, the cleaved products could usually be separated from the full-
length cytoplasmic YfiN constructs and initial crystallization was pursued 
with Ps.aer. and Ye.ent YfiNHAMP-GGDEF. However, in many drops only 
precipitation and severe oiling out were observed, most probably due to the 
heterogeneity of the proteins as a result of nucleotide binding and 
proteolysis. It should be investigated if the protein is stable after SEC or if 
time-dependent proteolysis is occurring, which would in turn hinder 
crystallization.  As for the full-length YfiN, the cytoplasmic constructs could 
also be run on a S200 26/60 column at a low flow speed, in order to 
separate the protein from the bound nucleotide (Figure 3-12). Further 
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crystallization trials could be performed in the presence of a non-
hydrolyzable GTP analogue, such as GTPαS, in order to trap the protein in 
one state.  
As initial crystallization attempts failed, it was decided to do a functional 
characterization of the Ps.aer. YfiNHAMP-GGDEF construct. The phosphate 
sensor assay was used to determine the kcat of YfiNHAMP-GGDEF, which 
amounted to 3.4E-04 s-1. This might seem very low, however the value is in 
the same order of magnitude as the kcat of non-activated PleD, which 
amounted to 9.0E-04 s-1 [24]. DGCs activity requires the formation of a 
dimer, which depends on the diffusion as well as the proper orientation of 
the two GGDEF domains, where each domain contributes one GTP 
substrate molecule to the reaction. However, it is likely that nature 
optimized the macroscopic electrostatic interactions involved in dimer 
formation in order to facilitate the proper orientation of the two domains 
with respect to each other. Therefore, the process of dimer formation 
predominantly depends on diffusion, which can in turn be increased due to 
law of mass action by raising the concentration of the proteins. A 
monomeric GGDEF domain is thus still expected to show some basal 
activity, which is indeed what is observed for the monomeric Ps.aer. 
YfiNHAMP-GGDEF.  
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4 Conclusion and Outlook 
 
To better understand the formation of P. aeruginosa small-colony variants 
(SCVs) during long-term lung infections, knowledge about the interaction 
mechanisms of the involved YfiBNR proteins is essential. In vivo and in 
vitro studies partly characterized these interactions, however, according to 
my knowledge, no structural information was available to date. 
Furthermore, in vitro functional studies of the effector of the system YfiN 
and its repressor YfiR were still missing. 
Within the framework of this thesis, YfiN and YfiR have therefore been 
analyzed by structural, functional and biochemical means. Together with 
the results from the previous studies, this facilitates a better insight into the 
mechanism of how YfiN activity is being regulated. 
The three-dimensional structure of YfiR was solved using X-ray 
Crystallography, which revealed that it is adopting a novel fold. Moreover, 
the fact that a dimeric YfiR was found in the crystal structure, raised 
questions about the physiological relevance of this dimer. Probing the 
oligomeric state of YfiR by SEC-MALLS confirmed that it indeed dimerizes 
in solution with a dissociation constant (Kd) in the nanomolar range. 
Furthermore, a mutation in the putative dimerization interface was shown 
to significantly weaken the dimerization by two orders of magnitude 
compared to the wildtype. This indicates that the same kind of dimer is 
adopted in solution as in the crystal structure.  
In order to characterize the YfiR-YfiN interaction in vitro, a functional 
assay was established using membrane-bound YfiN. Time-dependent c-di-
GMP production was observed, which confirmed that YfiN showed catalytic 
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activity in vitro. Upon addition of YfiR, significant repression of YfiN 
activity was demonstrated, with a Kd in the lower micromolar range. 
Considering that the Kd of YfiR dimerization is two orders of magnitude 
lower, it is therefore proposed that YfiR is binding to YfiN in a dimeric 
state.  
Furthermore, membrane-bound YfiN appeared to be subjected to non-
competitive feedback inhibition, which was in agreement with the 
observations that all YfiN constructs investigated during this thesis co-
eluted with c-di-GMP. This clearly indicates the presence of an intact 
primary I-site on the GGDEF domain and an intact secondary I-site 
localized either on the HAMP or the GGDEF domain. Further insights were 
gained by the crystal structure of YfiNGGDEF, solved by Giardina et al. [151], 
which revealed that the secondary I-site on the GGDEF domain is 
degenerate and thus incapable of c-di-GMP binding. This in turn prompted 
the generation of a homology model of the product-inhibited state of YfiN, 
involving the primary I-site on the GGDEF domain and one highly 
conserved arginine R208 on the HAMP domain, which could serve as the 
potential secondary I-site. To identify the domain rearrangements required 
to switch between inactive and active state, a second homology model was 
generated of the presumable activated state of YfiN. The resulting overlay 
of both states revealed a rather massive rearrangement of the GGDEF 
domain, of which the physiological occurrence could, however, still be 
envisaged. 
Preliminary attempts to investigate the activity of detergent-solubilized 
YfiN not been successful so far due to low protein yields.  
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In conclusion, Figure 4-1 shows an updated version of the proposed 
mechanism by which YfiN activity is regulated in the cell, incorporating all 
relevant findings of this study.  
 
In the future, the established activity assay using membrane-bound YfiN 
should be applied for further investigations. Among others, the performed 
experiments should be repeated to verify the reproducibility of the results. 
In addition, a more accurate determination of the dissociation constant for 
the YfiR-YfiN binding should be obtained by repeating the same experiment 
at different YfiR concentrations. The assay could then be used to further 
study the interactions between the currently available YfiR and YfiN gain-
of-function mutants and between YfiN and the YfiR dimerization interface 
mutant.  
For the solubilization of YfiN, more elaborate efforts are required to screen 
for buffers, additives and detergents, which increase the amount of 
solubilized protein for downstream applications. Once a purification protocol 
has been established, the application of nanodiscs should be pursued for 
further functional assays in vitro. 
Ultimately, the role of R208 as the putative secondary I-site remains to be 
investigated by in vitro or in vivo experiments. 
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Figure 4-1: Overview of the YfiBNR system in the off state (left) and in the on state (right). All three 
proteins as well as GTP and c-di-GMP are depicted in a schematically. Three different 
conformational states are proposed, a YfiR-inhibited, an active and a transient product inhibited state 
to limit excess substrate consumption.  
Contrasting Mechanism of Inhibition of SHV5 and KPC2 β-Lactamases 
 
  165 
5 Contrasting Mechanism of Inhibition of 
SHV5 and KPC2 β-Lactamases 
 
5.1 Research article II (Kauer and Zähringer et 
al., in preparation) 
 
Contrasting Mechanisms of Inhibition of SHV-5 
and KPC-2 Class A β-Lactamases by Sulbactam, 
(3R)-3-Acetamido-2-hydroxy-3,4-dihydro-1,2-
benzoxaborinine-8-carboxylic Acid and Avibactam  
 
Stefanie Kauer‡1, Franziska Zähringer‡1, Patrick Caspers2†, Clothilde 
Dantier2, Eric Desarbre2, Stefan Reinelt2, Tilman Schirmer1, Malcolm G. P. 
Page2* 
1. Structural Biology and Biophysics, Biozentrum, University of Basel, 
Klingelbergstrasse 50/70 CH - 4056 Basel, Switzerland. 2 Basilea 
Pharmaceutica International Ltd, Grenzacherstrasse 487, CH-4058 Basel, 
Switzerland. 
 
Contrasting Mechanism of Inhibition of SHV5 and KPC2 β-Lactamases 
 
   166 
‡These authors contributed equally.   
*Corresponding author. 
Manuscript in preparation 
 
Statement of my own contributions 
I contributed to the manuscript by co-crystallizing SHV-5 in presence of 
(3R)-3-Acetamido-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic 
Acid and solving the crystal structure of the complex. I wrote the methods 
sections “Crystal Growth and Structure Determination of Purified SHV-5 “ 
and “Data collection and Processing“. I furthermore wrote the results section 
“Crystal structure of the covalent AHB-SHV-5 complex”. Figure 5 and 
figure 7 have been prepared by me, as well as the original drafts to figures 6 
and 8. I also prepared tables 1 and 3.  
 
 
 
 
 
 
 
 
Contrasting Mechanism of Inhibition of SHV5 and KPC2 β-Lactamases 
 
  167 
Contrasting Mechanisms of Inhibition of SHV-5 
and KPC-2 Class A β-Lactamases by Sulbactam, 
(3R)-3-Acetamido-2-hydroxy-3,4-dihydro-1,2-
benzoxaborinine-8-carboxylic Acid and Avibactam  
Stefanie Kauer‡1, Franziska Zähringer‡1, Patrick Caspers2†, Clothilde 
Dantier2, Eric Desarbre2, Stefan Reinelt2, Tilman Schirmer1, Malcolm G. P. 
Page2* 
1. Structural Biology and Biophysics, Biozentrum, University of Basel, 
Klingelbergstrasse 50/70 CH - 4056 Basel, Switzerland. 2 Basilea 
Pharmaceutica International Ltd, Grenzacherstrasse 487, CH-4058 Basel, 
Switzerland. 
 
‡These authors contributed equally.   
*Corresponding author. 
 
 
ABSTRACT: This study examines the reaction of the Ambler class A 
extended-spectrum β-lactamase, SHV-5, and the Ambler class A 
carbapenemase, KPC-2, with a mechanism-based inhibitor (sulbactam), a 
potential transition-state analogue (3-acetamido-2-hydroxy-3,4-dihydro-1,2-
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benzoxaborinine-8-carboxylic acid) and the  non-β-lactam, avibactam.  
Branched pathways that result in stabilized intermediates appear to make a 
significant contribution to the inhibition of SHV-5 and the crystal structure 
of one such inhibitor complex formed with (3-acetamido-2-hydroxy-3,4-
dihydro-1,2-benzoxaborinine-8-carboxylic acid) is described. The inhibitor 
moiety forms a closed structure with boron in tetrahedral configuration, 
potentially analogous to the transition state for acyl-enzyme formation, 
rather than a previously reported open structure previously reported for the 
complex formed with TEM-1 (Ness, S., Martin, R., Kindler, A. M., Paetzel, 
M., Gold, M., Jensen, S.E., Jones, J.B., Strynadka, N.C. (2000). 
Biochemistry 39, 5312-5321). In contrast, although there is evidence for a 
branched pathway in the reaction between sulbactam and KPC-2, this does 
not result in stable intermediates. Avibactam reacts more slowly than either 
of the other types of inhibitor and follows a two-step reaction to form a 
stable carbamoyl ester with the active site serine. The crystal structure 
shows that the inhibitor moiety adopts a subtly different conformation in 
the active site that could account for its degradation pathway. 
 
 
 
 
 
β-Lactam antibiotics have been a cornerstone of the treatment of 
infections caused by Gram-negative bacteria for the last several decades.1 
The β-lactams inhibit  penicillin-binding proteins, preventing an essential 
transpeptidation reaction and thereby triggering a series of, as yet 
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incompletely understood, reactions that lead to cell lysis and death.2,3 The 
Gram-negative bacteria have acquired resistance to β-lactam antibiotics 
through mutations that increase the filtration effect of their outer 
membrane, or enhance the rate at which the antibiotic is extruded from the 
cell and, above all, through the expression of β-lactamases that hydrolyze 
the β-lactam ring, rendering the antibiotic inactive.4,5  Four classes of β-
lactamases, A, B, C and D, are commonly recognized, based on their amino 
acid sequences.6-8 The class A β-lactamases are the most prevalent in human 
pathogens and have evolved into a number of lineages with modified kinetic 
properties that extend their substrate specificity profile to include advanced 
generation cephalosporins (extended-spectrum β-lactamases, or ESBLs) or 
carbapenemases that can hydrolyze carbapenem antibiotics that normally 
inhibit these enzymes.9,10 Members of the SHV lineage of class A β-
lactamases are commonly found in Klebsiella  pneumoniae and Escherichia 
coli. SHV-5 acquires an ESBL phenotype compared to SHV-1 through 
substitutions at positions Gly-238, to Ser, and Glu-240, to Lys, that extend 
its substrate specificity to include aminothiazolyloxyimino-cephalosporins 
such as cefotaxime, ceftriaxone and ceftazidime.11 The changes in kinetic 
properties, which are associated with branched pathways driven by enzyme 
conformational changes dependent on the reaction with substrates, has the 
unexpected consequence of rendering the mutant enzymes more susceptible 
to mechanism-based inhibitors such as the clinically used β-lactamase 
inhibitors clavulanic acid, sulbactam and tazobactam.12,13 Nevertheless, 
because of their abundance, diversity and potential high-level expression, 
the ESBL enzymes of this type remain a concern and there is considerable 
interest in the development of new, more potent inhibitors to combine with 
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β-lactamase-labile antibiotics.  More challenging, in 2013, the Centers for 
Disease Control and Prevention (CDC) in the United States announced that 
carbapenem-resistant Enterobacteriaceae (CRE) are one of the highest 
priority target pathogens for the identification and development of novel 
antibacterials.14 Klebsiellae expressing the class A carbapenemase KPC-215 
are among the most prevalent CRE in many parts of the world including 
the United States, Europe and Israel.16 Although designated a 
carbapenemase, KPC-2 is able hydrolyze β-lactams from all classes17 with 
only a few agents, such as BAL30072, being hydrolyzed slowly enough to 
retain antimicrobial activity in the presence of KPC-2.18 Further, KPC-2 is 
not susceptible to the commercially available β-lactamase inhibitors and 
only the newly approved avibactam is able to afford significant protection to 
labile β-lactam antibiotics.19,20,24  Boronic acid-based inhibitors have been 
studied by several laboratories as potential inhibitors of β-lactamases 
including KPC-2.21,22 23 The inhibitor (3R)-3-acetamido-2-hydroxy-3,4-
dihydro-1,2-benzoxaborinine-8-carboxylic acid (AHB) was described as the 
product of structure-based design and is one of the most potent boronic 
acid-based inhibitors of class A β-lactamases.22  
Sulbactam  (Fig 1A) is a mechanism-based  inhibitor that reacts with 
the β-lactamases in the same way as simple substrates, such as penicillins, 
do forming an acyl-enzyme intermediate (cf Scheme 1A) but then undergoes 
a complicated series of chemical rearrangements that lead to enamine 
intermediates (Scheme 2) in which the acyl ester is deactivated.12,13 The 
boronic acid-based AHB (Fig. 1B) was postulated to be a transition-state 
analogue forming a tetrahedral boronyl ester that resembles the 
hypothetical tetrahedral intermediate for the hydrolysis of the acyl-enzyme 
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formed with β-lactams (Scheme 1B).22 Avibactam, (1R,2S,5R)-2-carbamoyl-
5-methyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate (Fig. 1C), 
represents a new class of β-lactamase inhibitors that are able to modify the 
active site serine to form a carbamoyl ester (Scheme 1B), which is 
significantly less susceptible to hydrolysis than acyl esters.20  It has been 
established that regeneration of the free enzyme from  the carbamoyl 
intermediate does not proceed through direct hydrolysis, but may involve 
either  neighbouring group attack of N6 on the carbamoyl ester to release 
the starting compound, or fragmentation of the inhibitor moiety (Scheme 
1C).24  
While studying the kinetics of inhibition of ESBLs by model β-
lactamase inhibitors including sulbactam, AHB and avibactam, we observed 
some interesting features in the reaction of SHV-5 and KPC-2 and we 
describe here the inhibition kinetics and crystal structure of complexes 
formed between these two inhibitors and the enzymes.   
 
EXPERIMENTAL PROCEDURES 
Bacterial Strains, Cloning and Expression. Plasmids carrying the β-
lactamase genes were extracted using standard methods25 from the host 
organisms:  Klebsiella pneumoniae (pYW1) for KPC-2, Escherichia 
coliHB101for SHV-1 and Escherichia coli MPA-5 for SHV-5, all isolates 
were from the Basilea strain collection.   The PCR products were purified, 
digested with appropriate restriction enzymes and cloned into the 
correspondingly digested E. coli inducible expression vector pPC56. The 
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ligation reactions were transformed into E. coli M15 containing the 
compatible plasmid pREP4, coding for the lacI repressor and kanamycin 
resistance.26 (Stueber et al). Transformants were selected on LB agar plates 
containing chloramphenicol (15mg/L) and kanamycin (25 mg/L). Individual 
clones were tested for the presence of an insert of the expected size. The 
DNA of the inserts were completely sequenced using vector-based flanking 
primers and a set of internal sequencing primers.  The strains expressing the 
appropriate enzyme were grown overnight in Luria broth (LB) containing 25 
µg/ml kanamycin and 15 µg/ml chloramphenicol, 20% by volume of glycerol 
was added and the suspension stored at -80°C for further use. For growth,  
5 ml of LB + 25 µg/ml kanamycin + 15 µg/ml chloramphenicol was 
inoculated with bacteria from the -80°C  stock and cultured overnight at at 
37°C with gentle shaking. 2.5 mL of this overnight culture was introduced 
into a conical flask containing 100 ml LB + 25 µg/ml kanamycin + 15 
µg/ml chloramphenicol and culture continued overnight at 37°C. This 
culture was used to inoculate 6 x 1L of Terrific broth + 25 µg/ml 
kanamycin + 15 µg/ml chloramphenicol (10 ml per flask) and the cultures 
were grown to  OD 600nm between 0.7 and 0.8 when isopropylthio-β-D-
galactoside was added at a final concentration of 0.1 mM  to induce β-
lactamase expression. The cultures were incubated for 2h at 30°C with 
orbital shaking at 100 r.p.m. The bacteria were collected by centrifugation 
and the cell pellets were frozen at -80°C for further use.  
β-Lactamase purification.  The cell pellets were thawed on ice and the cells 
re-suspended in 20mM Tris-HCl pH 7.5, 10mM MgCl2 containing 10 µg/mL 
DNase I. The cell suspension was passed twice through a pre-cooled (4°C) 
French Press cell (SLM AMINCO Instruments) at 1250 PSI and  then 
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centrifuged at 35000g, 1 hour, 4°C.  Activity in the supernatant and the 
pellet was determined with nitrocefin as reporter substrate and protein 
quantification using Lowry method. The supernatant was dialysed against 
two changes of 2L of 20mM Tris-HCl pH7.5 at 4°C.  Ammonium acetate 
(5M, pH 5.0) was added drop-wise, while stirring, on ice to give 0.1M final 
concentration and the cloudy suspension was centrifuged at 46000g for 
10min. at 4°C. The supernatant was loaded onto a cm x cm SP sepharose 
FF equilibrated with 0.1M ammonium acetate pH 5.0 at 1.5mL/min. The 
column was washed overnight with 0.1M ammonium acetate pH 5.0. The 
protein was elution using a linear gradient of 1M ammonium acetate pH8.5. 
Fractions were collected and tested for β-lactamase activitiy and protein 
concentration. For purification of SHV-5 β-lactamase, the eluate from the  
SP sepharose FF was dialysed against 20 mM Tris-HCl pH 7.4, concentrated 
using  10kDa Amicon concentrators at 3000g at 4°C in a swing- rotor 
centrifuge and applied to a Superdex 200 Hi Load  Prep grade column 
equilibrated with20 mM Tris-HCl pH 7.4. The protein was eluted in an 
isocratic run in the same buffer.  For the purification of KPC-2 β-lactamase, 
the active fractions eluted from the SP sepharose FF column were pooled 
and dialysed against two changes of 2L of 20mM Tris-HCl pH7.5 at 4°C. 
The dialysate was concentrated before loading on to a  Superdex 200 Hi 
Load  Prep grade column (GE Code No.: 17-1071-01) equilibrated with 
50mM sodium phosphate buffer pH7.5 at 1.5mL/min and the protein was 
eluted in an isocratic run in the same buffer.   
Reagents. Sulbactam, (3R)-3-acetamido-2-hydroxy-3,4-dihydro-1,2-
benzoxaborinine-8-carboxylic acid, avibactam and nitrocefin were 
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synthesized in the laboratories of Basilea Pharmaceutica International Ltd 
according to published procedures. 
 Enzyme Inhibition Kinetics The interactions of the inhibitors with the two 
β-lactamases were studied using nitrocefin as reporter substrate. Preliminary 
apparent affinities (IC50) were determined by incubating the enzymes with a 
range of concentrations of the inhibitor for 5 min. and then diluting with 
100 µL 100µM nitrocefin solution. The observed rates of modification of the 
enzyme by inhibitor were determined by incubating a 2 µL reaction mixture 
containing the enzymes and the inhibitor for times between 1s and 180 min. 
before diluting with 100 µL 100 µM nitrocefin solution. Reactions requiring 
incubations less than 30s were performed using a SF61 multimixing stopped 
flow spectrophotometer (HI-Tech Scientific, Salisbury, UK). The recovery 
rates of free enzyme from inhibition were determined by incubating a 2 µL 
reaction mixture containing the enzymes and the inhibitor to allow complete 
modification before diluting with 100 µL 100µM nitrocefin solution.  The 
reaction of the two enzymes with sulbactam was followed at 233nm and 
270nm using a SF61 multimixing stopped flow spectrophotometer (Hi-Tech 
Scientific, Salisbury, UK). Enzyme concentrations were 50nM, for multiple 
turnovers, to 5 µM for single turnover. Sulbactam concentrations were from 
4 to 500 µM. Curve fitting was performed using Grafit (Erithacus Software). 
Crystal Growth and Structure Determination Purified SHV-5 samples [20 
mM Tris-HCL, pH 8.0] were concentrated to between 22 mg/mL and 26.5 
mg/mL, AHB dissolved in 100 % DMSO was added in a 1:4 molar excess to 
the protein and the solution was incubated for 1 hour. The drops were 
prepared by mixing 0.2 µL SHV-5 - inhibitor solution with 0.2 µL reservoir 
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solution from various commercial screens, resulting in a final DMSO 
concentration of 3 % and a ligand concentration of 4 mM respectively in the 
crystallization drops, and the drops were equilibrated against 50 µL 
reservoir buffer. Thin, elongated, plate-like crystals grew within a few hours 
to one day to a sufficient size of 3 mm in length in 1.8 M Ammonium 
sulfate, 0.1 M BIS-TRIS pH 6.5, 2% PEG monomethyl ether 530]. For 
cryoprotection, 1 µl of perfluropolyether (Hampton Research) was added on 
top of the crystallization drop from a condition containing 1.8 M ammonium 
sulfate, 0.1 M Bis-Tris pH 6.5, 2% PEG monomethyl ether 530, and 
subsequently crystals were fished and flash frozen in liquid nitrogen. 
Purified KPC-2 samples were concentrated to 15 - 18 mg/mL. Vapor 
diffusion using the crystallization conditions described by Ke et al.27 were 
tested first (Table 1). The drops were prepared by mixing 1 µL KPC-2 (17 
mg/mL, in 20 mM Tris pH 7.6) with 0.5 µL reservoir solution and were 
equilibrated against 500 µL reservoir buffer. Most conditions yielded 
crystals but the crystallization drops contained many nuclei from 
which long thin rods of crystals up to a size of 1000 x 40 x 40 µm3 
emanated. To reduce the number of crystallization nuclei, the precipitant 
concentration, the pH value, the protein concentration and the 
crystallization temperature were varied. Decreasing temperature, PEG 6’000 
or protein concentration did not result in bigger crystals. The crystals grew 
more slowly, but there were still a lot of nuclei and they never 
reached the size reported by Ke et al.27. Single crystals of sufficient size 
were obtained by adding 10 mM spermine to the original crystallization 
condition. The crystals grew to a final size of 400 x 40 x 40 µm3 within 5 
days. In order to get KPC-2 inhibitor complex crystals, native KPC-2 
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crystals were soaked in a 5 µL soaking solution, containing 100 mM bicine 
pH 9, 16% PEG 6’000, 10 mM spermine and 2 mM inhibitor for 4 h. For 
cryoprotection, the soaked crystals were successively placed in soaking 
solution with 5, 10, 15% (v/v) added glycerol with soaking times of 20 
sec per step. Subsequently crystals were flash frozen in liquid nitrogen. 
Data collection and processing  
Data collection was performed at the beamline PXIII X06DA at the Swiss 
Light Source (Villigen, Switzerland). A complete dataset was collected to a 
resolution of 2.4 Å. For processing and scaling the programs 
MOSFLM/SCALA28 [collab] were used. The parameters of the data collection 
and the statistics of the collected data set are summarized in Table 1. 
RESULTS 
Inhibition of SHV-5. SHV5 β-lactamase was strongly inhibited by 
sulbactam. At low concentrations, there was an initial rapid loss of 
approximately 20% of the initial activity (Fig. 2A), accompanied by a burst 
of increased absorbance (Fig 3A) at peak wavelengths of 233 nm, which 
accompanies acylation, and 278 nm and a shoulder around 300 nm, which 
accompany imine and enamine intermediate formation (Scheme 2). The 
initial rate of modification increased linearly with sulbactam concentration 
over the range studied (Fig. 2B), with an apparent second order rate 
constant 0.5 ± 0.08 x 106 M-1.s-1.  Further loss of activity occurred at a lower 
rate that showed saturation kinetics (Fig. 2C) and the inhibition eventually 
reached a limiting fractional residual activity, F = 0.15. This is expected in 
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a reaction where the rate of breakdown of the acyl intermediate is slower 
than the rate of its formation (eqn 1) 29   
E+ I   !!! EI   !! E+ P       Eqn 1 
where k!! = k!"   I /(K! + I )    Eqn 2   
Fitting the observed rate of modification to Eqn 2 gives a limiting rate, kac 
= 0.45 ± 0.03 s-1 and the apparent affinity, KI = 16 µM.  That the residual 
activity does not go to zero but reaches a limiting value is attributable 
breakdown of the intermediate EI in Eqn 1 to regenerate free enzyme at a 
rate krec. The limiting fractional residual activity (F∞) is given by F∞ = 
krec/kac,30 from which krec can be calculated to be 0.068 s-1.  The increase in 
A278 continued at a decreased rate during the secondary phase of inhibition, 
rising to a plateau value at about the same concentration as the limiting 
level of inhibition (Fig. 3). The change in A233 approached a steady-state 
rate of hydrolysis through a hyperstoichiometric burst, consistent with the 
branched pathway (Scheme 3A) expected for the reaction of sulbactam and 
class A β-lactamases.12, 31 The absorbance at 300 nm passed through a 
maximum early in the approach to the steady-state, suggesting the 
formation of an intermediate (Y in Scheme 3A) in the initial phase of 
reaction that decays in favor of a more stable complex (Z in Scheme 3A), 
through which most of the reaction flows in the steady-state. SHV-5 has 
been shown to accumulate the trans-enamine intermediate in an enzyme 
complex that has a conformation with decreased β-sheet structure during 
the steady-state phase of the reaction of sulbactam.13 After single turnovers, 
or when the sulbactam is depleted in multi-turnover experiments, the 
activity of the enzyme recovered at approximately the same rate as the 
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decay in A278 (Fig. 4). The rate of either recovery of activity or decay in A278 
after single turnover was biphasic with an initial concentration-dependent 
phase that decreased from 0.12 s-1 at 0.25 µM sulbactam to 0.05 ± 0.01 s-1 at 
2 µM and a slower concentration-independent phase with a rate of 0.015 ± 
0.004 s-1. The concentration-dependent phase of recovery is dominated by 
the redistribution between intermediates X and Y (k+5, upper limit 0.068 s-
1), whereas the concentration independent phase most likely approaches the 
decay of Z to X (k-4).32  After multiple turnovers, the rate of recovery was 
also biphasic, independent of the initial sulbactam concentration, with rates 
of 0.012s-1 (amplitude approximately 10% of total activity) and 0.003s-1 
(amplitude approximately 90% of total activity). These two phases of 
recovery can be most simply identified with decay of intermediate Z through 
Y (k-4, k+5 = 0.012s-1) and the slower decay of Z directly to regenerate free 
enzyme (k+6 = 0.003s-1). 
The boronic acid inhibitor, AHB, modified SHV-5 with an initial rapid loss 
of approximately 70% of the initial activity. The initial rate of modification 
increased linearly with AHB concentration over the range studied (Fig. 2B), 
giving an apparent second order rate constant of 2.1 ± 0.1 x 106 M-1.s-1. 
Further loss of activity occurred at a lower rate that showed saturation 
kinetics (Fig. 2C). Boronic acids are generally considered to react with β-
lactamases in a two-step mechanism in which a rapid equilibrium (non-
covalent binding step) precedes a rate-determining step where covalent 
attachment occurs21 
      Eqn 3 
E + I 
Ki
E.I 
k+2 
k-2 
E.I* 
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The overall dissociation constant Ki* is related to the dissociation constant 
of the first step by: 
     Eqn 4 
and the observed rate of modification is given by kobs = k-2 + (k+2 . [I]/Ki).  
The second order rate constant determined above = k+2 /Ki = 2.1 ± 0.1 x 
106 M-1.s-1.  
Determination of the AHB IC50 with 5 min incubation of enzyme and 
inhibitor  gave biphasic dose response curves with 70 % of activity inhibited 
with high apparent affinity (20 nM) and the 30% of residual activity being 
inhibited with lower apparent affinity (9.5 µM) (Table 2). The recovery of 
free enzyme once the enzyme-inhibitor complex was diluted in the presence 
of excess nitrocefin over AHB was also biphasic, independent of the initial 
AHB concentration, with rates of 0.05 s-1 (amplitude approximately 30% of 
total activity) and 0.0009 s-1 (amplitude approximately 70% of total 
activity).  The interaction of AHB with SHV-5 is thus not consistent with 
the simple two-step reaction represented in Eqn 3, but it is consistent with a 
modified branched pathway, analogous to that observed with sulbactam, 
where the isomerized enzyme-inhibitor complex Z, yields the starting 
molecule AHB and free enzyme (Scheme 3B).   
SHV-5 was relatively slowly inhibited by avibactam. The reaction kinetics 
conformed with the two-step binding model proposed for the ESBL CTX-M 
15. 24(Ehmann).    There was an initial loss of approximately 90% of the initial 
activity with a rate of modification that increased linearly with avibactam 
concentration over the range studied (Fig. 2B), giving an apparent second 
Ki*  =  Ki .
k-2
(k+2 k-2)+
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order rate constant of 1.5 ± 0.07 x 105  M-1.s-1. Recovery of the enzyme 
activity after dilution into nitrocefin was slow and apparently monophasic 
with a recovery rate of 2 x 10-4 s-1.  
 Crystal structure of a covalent AHB-SHV-5 complex.  The crystals 
belonged to space group P21212 with 2 molecules in the asymmetric unit and 
a solvent content of 43 %. The measured intensities were rather weak owing 
to the thinness of the crystals, which resulted in a relatively high overall 
Rmeas (17.2 %). Analysis of the data by HKLVIEW28 revealed that pseudo B-
centering was present at low resolution. Indeed, a pseudo-origin peak was 
found in the Patterson map at 0.5, 0.0, 0.5, displaying half the height of the 
origin peak. The final model is comprised of all 264 residues in both 
subunits, 50 water molecules and two inhibitor molecules. The two 
molecules in the asymmetric unit of the complex structure were considered 
identical because the rmsd of the corresponding Cα position was 0.35 Å. In 
the following the structure of subunit A is described. The SHV-5-inhibitor 
structure was solved by molecular replacement using PHASER33 with chain 
A of SHV-1 D104K mutant (PDB entry code 2G2W,34) as the initial search 
model. A unique solution with two molecules in the asymmetric unit was 
identified. The two subunits in the asymmetric unit form a dimer with 2-
fold symmetry. Consistent with the pseudo B-centering subunit A and a 
symmetry mate of B are almost identically oriented and are related by a 
translation vector of (0.5, 0.0, 0.5). The model was refined with REFMAC 
(5.6.0117).28  NCS restraints were applied for the two chains, and TLS 
refinement was carried out treating each subunit as an individual group. 
After refinement of the protein to an R/Rfree of 28 % / 32 %, clear difference 
density for the ligand remained close to the active site Ser70. The inhibitor 
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was modeled into the electron density in the closed conformation with 
COOT.31 Water molecules were added manually and checked with COOT. 
The quality of the model was analyzed using MOLPROBITY32 and 
PROCHECK33. All figures were prepared with PyMOL. Difference density 
for the inhibitor bound in the active site of the enzyme (Fig. 5) was already 
apparent in the first electron density map. Unexpectedly, the 2Fo-Fc map 
clearly suggested that the inhibitor was present in the closed conformation 
(Fig. 6) instead of the open conformation reported by Ness et al.21 No 
structure factors were deposited for that structure (PDB entry code 1ERQ), 
therefore an omit map could not be calculated to compare the ligand 
difference density obtained for both structures.  There is clear evidence for 
the covalent link of the boron atom to the Oγ side chain oxygen of Ser70 
and to the exocyclic oxygen (O5) of the inhibitor, resulting in a tetrahedral 
stereochemistry of the boronate center. The inhibitor is stabilized via H-
bonds with residues Ser70, Ser130, Asn132, Thr235, Ala237 and Arg243 
(Fig. 6). The distances are listed in Table 3. The average B-factor for the 
inhibitor in molecule A is 19.1 Å2 and 17.9 Å2 for molecule B respectively.  
In the active site (Fig. 6), a water molecule is found in the same position as 
the deacylation water observed in many β-lactamase structures before.38,39 It 
is interacting with Ser70, Glu166 and Asn170 via hydrogen bonds and has a 
B-factor of 10.9 Å2.   
Inhibition of KPC-2 Compared to SHV-5, KPC-2 was slowly and 
inefficiently modified by sulbactam: stable acylation, as seen with SHV-5, 
could not be demonstrated and sulbactam behaved as a competing substrate 
towards nitrocefin.  The enamine intermediates with absorption around 280 
nm were only observed at an early stage of the reaction, prior to 
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establishment of the steady-state hydrolysis (Fig. 3B). Their abundance 
decayed as the steady-state was established and they were only present a 
very low level during the steady-state, consistent with the lack of stable 
acylation. It appears that KPC-2 establishes a branched pathway (Scheme 
3) in which direct hydrolysis of the acyl-enzyme intermediate (equivalent to 
intermediate Y in the reaction with SHV-5) is favoured over the chemical 
rearrangement leading to enamine intermediates and a stabilizing enzyme 
conformation (intermediate Z in the reaction with SHV-5). 
Modification of KPC-2 by both AHB and avibactam conformed with the 
two-step reaction previously proposed for avibactam and KPC-2.24 The rate 
of modification was slow compared to SHV-5 and the  monophasic dose 
response curves gave lower apparent affinities (IC50)   around 500 and  200  
nM for AHB and  avibactam, respectively (Table 2).  The recovery of free 
enzyme after dilution of the modified enzyme into excess nitrocefin was slow 
for both types of inhibitor. In both cases, the effective dissociation constant 
(Kd, = recovery rate/modification rate)24 was similar to the IC50 determined 
by competition  (0.51 vs  0.50 and 0.2 vs 0.17 for Kd and IC50 for AHB and 
avibactam,  respectively).  
Crystal structure of the avibactam-KPC-2 complex A complete dataset was 
collected to a resolution of 2.2 Å. For processing and scaling the programs 
MOSFLM/SCALA28 were used. The parameters of the data collection 
and the statistics of the collected data set are summarized in Table 1. 
The crystals belonged to space group P31 with 3 molecules in the 
asymmetric unit and a solvent content of 50.5%. Unfortunately, the data set 
turned out to be twinned, as indicated by the Merohedral Crystal 
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Twinning Server.4 0  The twinning operation was (h, -h-k, -l) and the 
twinning fraction 0.41. The dataset was detwinned using DETWIN28 
and the structure was determined with the detwinned data by molecular 
replacement using MOLREP41 using chain A of the KPC-2 structure 
(PDB entry 2OV5) as the initial search model. MOLREP found a 
unique solution with three molecules in the asymmetric unit. The model 
was refined with REFMAC5.28  NCS restrains were applied between the 
three chains, and TLS refinement was carried out using each chain as an 
individual group. The model of the inhibitor was generated with 
PRODRG42 and modeled into electron density with COOT.35 Water 
molecules were added with ARP4 3 and manually checked with COOT. 
The quality of the model was analyzed using PROCHECK37. All figures 
were prepared with PyMol. Considering that the data had to be detwinned, 
the model has good quality indicators (Table 4) and 99.5% of the residues 
had Φ and Ψ angles in the allowed regions of the Ramachandran plot. The 
final model is comprised of all 261 residues in all three chains, 93 water 
molecules and three inhibitor molecules. The complexed protein structure 
is virtually identical to the native structure (rmsd Cα of 0.06 Å). The 
three molecules in the asymmetric unit of the complex structure were 
considered identical, because the rms Cα differences of the pairwise 
comparisons were below 0.06 Å. In the following, we describe the structure 
of molecule A. The inhibitor appears covalently linked by an ester bond to 
Ser70 and extends into the active side cleft (Figure 7). KPC-2 molecule A 
showed the best density. The omit electron density is shown in Figure 8. 
The average B factor for the inhibitor in KPC-2 molecule A is 36.2 Å2, for 
molecules B and C the average B factors are somewhat higher (43.6 Å2 
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and 52.8 Å2). The inhibitor is stabilized via H-bonds with residues Ser70, 
Ser130, Asn132, Thr235 and Thr237 and hydrophobic contact with the 
residue Trp105 (Figure 6). The distances are listed in Table 3. A water 
molecule is found in the active site in a position to potentially deacylate 
the enzyme (Figure 8). It is interacting with Glu166 and Asn170 and has 
a B factor of 37.4 Å2.   
 
DISCUSSION 
 The kinetic analysis suggests that branched pathways involving enzyme 
conformation change as well as chemical modification of reactive 
intermediates, which were expected for the reaction between sulbactam and 
SHV-5, are may underlie  the reactions of both this ESBL and the 
carbapenemase KPC-2 with other, non-β-lactam, classes of inhibitor. The 
structure of the KPC enzymes appears have evolved to disfavor the 
formation of chemically stabilized intermediates, such as the enamines 
formed with clavulanic acid, sulbactam and tazobactam, as well as the Δ1-
tautomer of the pyrroline double bond in the acyl-enzyme species that 
occurs in the reaction with carbapenems.12 
The structure of the AHB/SHV-5  complex was compared to structures of 
the closely-related class-A β-lactamases SHV-1, SHV-2 and TEM-1.22,39,44,45 
As expected from the high sequence similarity of these proteins, a good 
superposition of the overall-structures is observed (RMSD 1.0-1.2Å). 
Interestingly, the conformation of the H10-helix of SHV-5 (residues 218-230) 
deviates significantly from the ones observed in the structure of SHV-1 and 
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SHV-2 but is identical to the one in the structure of AHB-TEM-1 complex. 
Since this deviation has been observed previously34 and has been linked to 
the presence of a detergent molecule, this observation is not discussed in 
detail here.  Relative to the wild-type enzyme SHV-1, SHV-5 differs by the 
mutations Gly238Ser and Glu239Lys, which are located in a short loop 
which connects B3 and B4 β-sheets.  Very similar conformations are 
observed for this loop in both monomers but only weak electron density is 
observed for residues Lys239 and Arg240 in monomer A, which reflects the 
conformational plasticity of this loop. However, the loop conformation of 
SHV-5 deviates significantly to the ones observed in X-ray structures of 
SHV-1.44,45 Residues 240–241 have flipped, resulting in a drastic shift of the 
corresponding Cα-positions (3.8 Å for of Lys239 monomer B). The finding 
correlates well with the structure of SHV-2, for which an altered 
conformation of this loop is also described, albeit to a lesser extent.39 As in 
case of the structure of SHV-2, no significant alteration of the catalytic 
residues in the active site is observed. 
Interestingly, the electron density suggests binding of the inhibitor in the 
form of a bicyclic boronate ester, which is in contrast to its TEM-1 binding 
mode22 where the boronic acid state is observed. Despite this difference, the 
key interactions of the inhibitor observed in the SHV-5 structure are highly 
similar to the ones observed for TEM-1. In brief, strong hydrogen-bond 
interactions are formed to the the main chain nitrogens of Ser70 and 
Ala237, the side chains of Arg244 and Lys234 and to the backbone-carbonyl, 
the main chain carbonyl at Ala237 and the side chain amide nitrogen of 
Asn132. Also similar to TEM-1, favorable van der Waals interactions 
between the aromatic side chain of Tyr105 and the aromatic ring of the 
Contrasting Mechanism of Inhibition of SHV5 and KPC2 β-Lactamases 
 
   186 
inhibitor is observed. However, since an alternative conformation is observed 
for Tyr105 in which the side-chain is rotated by almost 120 degrees, this 
interaction might be less relevant compared to TEM-1. 
A high similarity of the overall-structures was observed upon superposition 
of the structure of the KPC-2/avibactam-complex with the structures 
reported by Ke et al., 27,47 in which either a bicine molecule (pdb-code 
2OV5) or a 3-nitrophenyl-boronic acid (3-NBA, pdb-code 3RXX) are 
present in the active site. A good similarity is also observed for the active 
sites, including the catalytic residues and the di-sulfide bridge formed by 
Cys69 and Cys238. However, significant differences could be observed for 
the orientation of the loop at the end of the β3-strand. Whereas the 
structures of the avibactam and the bicine-complex superimpose well, the 
loop adopts a different conformation in case of the 3-NBA complex resulting 
in the shift of the carbonyl-oxygen of Gly239 by 2.9Å. Furthermore, a 
significant deviation of the 3-NBA-complex-structure is observed on the 
opposite side of the pocket. Here the loop between Val103 and Ser106 is 
shifted, which also affects the side-chain conformation of Trp105. This 
strong conformational plasticity is reflected by a distance of 6.5 Å between 
the positions of the aromatic nitrogen of Trp105 of the avibactam and 3-
TBA-complex. Also a high similarity of the KPC-2/avibactam-complex is 
observed to the structure KPC-2 in the apo-state (pdb-code 3DW0),48 which 
closely resembles the structure of the 3-NBA-complex, in particular 
regarding the orientation of Trp105. However, a significant deviation is 
observed for the side-chain orientation of catalytic residue Ser130. Here, the 
side-chain is directed towards a water molecule located between Thr235 and 
Val127, whereas in the other structures, the side-chain is pointing towards 
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Ser90. The importance of the de-acylation water molecule, which is located 
between the residues Ser70 and Asn170, is reflected by the only minor 
variation of its position observed in the different structures. 
The binding mode of avibactam to KPC-2 was compared to the ones 
observed for complexes with the class-A β-lactamase CTX-M 15.49, 50  As 
expected from the high similarity of the active sites of CTX-M 15 and KPC-
2, the inhibitors superimpose well in the respective structures, with an 
average distance of approx. 0.5 Å for atoms of the piperidine ring. The 
amide-groups are located in an almost identical position and the piperidine 
rings share a similar conformation. However, a notable difference is observed 
for the orientation of the sulfoxyamino-groups. Whereas the sulfur-atoms are 
located in close proximity, the nitrogen and oxygen atoms of the linker 
adopt different positions. In case of the KPC-2/avibactam complex, the 
oxygen is in a position beneath the piperidine ring whereas for CTX-M 15, 
the N-O bond is pointing away from the piperidine. As a consequence, 
protons of the nitrogen are modeled in a more distant position from the 
catalytic serine residues in case of KPC-2 (2.4 and 3.4 Å to Ser130 and 
Ser70 compared to 1.9 and 2.5 Å in case of CTX-M 15). The difference in 
conformation of the N-O bond and consequent different hydrogen-bonding 
may decrease the propensity for neighbouring group attack by N6 to 
regenerate the starting inhibitor molecule and free KPC-2 and therefore 
account for the unique degradation pathway observed for KPC-2.24  
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FIGURES  
Fig. 1 Structures of (A) sulbactam, (B) (3R)-3-acetamido-2-hydroxy-3,4-
dihydro-1,2-benzoxaborinine-8-carboxylic acid (AHB) and (C) avibactam. 
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Figure 2. Inhibition of SHV-5: (A) time course for the initial modification by 
sulbactam at 1 µM (solid circles), 2 µM (solid triangles), 5 µM (solid 
squares),  10 µM (solid diamonds), 20 µM (open circles), 40 µM (open 
triangles) and 80 µM (open squares);  (B) initial second order rates of 
modification by sulbactam (solid circles), AHB (solid squares) and 
avibactam (solid triangles); (C) limiting first order rates of modification by 
sulbactam (circles) and AHB (solid squares)   
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Figure 3: Time course of the reaction between sulbactam (500 µM) and 
either (A) SHV-5 at 1 µM or (B) KPC-2 at 5 µM, followed at 233 nm 
(purple lines), 278 nm (blue lines and 300 nm (orange line). 
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Figure 4: (A) Time course of the reaction between sulbactam and SHV-5 (1 
µM) at 2 µM (blue line and triangles) and 20 µM (orange line and 
triangles). The solid lines show the absorbance change at 278nm, normalized 
with respect to the mean steady-state absorbance, and the triangles show 
the fractional residual activity towards nitrocefin hydrolysis. (B) Semi-
logarithmic replots of the data shown in A, for sulbactam 2 µM (blue line 
and circles). and 20 µM (orange line and circles: time points recalculated to 
show the time elapsed after the end of the steady-state) with the residual 
activity transformed to fractional inhibition. Also shown are the fractional 
inhibition of SHV-5 (squares) and KPC-2 (triangles) by (3R)-3-acetamido-2-
hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid after multiple 
turnovers.   
 
 
  
Contrasting Mechanism of Inhibition of SHV5 and KPC2 β-Lactamases 
 
   192 
Figure 5: Structure of SHV-5 β-lactamase in complex with the inhibitor 
(3R)-3-acetamido-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic 
acid. (A) Cartoon diagram of SHV-5; the inhibitor moiety is covalently 
bound to Ser70 (shown in sticks). (B) Surface representation of SHV-5; the 
inhibitor moiety is located in the catalytic cleft. 
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Figure 6: Two stereo views of the active site of the SHV-5 β-
lactamase with bound AHB. The interaction residues and the 
inhibitor are shown in full. The H-bonds are shown as dashed lines. 
The omit map for the ligand is contoured at 2 σ. The Fo-Fc omit map, 
contoured at 2 σ, clearly supports the scenario in which the ligand binds 
to Ser70 in the closed conformation. 
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Figure 7. Structure of the KPC-2 β-lactamase in complex with the 
inhibitor avibactam. (A) Ribbon diagram of the KPC-2; the inhibitor 
moiety is covalently bound to Ser70 (shown in sticks). (B) Surface 
representation of the KPC-2; the inhibitor moiety is located in the 
catalytic cleft. 
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Figure 8. Two stereo views of the active site of the KPC-2 β-
lactamase with bound avibactam. The interaction residues and the 
inhibitor are shown in full. The H-bonds are shown as dashed lines. 
The omit map for the ligand is contoured at 2 σ. 
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Scheme 1. Schematic representation of the intermediates possible during 
reaction of a β-lactamase with (A) a penicillin, (B) 3-acetamido-2-hydroxy-
3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid and (C) avibactam 
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Scheme 2. Schematic representation of the intermediates possible during 
rearrangement of the acyl-enzyme intermediate formed with sulbactam   
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Scheme 3. Branched pathways involving enzyme conformation change, 
modified from Frere (1981) and Waley (1991), showing (A) a reaction 
pathway proceeding to a product (e.g. sulbactam and SHV-5) and (B) 
and inhibition pathway regenerating the inhibitor and free enzyme (e. 
g. AHB and SHV-5). 
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Table 1: Data collection and refinement statistics. Statistics for the highest-resolution shell 
are shown in parentheses. 
 
 
 Parameter SHV5 KPC-2 
Wavelength [Å] 1 1 
Resolution range [Å] 27  - 2.4 (2.486  - 2.4) 30 – 2.2 
Space group P 21 21 2 P31 
Unit cell [Å,°] 69.7 106.8 62.6 90 90 90 116.29 116.29 52.79 120 120 120 
Total reflections 41629 (6276) 95396 (13326) 
Unique reflections 17676 (2616) 40113 (5809) 
Multiplicity 2.6 (2.4) 2.4 (2.3) 
Completeness [%] 93.0 (97.6) 99.0 (98.1) 
Mean I/sigma(I) 4.6 (2.3) 15.7 (2.4) 
R-merge [%] 12.4 (35.2) 7.1 (30.2) 
R-meas [%] 17.2 (48.8) 9.1 (39.1) 
R-work [%] 22.2  23.6  
R-free [%] 28.8  27.5 
Numbers of non-hydrogen atoms 
                 protein 4111 11652 
                 ligands 36 51 
RMS(bonds) [Å2] 0.021 0.010 
RMS(angles) [°] 1.85 1.174 
Ramachandran favored [%] 96 94.3 
Ramachandran allowed [%] 3.8 5.1 
Average B-factors [Å2] 
               protein 17.07 40.4 
               ligands 18.52 44.2 
               solvent 12.43 33.6 
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Table 2. Observed Kinetic Parameters Describing Inhibition of SHV-5 and  
KPC-2  
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Parameter 
SHV-5 KPC-2 
SUL AHB AVI SUL AHB AVI 
Apparent 
affinity 
(µM) 
IC50  
 (Residual activity, %) 
 
0.6 
0.028 
(72)  
9.5 
(28) 
0.019 
(95) 
2.8 
(5) 
>100 
0.51 
(100) 
0.17 
(100) 
 
KI, initial phase of 
modification 
 
16 
 
6 
 
ND 
 
ND 
 
ND 
 
ND 
 
Kd, effective dissociation 
constant   
 
ND 
 
ND 
 
 0.023 
 
ND 
 
0.50 
 
0.20 
Modification  
rate 
Apparent 2nd order rate 
constant, initial phase,  
M-1.s-1 
5.1 x 
105 
2.1 
x106 
1.5 x 
105 
ND 
7.5 x 
104 
1.4 x 
104 
 
Limiting rate of 
modification, kac, s-1 
 
0.45 
 
1.7 
 
ND 
 
ND 
 
ND 
 
ND 
Recovery rate 
(s-1) 
Calculated rate from 
limiting fractional actvity, 
krec 
    
0.068 ND ND ND ND ND 
Recovery rate , Single 
turnover 
(Residual activity, %) 
 
0.05 
(60%) 
0.015 
(40%) 
ND ND ND ND ND 
 
Recovery rate - Multiple 
turnover or equilibrium 
mixture for AHB and 
avibactam. (Residual 
activity, %) 
 
0.012 
(10%) 
0.003 
(90%) 
 
0.05 
(30%)  
0.0009 
(70%) 
2 x 
10-4 
(100) 
 
3.8 x 
10-4 
(100) 
0.003 
(100) 
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Table 3: Hydrogen Bonding Distances in the Inhibitor/Enzyme Complexes 
 
Location Inhibitor 
Atom  
Enzyme atom Deacylation 
water 
Distance (Å) 
        SHV-5 TEM-1a 
Boronate 
 
 
OB1 Ser70N - 2.40 (Ser70 N) 2.80  
OB1 Ser70OG - 2.51 (Ser70 OG) 2.31  
O5 Ser130 OG - 3.06  (Ser130 OG) 2.73 
O2 Asn132 ND2 - 3.10  (Asn132 ND2) 2.90 
O3 Thr235 OG1 - 2.88 (Ser235 
OG1)     2.80 
N1 Ala237 O - 3.01 (Ala237 O) 3.20 
OB1 Ala 237 N - 3.15 (Ala237 N) 3.07  
O4 Arg243 NH1 - 2.85 (Arg243 
NH1)    2.80 
Deacylation 
water 
  Glu166 OE2 H2O 37 2.48  2.50 
  Asn170 OD1 H2O 37 2.78  2.70 
        KPC-2 CTXM-15 b 
Avibactam 
O7 Ser70 N - 2.87  (Ser70 N) 2.71 
O3 Ser130 OG - 3.32 (Ser130 OG) 3.08  
O14 Asn132 ND2 - 3.21 (Asn132 ND2) 2.85  
O3 Thr235 OG1 - 2.77 (Thr235 OG1) 2.62  
O4 Thr237 OG1 - 2.42  (Ser237 OG) 3.29 
O7 Thr237 N - 2.95  (Ser237 N) 2.90 
Deacylation 
water 
  Glu166 OE2 H2O 35 2.48 (Glu166 OE2) 2.60  
  Asn170 OD1 H2O 35 2.32 (Asn170 OD1) 2.71  
    H2O 35 2.89   
aNess et al. (2000) Biochemistry 39, 5312-5321. bLahiri et al. (2013) 
Antimicrob. Agents Chemother.  57, 2496-2505. 
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  bereitet	  mir	  keine	  Mühe,	  mich	  in	  einer	  bestehenden	  Gruppe	  einzufügen:	  Ich	  
kann	   mich,	   wenn	   nötig,	   unterordnen,	   aber	   auch	   eine	   Leitungsposition	  
einnehmen,	   um	   gemeinsam	   und	   koordiniert	   mit	   meiner	   Gruppe	   ein	   Ziel	   zu	  
erreichen.	  
	  
	  
FACHKOMPETENZ	  
	  
- Ich	   spreche	   und	   schreibe	   fliessend	  Deutsch,	   Englisch	   sowie	   Französisch.	   Dabei	  
lege	  ich	  	  grossen	  Wert	  auf	  Schreibrichtigkeit.	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METHODENKOMPETENZ	  
	  
- Ich	  besitze	  eine	  schnelle	  Auffassungsgabe.	  Ich	  schrecke	  nicht	  davor	  zurück,	  neue	  
Hürden	   und	   Herausforderungen	   in	   Angriff	   zu	   nehmen;	   ich	   meistere	   diese	  
grundsätzlich	  auf	  eine	  effiziente	  Art	  und	  Weise.	  
- Durch	  meinen	  wissenschaftlichen	  Hintergrund	  verfüge	  ich	  über	  ein	  ausgeprägtes	  
analytisches	  Denken.	  	  
 
 
